Formulations comprising acid neutralizing polymers for oral active agents
By neutralizing gastric acid with polymers of multiple basic groups, the degradation and malabsorption of oral peptides and protein drugs in the digestive system are solved, and their bioavailability and absorption efficiency are improved.
Patent Information
- Application Number
- CN202380034392.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-24
- Filing Date
- 2023-02-23
- Publication Date
- 2024-11-29
Smart Images

Figure CN119053335A_ABST
Abstract
Description
[0001] Related Applications
[0002] This application claims priority under 35 USC §119(e) to U.S. Provisional Patent Application No. 63 / 313,363, filed on February 24, 2022, the entire contents of which are incorporated herein by reference.
[0003] Technical Field and Background Art
[0004] The present invention, in some embodiments thereof, relates to drug delivery, and more particularly, but not exclusively, to formulations and / or systems for oral administration of therapeutically active agents, such as, but not limited to, peptide and / or protein drugs.
[0005] Oral administration of peptide and / or protein drugs is problematic due to degradation of the peptide and / or protein in the digestive system and poor absorption of larger molecules.
[0006] Qi and Ping [Journal of Microencapsulation 2004, 21:37-45] describe the administration of enteric-coated microspheres containing insulin and SNAC (sodium 8-N-(2-hydroxybenzoyl)aminocaprylate). The enteric-coated microspheres are used to protect the insulin from the effects of gastric and small intestinal digestive enzymes, and the SNAC is used to enhance absorption.
[0007] U.S. Patent Application Publication No. 2011 / 0142800 describes a composition for oral protein administration comprising a protein with a molecular weight of up to 100,000 Da, a protease inhibitor, and an absorption enhancer, such as SNAC, N-(10-[2-hydroxybenzoyl]amino)decanoic acid (SNAD), 8-[N-(2-hydroxy-4-methoxybenzoyl)amino]octanoic acid (4-MOAC), 8-[N-(2-hydroxy-5-chlorobenzoyl)amino]octanoic acid (5-CNAC), and 4-[(4-chloro-2-hydroxybenzoyl)amino]butyric acid (4-CNAB) and its sodium salt.
[0008] International Patent Application Publication No. WO 00 / 48589 describes a solid oral dosage form comprising a heparin drug mixed with SNAC or SNAD to promote absorption and / or improve bioavailability of the heparin drug, wherein the heparin drug reportedly protects SNAC or SNAD from precipitation during passage through the acidic region of the gastrointestinal (GI) tract.
[0009] International Patent Application Publication No. WO 2016 / 128974 describes a pharmaceutical composition for oral administration comprising a therapeutically active agent, SNAC, and at least one antacid compound; and a unit dosage form of a pharmaceutical composition for oral administration comprising a core comprising a therapeutically active agent and SNAC, and an outer layer comprising at least one of an antacid compound and a protease inhibitor.
[0010] Buckley et al. [Science Translational Medicine 2018, 10:eaar7047] reported that after oral administration of a tablet containing the peptide agent semaglutide and SNAC, absorption of semaglutide occurred in the stomach and was limited to areas close to the tablet surface, with SNAC preventing enzymatic degradation through local buffering and only transiently enhancing absorption.
[0011] Sodium carboxymethylcellulose (CMC) is prepared by modifying cellulose with chloroacetic acid and can be cross-linked or non-cross-linked. In its cross-linked form, the cross-linking is achieved by forming multiple ester bonds between multiple carboxymethyl groups and cellulose. It is commonly known as croscarmellose sodium (CCS) or sodium croscarmellose and is used as a superdisintegrant in pharmaceutical formulations.
[0012] Similarly, sodium starch glycolate (SSG) can be prepared by modifying starch with chloroacetic acid to form carboxymethyl groups. Sodium starch glycolate can be prepared by modifying starch with chloroacetic acid to form carboxymethyl groups. - )-O-) is further cross-linked and acts as a super disintegrant.
[0013] Other background technologies include Qi et al. [Acta Pharmaceutical Sinica 2004, 39: 844-848]; International Patent Application Publication Nos. WO 00 / 50386, WO 01 / 32130, WO 01 / 32596, WO 03 / 045306, WO 03 / 045331, WO2006 / 076692, WO 2007 / 121471, WO 2010 / 020978, WO 2012 / 080471, WO 2016 / 128970, WO 2016 / 128971, WO 2016 / 128972, WO 2016 / 128973, WO 2016 / 128974 and WO No. 2018 / 033927; Japanese Patent Application Nos. 2005281231 and 2006111558; U.S. Patent No. 8,110,547; and U.S. Patent Application Publication Nos. 2006 / 0234913, 2007 / 0087957, and 2013 / 0224300. Summary of the invention
[0014] According to an aspect of some embodiments of the present invention, there is provided a pharmaceutical composition comprising a therapeutically active agent, an absorption enhancer and a polymer comprising a plurality of basic groups.
[0015] According to an embodiment of the present invention, the concentration of the polymer in the composition is at least 10 weight percent of the total weight of the pharmaceutical composition.
[0016] According to an embodiment of the present invention, the absorption enhancer is a substituted or unsubstituted fatty acid or a salt thereof.
[0017] According to one aspect of some embodiments of the present invention, there is provided a method of treating a condition treatable by the therapeutically active agents described herein in a subject in need thereof, the method comprising orally administering to the subject a pharmaceutical composition as described in any corresponding embodiment and any combination thereof.
[0018] According to any some embodiments of the various embodiments of the present invention, the plurality of basic groups are a plurality of carboxylate groups and / or a plurality of amine groups.
[0019] According to any some of the various embodiments of the invention, at least a portion of the plurality of basic groups are a plurality of carboxylate groups.
[0020] According to any of the various embodiments involving carboxylate groups, at least a portion of the plurality of carboxylate groups are in the form of a pharmaceutically acceptable salt.
[0021] According to any of the embodiments involving carboxylate groups, at least a portion of the plurality of carboxylate groups are in the form of a sodium salt.
[0022] According to any some embodiments of the multiple embodiments of the present invention, the absorption enhancer is selected from NAC (8-N-(2-hydroxybenzoyl) aminocaprylic acid), NAD (10-N-(2-hydroxybenzoyl) aminodecanoic acid), 5-CNAC (8-N(5-chlorosalicyloyl) aminocaprylic acid), 4-MOAC (8-N-(2-hydroxy-4-methoxybenzoyl) aminocaprylic acid), 4-CNAB (4-N-(2-hydroxy-4-chlorobenzoyl) aminobutyric acid) and salts thereof.
[0023] According to any some of the various embodiments of the present invention, the absorption enhancer comprises NAC or a salt thereof.
[0024] According to any some of the various embodiments of the present invention, the concentration of the absorption enhancer is at least 50 weight percent of the total weight of the pharmaceutical composition.
[0025] According to any some of the various embodiments of the present invention, the concentration of the polymer is at least 20 weight percent of the total weight of the pharmaceutical composition.
[0026] According to any some of the various embodiments of the present invention, the total concentration of the absorption enhancer and the polymer is at least 80 weight percent of the total weight of the pharmaceutical composition.
[0027] According to any some of the various embodiments of the present invention, the concentration of the basic group in the pharmaceutical composition is at least 0.1 mmol / g.
[0028] According to any some of the various embodiments of the present invention, the polymer is a cross-linked polymer.
[0029] According to any some of the various embodiments of the invention, the polymer comprises a polysaccharide.
[0030] According to any of the various embodiments relating to the polysaccharide, the polysaccharide is selected from the group consisting of starch derivatives and cellulose derivatives.
[0031] According to any some of the various embodiments of the invention, the polymer comprises carboxymethyl groups.
[0032] According to any some of the various embodiments of the invention, the polymer is characterized by a pKa in the range from 1.2 to 7.5, including any intermediate values and subranges therebetween.
[0033] According to any some of the embodiments of the present invention, the polymer is sodium starch glycolate and / or cross-linked sodium carboxymethyl cellulose.
[0034] According to any of some embodiments of the present invention, the composition has a C 最大 and / or bioavailability compared to a corresponding composition not containing the polymer (e.g., a composition comprising the same therapeutically active agent, the same absorption enhancer, and optionally other ingredients, each in the same amount, but without the polymer comprising multiple basic groups as described herein in any corresponding embodiment) 最大 and / or at least 50% higher bioavailability.
[0035] According to any some of the various embodiments of the invention, the molecular weight of the therapeutically active agent is in the range of 0.5 kDa to 100 kDa.
[0036] According to any some of the various embodiments of the present invention, the therapeutically active agent is a BCS class III agent.
[0037] According to any some of the various embodiments of the invention, the therapeutically active agent is a polypeptide or a nucleic acid.
[0038] According to any of the embodiments of the present invention, the polypeptide is selected from antibodies, anti-pathogenic polypeptides, antiviral peptides, coagulation factors, C-type natriuretic peptides, calcitonin, desitatide, endomorphin, erythropoietin, gastric inhibitory peptide (GIP), gastric inhibitory peptide receptor agonist, glucagon, glucagon receptor agonist, GLP-1 (glucagon-like peptide-1), GLP-1 receptor agonist, GLP-2 (glucagon-like peptide-2), GLP-2 receptor agonist, GLP-1 receptor / glucagon receptor dual agonist, GIP receptor / GLP-1 receptor dual agonist, glucagon receptor / GIP receptor / GLP-1 receptor triple agonist, GLP-2 receptor / glucagon receptor dual agonist, GLP-2 receptor / GLP-1 receptor dual agonist, GLP-2 receptor / GLP-1 receptor dual agonist, GLP-2 receptor / GLP-2 receptor dual agonist, GLP-2 receptor a dual agonist of the steroid / GIP receptor, a glucocerebrosidase, a gonadotropin, a gonadotropin-releasing hormone, a gonadotropin-releasing hormone receptor agonist, a gonadotropin-releasing hormone receptor antagonist, a granulocyte colony stimulating factor, a growth factor, a growth hormone, a somatostatin, a somatostatin receptor agonist, a growth hormone-releasing hormone, an icatibant, a brevitide, a somapatan, an insulin, an interferon, an interleukin, a kappa opioid receptor agonist, a leptin, an oxytocin, an oxytocin receptor agonist, a melanocortin, a melanocortin receptor agonist, a motilin, an omentin, a parathyroid hormone or a fragment thereof, a parathyroid hormone-related protein, a peptide YY, a pituitary adenylate cyclase activating peptide (PACAP), a thymopentin, a thymosin, a TNF inhibitor, a vasoactive intestinal peptide, a vasopressin and analogs thereof, including long-acting analogs thereof.
[0039] According to any some of the various embodiments of the present invention, the therapeutically active agent is a polypeptide comprising teriparatide.
[0040] According to any some of the various embodiments of the invention, the therapeutically active agent is an antibody comprising a single domain antibody.
[0041] According to any of some embodiments of the present invention, the pharmaceutical composition is in the form of a unit dosage form.
[0042] According to any of the various embodiments relating to the invention concerning unit dosage forms, the amount of the basic group in the unit dosage form is at least 0.03 mmol.
[0043] According to any of the various embodiments of the invention relating to unit dosage forms, said unit dosage form comprises at least 50 mg of said absorption enhancer.
[0044] According to any of the various embodiments involving the invention relating to unit dosage forms, the unit dosage form comprises one or more tablets.
[0045] According to any of some of the various embodiments of the present invention, the pharmaceutical composition is used to treat a condition treatable by the therapeutically active agent, and the treatment comprises orally administering the pharmaceutical composition.
[0046] Unless otherwise defined, all technical and / or scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the present invention belongs. Although similar or equivalent methods and materials as described herein may be used in the practice or testing of embodiments of the present invention, exemplary methods and / or materials are described below. In the event of a conflict, the patent specification (including definitions) shall prevail. In addition, materials, methods and examples are illustrative only and are not intended to necessarily limit. BRIEF DESCRIPTION OF THE DRAWINGS
[0047] Some embodiments of the present invention are described herein by way of example only with reference to the accompanying drawings. With specific and detailed reference now to the drawings, it should be emphasized that the details shown are only examples for illustrative discussion of embodiments of the present invention. In this regard, the description in conjunction with the drawings makes it clear to those skilled in the art how to practice the embodiments of the present invention.
[0048] In the drawings of the specification:
[0049] Figure 1 Shown is a graph of the measured pH as a function of SNAC concentration after adding SNAC to HCl solution (pH 1.2).
[0050] Figure 2 Shown is the percentage of human parathyroid hormone (1-34) (PTH) (initial concentration 0.135 mg / mL) as a function of pH after incubation with pepsin (150 μg / mL) for 3 minutes at 37°C.
[0051] Figures 3A to 3B The results show that the use of an ELC-10-00 electrode (MRC, Israel) Figure 2 A) or thin electrode HI1083 (Hana Instrument Co., Ltd.) Figure 2 B) A graph of the pH as a function of the added polymer concentration when sodium alginate, sodium carboxymethylcellulose (Na-CMC), sodium starch glycolate (SSG) or cross-linked sodium carboxymethylcellulose (CCS) was added to HCl solution (pH 1.2) measured with an MP-103 pH meter (MRC Corporation, Israel).
[0052] Figure 4Shown are graphs of the median plasma concentration of hPTH(1-34) as a function of time in rats following oral administration of mini-tablets containing 90 μg of hPTH(1-34), SNAC, and SBTI (soybean trypsin inhibitor) with or without 20% sodium starch glycolate (solid line) or sodium starch glycolate (dashed line).
[0053] Figure 5 Shown are graphs of the median plasma concentration of hPTH(1-34) as a function of time following oral administration of mini-tablets containing 90 μg of hPTH(1-34) and SNAC with 30% sodium starch glycolate (solid line) or without sodium starch glycolate (dashed line) to rats.
[0054] Figures 6A to 6D The results show that sodium starch glycolate (SSG; Figure 3A ), cross-linked carboxymethyl cellulose sodium (CCS; Figure 6B )、Sodium carboxymethyl cellulose (CMC-Na; Figure 6C ) and sodium alginate (Alg-Na; FIG3D ) after swelling in 0.01 M HCl (pH = 2) at room temperature, and the pH values measured at four points for each tablet (white triangles).
[0055] Figures 7A to 7B The results show that sodium starch glycolate (SSG; Figure 4 A) and sodium carboxymethylcellulose (CMC-Na; Figure 4 B) Photographs of tablets made from various polymers after swelling in porcine gastric fluid at room temperature, and the pH values measured at four points for each tablet (white triangles).
[0056] Figure 8 is a graph showing the median plasma concentration of teduglutide in male Sprague Dawley rats (body weight approximately 299 g, n=7) following oral administration of a tablet containing 0.7 mg of teduglutide (2.34 mg / kg), SNAC (15 mg), and SSG (5.33 mg).
[0057] Fig. 9 A comparison of median plasma concentrations (AUC) of an exemplary 1 kD therapeutic peptide following oral administration of tablets containing the therapeutic peptide (0.1 mg / kg), SNAC and SSG at 10% by weight (dashed line) or 30% by weight (black line) to male dogs (n=6 per group) is shown. The AUC measurements between the two groups were statistically significant (t-test, p<0.05). DETAILED DESCRIPTION
[0058] The present invention, in some embodiments thereof, relates to drug delivery, and more particularly, but not exclusively, to formulations and / or systems for oral administration of therapeutically active agents, such as, but not limited to, peptide and / or protein drugs.
[0059] Before explaining at least one embodiment of the present invention in detail, it should be understood that the application of the present invention is not necessarily limited to the details set forth in the following description or exemplified by the embodiments. The present invention is capable of other embodiments or can be practiced or implemented in various ways.
[0060] While studying the enhancement of the absorption of therapeutically active agents by exemplary absorption enhancers such as SNAC (sodium 8-N-(2-hydroxybenzoyl)aminocaprylate), the present inventors discovered that such various absorption enhancers enhance the ability of the therapeutically active agent to be absorbed (e.g., as measured by bioavailability and / or C 最大 The inventors have conceived of using basic (alkaline) compounds to enhance the performance of oral absorption enhancers by neutralizing gastric acid and have found that a variety of polymers containing multiple basic groups such as carboxylates are particularly effective in protecting absorption enhancers from gastric acid and improving the bioavailability of therapeutically active agents in compositions containing absorption enhancers and therapeutically active agents.
[0061] While putting the present invention into practice, the inventors have demonstrated that various exemplary polymers comprising multiple carboxylate groups produce a localized increase in pH in simulated gastric fluid (which can reduce the protonation of an absorption enhancer such as SNAC) and significantly enhance the absorption of a therapeutically active agent compared to corresponding compositions having the same absorption enhancer but without the polymer.
[0062] Now refer to the accompanying drawings, Figure 1 The exemplary absorption enhancer SNAC is shown to be protonated upon contact with HCl (as present in stomach acid).
[0063] Figure 2 It was shown that increasing the pH to about 6 significantly reduced peptide degradation by pepsin.
[0064] Figures 3A to 3B Various carboxylate-containing polymers were shown to increase pH in a concentration-dependent manner.
[0065] Figure 4 and Figure 5 Exemplary carboxylate group-containing polymers were shown to significantly enhance the absorption of therapeutically active agents in in vivo models.
[0066] Figures 6A to 6D7A to 7B show the increase in local pH inside tablets made from different carboxylate-containing polymers after hydration in an acidic aqueous solution.
[0067] Figure 8 and Fig. 9 Exemplary carboxylate group-containing polymers were shown to significantly enhance the absorption of therapeutically active agents in in vivo models.
[0068] According to one aspect of some embodiments of the present invention, there is provided a pharmaceutical composition comprising a therapeutically active agent, an absorption enhancer, and a polymer comprising a plurality of basic groups (also referred to herein as "polymer containing" or "polymer of at least basic groups" or "alkaline polymer or basic polymer" or simply "polymer" for brevity). In some such embodiments, the composition is in the form of a unit dosage form, such as a tablet or a combination of more than one tablet (e.g., a mini-tablet).
[0069] As explained in detail below, polymers containing basic groups are also referred to herein as acid-neutralized polymers.
[0070] As used herein, the singular forms "a", "an" and "the" include plural referents unless the context clearly indicates otherwise. For example, the term "polymer" or "at least one polymer" may include a plurality of polymers, and mixtures thereof.
[0071] The term "unit dosage form" as used herein describes physically discrete units, each unit containing a predetermined amount of one or more active ingredients calculated to produce the desired therapeutic effect in combination with at least one pharmaceutically acceptable carrier, diluent, excipient, or combination thereof. Examples of suitable unit dosage forms include, but are not limited to, tablets, capsules, lozenges, troches, films, sachets, patches, ampoules, vials, loaded syringes, and metered dose dispensers. Each unit may optionally contain a discrete plurality of subunits (e.g., wherein each subunit is in a form described herein, such as a tablet, capsule, lozenge, troche, etc.), which may be bonded to or separated from each other.
[0072] For example, as described in International Patent Application Publication No. WO 2018 / 033927, a unit dosage form comprising a plurality of subunits according to an embodiment of the present invention may optionally be in the form of a unit dosage form comprising a plurality of discrete subunits bound to each other by a coating and / or a matrix, or in the form of a set of multiple dosage forms in a kit (e.g., a plurality of discrete dosage form groups packaged), which is incorporated herein by reference as if fully set forth herein.
[0073] The pharmaceutical composition and / or unit dosage form according to any corresponding embodiment described herein are preferably formulated to be suitable for oral administration, for example, as described in more detail herein. The example of the unit dosage form for oral administration includes but is not limited to tablets, capsules, lozenges, lozenges, films, pouches, ampoules and vials. In an exemplary embodiment, the pharmaceutical composition and / or unit dosage form according to any corresponding embodiment described herein are formulated into tablets or multiple mini tablets. In an exemplary embodiment, the pharmaceutical composition and / or unit dosage form according to any corresponding embodiment described herein do not have a gastroenteric coating, or otherwise include a coating that is soluble in gastric juice and / or releases the contents of the composition immediately (for example, in less than 5 minutes, less than 2 minutes or less than 1 minute) when contacting gastric juice.
[0074] As used herein, the phrases "oral administration," "orally administering," and the like refer to any administration by mouth, preferably by oral ingestion, such as by swallowing (eg, as opposed to buccal administration).
[0075] In some embodiments described herein, the compositions are formulated to allow absorption of the therapeutically active agent in the stomach, for example, by lacking an enteric coating, ie, a coating that prevents the release of the drug and dissolves only in the intestine.
[0076] Polymers containing basic groups:
[0077] As used herein, the term "polymer" refers to a compound having at least 4 repeating (backbone) units (more preferably at least 10 repeating units, e.g., 4 to 1000 or 10 to 1000 repeating units), the repeating units being identical or similar. The term "polymer" also includes copolymers comprising two or more types of repeating units as described herein, e.g., at least 4, or preferably at least 10 repeating units of one type, and at least 4, or preferably at least 10 repeating units of another different type. The units in the copolymer may be arranged in any order.
[0078] As described herein, the backbone (repeating) units that make up a polymer or copolymer are also interchangeably referred to herein as monomer units or simply monomers.
[0079] Each molecule of the polymer containing basic groups comprises multiple (i.e. at least 2) basic groups. In some embodiments of any embodiment described herein, the average number of basic groups per molecule of the polymer containing basic groups comprises at least 4 basic groups, or at least 10 basic groups, or at least 25 basic groups, or at least 50 basic groups, or at least 100 basic groups. In some embodiments of any embodiment described herein, the average number of basic groups per polymer molecule is from about 4 to about 1000, or from about 10 to about 1000, or from about 25 to about 1000, or from about 50 to about 1000, or from about 100 to about 1000, and for each of these ranges, higher upper limits are also considered.
[0080] In some embodiments of any embodiment described herein, the average molecular weight of the polymer containing basic groups is at least 1 kDa, or at least 2 kDa, or at least 3 kDa, or at least 5 kDa, or at least 10 kDa. In some embodiments of any embodiment described herein, the average molecular weight of the polymer containing basic groups ranges from about 1 kDa, or from about 2 kDa, or from about 3 kDa, or from about 5 kDa, or from about 10 kDa, or from about 100 kDa, or from about 200 kDa, or from about 300 kDa, or from about 400 kDa, or from about 500 kDa, or from about 500 kDa, to about 10000 kDa or more, including any intermediate values and subranges therebetween.
[0081] As used herein, the term "alkaline group" includes any functional group capable of accepting a proton in aqueous solution, such as a carboxylate or an amino group. It should be understood that a basic group can be converted to an acidic group (by protonation) or vice versa (by deprotonation) when in contact with a liquid having an appropriate acidity or alkalinity, as these terms are used in the art (e.g., depending on pH).
[0082] In any of some embodiments of the corresponding embodiments described herein, the polymer is characterized by a pKa of at least 1.2, optionally in the range of 1.2 to 7.5, and optionally in the range of 1.2 to 5.5 (including any intermediate values and subranges therebetween); for example, from 1.2 to 3 or from 2.5 to 3.5 or from 3 to 4 or from 3.5 to 4.5 or from 4 to 5 or from 4.5 to 5.5, including any intermediate values and subranges therebetween. In some such embodiments, the pKa is at least 2.5, or at least 3, or at least 3.5; for example, from 2.5 to 5.5, or from 3 to 5.5, or from 3.5 to 5.5, or from 4 to 5.5, or from 4.5 to 5.5, including any intermediate values and subranges therebetween.
[0083] As used herein, the "pKa" of a polymer refers to the pH value in 0.1 M NaCl aqueous solution at which 50% of the acid / base (eg, carboxylate) groups are protonated at 25°C.
[0084] According to some embodiments of the invention, carboxylate groups are exemplary basic groups.
[0085] As used herein, the term "carboxylate" refers to -C(=O)O - Groups (i.e., carboxylate anions) do not include carboxylic acid groups (-C(=O)OH) unless otherwise noted. It should be understood that when in contact with a liquid having appropriate acidity or alkalinity, the carboxylate group can be converted into a carboxylic acid group, and vice versa. For simplicity, some compounds and functional groups containing carboxylate groups (e.g., carboxymethyl, polyacrylic acid) described herein are named as being in the form of carboxylic acids, but unless otherwise specified, they should be understood to include multiple carboxylate groups.
[0086] The carboxylate group according to any of the corresponding embodiments described herein may optionally be accompanied by a counterion to form a salt, such as a pharmaceutically acceptable salt. Salts of compounds as described herein (pharmaceutically acceptable salts) may be formed during the synthesis of the compound, such as during separation of the compound from a reaction mixture or during recrystallization of the compound.
[0087] Examples of suitable counterions that the salts described herein may include include, but are not limited to, ammonium, guanidine, lithium, sodium, potassium, calcium, and magnesium. Sodium is an exemplary counterion.
[0088] Examples of suitable carboxylate group-containing polymers include, but are not limited to, alginates, salts of polyacrylic acid, polymethacrylic acid, and copolymers of acrylic acid and / or methacrylic acid, and carboxylate group-containing polysaccharide derivatives (e.g., derivatives obtained by oxidation or substitution with carboxylate-containing groups (e.g., carboxymethyl)).
[0089] Carboxylates can be optionally composed of repeating monomers (backbone units), and the repeating monomers include carboxylates, such as the urine form of carbohydrate units (such as mannuronic acid and guluronic acid monomers in alginate) and acrylates (such as in polyacrylates); by being connected to at least a portion of multiple monomers (for example, such as carboxymethyl cellulose and sodium starch glycolate) substituents (for example, carboxymethyl substituents, which can be optionally formed by polymers reacting with chloroacetic acid); and / or formed by oxidation of at least a portion of multiple monomers (backbone units), such as by destroying carbon-carbon bonds and / or oxidizing primary carbons (for example, in oxidized starch). In some exemplary embodiments, the polymer includes a carboxymethyl group connected to an oxygen atom.
[0090] The amino group may alternatively consist of repeating monomers (backbone units) comprising amino groups; for example, amino sugars, such as 2-amino-2-deoxy sugars (such as glucosamine in chitosan), and alkylene imine (such as ethylene imine) residues (such as the residue in polyethylene imine); and / or consist of substituents.
[0091] The polymer containing a basic group may optionally contain monomers (backbone units) that do not contain a basic group (e.g., acrylate, methacrylate, acrylamide, and methacrylamide), for example in a copolymer with acrylic or methacrylic monomers; and / or contain substituents that do not contain a basic group (e.g., substituted or unsubstituted alkyl groups such as methyl, ethyl, hydroxyethyl, and hydroxypropyl), for example, in a polymer that is also substituted with a basic group-containing substituent (e.g., a polysaccharide).
[0092] After oral administration, the basic group can neutralize the acid by protonation to form an acidic group (eg, a carboxylic acid group or an ammonium group), thereby increasing the pH of the solution in contact with the corresponding basic group-containing polymer.
[0093] Without being bound by any particular theory, the inventors believe that the acid-neutralizing polymers described herein are more suitable than traditional antacids because the polymer is a large molecule that is not easily diffused in the stomach (thus minimizing the dilution of the polymer), which can lead to a longer effective period. The inventors further believe that the polymers described herein provide the additional beneficial effect of forming a viscous medium (usually lacking in traditional antacids) that limits the influx of gastric acid into the absorption enhancer, thereby further reducing the inactivation of the absorption enhancer by gastric acid; and / or limits the diffusion of the absorption enhancer and / or therapeutically active agent throughout the stomach, thereby enhancing the effect of the absorption enhancer by maintaining a higher local concentration of the absorption enhancer near the therapeutically active agent. In this way, the composition can promote the absorption of the therapeutically effective agent over a longer period of time (e.g., by reducing the inactivation rate of the absorption enhancer through protonation and / or dilution) and / or increase the peak absorption rate of the therapeutically effective agent (e.g., as described herein, by providing a higher local concentration of the absorption enhancer in active form). The inventors further believe that this form of the viscous medium can promote adhesion of the composition to the stomach wall (eg, by increasing the contact area between the soft medium and the stomach wall), thereby promoting absorption through the stomach tissue.
[0094] In any of some embodiments of the embodiments described herein, the polymer containing basic groups swells when in contact with water (also referred to herein as "water-swellable" in the context of these embodiments). In some such embodiments, the polymer is not water-soluble.
[0095] As used herein, the phrase "swells upon contact with water" refers to the ability of a substance to absorb at least its own weight in water (i.e., the swelling capacity of the substance is at least 100%) when in contact with water (e.g., pure water) at 37°C, and optionally, to absorb at least twice its own weight in water (at least 200% swelling capacity), or at least 5 times its own weight (at least 500% swelling capacity), or at least 10 times its own weight, or at least 20 times its own weight.
[0096] "Swelling capacity" refers to the amount by which a material can increase its weight by a specified percentage of water before swelling. Swelling capacity (Qt) can be calculated using the following formula:
[0097] Qt = (Ws - Wd) / Ws * 100%.
[0098] Where Ws is the weight after expansion and Wd is the dry weight (weight before expansion).
[0099] As used herein, the term "water-soluble" means that the solubility of the compound in water (eg, pure water) at 37°C is at least 1 gram per liter.
[0100] As used herein, the term "water-insoluble" means that the solubility of the compound in water (eg, pure water) at 37°C is less than 1 g / L.
[0101] A common method for quantitatively determining the solubility of a substance is the "shake bottle method," in which an excess of the test substance is added to a volume (e.g., 100 ml) of a solvent (e.g., water) in a container (e.g., a flask or vial) and shaken under predetermined conditions (e.g., a temperature of 37° C.) to achieve thermodynamic equilibrium. The residual solids are then removed (e.g., by filtration and / or centrifugation), and the concentration of the dissolved substance is determined by techniques such as HPLC. The concentration can optionally be determined at different time points to determine that equilibrium has been reached.
[0102] Without being bound by any particular theory, the inventors believe that swelling upon contact with water (e.g., in gastric media) is advantageous because it enhances water penetration and maximizes contact between the surrounding solution and the basic groups upon oral administration. For example, even if the amount of basic groups is high, a polymer with a low degree of water penetration (e.g., into the polymer particles) may exhibit a slower than optimal gastric acid neutralization effect; for example, due to less effective diffusion of acid to the basic groups. The inventors further believe that water solubility, while also effective in maximizing contact between the surrounding solution and the basic groups, is less desirable than swelling because dissolution of the polymer disadvantageously results in less local effect (e.g., similar to the conventional antacids discussed herein).
[0103] In some embodiments described herein, the polymer is a cross-linked polymer.
[0104] The polymer can be cross-linked by covalent bonds, by cross-linking moieties that are covalently linked and thereby link two or more backbone units in the polymer, and / or by electrostatic bonds, by cross-linking moieties (e.g., cations, ions) that are electrostatically linked and thereby link two or more backbone units in the polymer. The number of cross-linking moieties determines the degree of cross-linking of the cross-linked polymer.
[0105] Without being bound by any particular theory, the inventors believe that cross-linking is advantageous because it minimizes dissolution of the polymer (e.g., in saliva and / or gastric acid), which may result in "wasting" of the polymer; and / or by enhancing water absorption (e.g., by disrupting bonds between different polymer chains, thereby facilitating the entry of water molecules between the chains). The degree of cross-linking may affect the ability to swell; for example, insufficient cross-linking may be associated with dissolution (the opposite of swelling) and / or reduced swelling and / or reduced water penetration. However, excessive cross-linking may reduce the swelling ability by limiting the swelling ability of the polymer and providing space for water to enter. The degree of cross-linking should not affect the acid neutralization ability of the polymer. The degree of cross-linking can be selected or predetermined based on the properties of each selected polymer to provide a desired level of hydration.
[0106] In some embodiments described herein, the polymer comprises a polysaccharide, such as a cross-linked polysaccharide. The polymer is optionally composed mainly (i.e., more than 50 weight percent) of glucose units, which may be optionally connected by glycosidic bonds, such as α(1→4) and / or α(1→6) glycosidic bonds (such as glycosidic bonds in starch) and / or β(1→4) glycosidic chains (such as glycosidic chains in cellulose).
[0107] The term "monosaccharide" as used herein and as is well known in the art refers to a simple form of sugar consisting of a single sugar molecule that cannot be further broken down by hydrolysis. The most common examples of monosaccharides include glucose (dextrose), fructose, galactose, and ribose. Monosaccharides can be classified according to the number of carbon atoms in the carbohydrate, i.e., trioses, which have 3 carbon atoms, such as glyceraldehyde and dihydroxyacetone; tetroses, which have 4 carbon atoms, such as erythrose, threose, and erythrulose; pentoses, which have 5 carbon atoms, such as arabinose, lyxose, ribose, xylose, ribulose, and xylulose; hexoses, which have 6 carbon atoms, such as allose, altrose, galactose, glucose, gulose, idose, mannose, talose, fructose, psicose, sorbose, and tagatose; heptoses, which have 7 carbon atoms, such as mannoheptulose and sedoheptulose; octose, which have 8 carbon atoms, such as 2-keto-3-deoxy-manno-octonate; nonoses, which have 9 carbon atoms, such as sialose; and decoses, which have 10 carbon atoms.
[0108] Monosaccharides are the building blocks of polysaccharides such as cellulose and starch.
[0109] The term "polysaccharide" as used herein refers to a compound comprising 10 or more monosaccharide units, as defined herein, which are linked to each other by glycosyl bonds (-O-). The glycosyl bonds between sugar units in the polysaccharide may all be the same, or may contain two or more glycosyl bonds, for example, glucose units are linked by α(1→4) and / or α(1→6) glycosidic bonds.
[0110] As used herein, the term "starch" encompasses polysaccharides composed of amylose (glucose units linked by α(1→4) glycosidic bonds) and amylopectin (glucose units linked by β(1→4) glycosidic bonds and α(1→6) glycosidic bonds). Different types of starch differ in the ratio between amylose and amylopectin, which generally depends on the source of the starch.
[0111] In any of the embodiments of some of the embodiments involving polysaccharides, the polysaccharide is a starch derivative and / or a cellulose derivative, i.e., starch and / or fibers (e.g., cross-linked starch and / or cross-linked cellulose) derivatized to contain basic (e.g., carboxylate) groups, e.g., by being substituted with carboxymethyl groups (e.g., wherein its oxygen atom is attached to the carboxymethyl group). Sodium starch glycolate is an exemplary starch derivative. Cross-linked sodium carboxymethyl cellulose is an exemplary cellulose derivative.
[0112] As used herein, "sodium starch glycolate" refers to any sodium starch salt substituted with carboxymethyl groups (as defined herein), which may be cross-linked or non-cross-linked. In any of some embodiments of certain corresponding embodiments, sodium starch glycolate is substituted with phosphate groups (-OP(=O)(-O - )-O-) covalent cross-links, with each phosphate group linking two (or more) sugar (glucose) units.
[0113] As used herein, "croscarmellose sodium" refers to any sodium salt of cellulose substituted with carboxymethyl groups (as defined herein) and covalently cross-linked by ester bonds between multiple carboxymethyl groups and sugar units.
[0114] A carboxymethyl group (or any other basic group) may be attached to one or more hydroxyl substituents of one or more sugar (e.g. glucose) units constituting the polysaccharide, thereby forming -O=CH 2 -C(=O)-O - Basic groups that replace monosaccharides at one or more positions. In some embodiments, a carboxymethyl group (or any other basic group) is at least connected to the hydroxymethyl groups of one or more glucose units that make up the polysaccharide. In some embodiments, a carboxymethyl group (or any other basic group) is connected to at least 10%, or at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90% or about all of the sugar units that make up the polysaccharide. In some of these embodiments, a carboxymethyl group (or any other basic group) is connected to the sugar units that contain the same; and in some of these embodiments, a carboxymethyl group (or any other basic group) is connected to the hydroxymethyl substituent of glucose.
[0115] In some embodiments described herein, the concentration of the polymer (according to any embodiment of the corresponding embodiments described herein) comprising multiple basic groups in the composition is at least 10 weight percent. In some such embodiments, the concentration of the polymer is at least 15 weight percent. In some embodiments, the concentration of the polymer is at least 20 weight percent. In some embodiments, the concentration of the polymer is at least 25 weight percent. In some embodiments, the concentration of the polymer is at least 30 weight percent. In some embodiments, the concentration of the polymer is at least 35 weight percent. In some embodiments, the concentration of the polymer is at least 40 weight percent. In some embodiments, the concentration of the polymer is at least 50 weight percent. In some embodiments, the concentration of the polymer is at least 60 weight percent. In some embodiments, the concentration of the polymer is at least 70 weight percent. In some embodiments, the concentration of the polymer is at least 80 weight percent. In some embodiments, the concentration of the polymer is at least 90 weight percent.
[0116] "Weight percent" (or w / w%, or % wt.) refers to the weight of the indicated substance in the total weight of the composition in which the substance is contained.
[0117] In some embodiments described herein, the concentration of the polymer comprising a plurality of basic groups in the composition (according to any of the corresponding embodiments described herein) ranges from 10 to 90 weight percent, or 10 to 80 weight percent, or 10 to 70 weight percent, or 10 to 50 weight percent, or 10 to 40 weight percent, or 10 to 30 weight percent, or 20 to 90 weight percent, or 20 to 80 weight percent, or 20 to 70 weight percent, or 20 to 60 weight percent, or 20 to 50 weight percent, or 20 to 40 weight percent, or 20 to 30 weight percent, or 30 to 90 weight percent, or 30 to 80 weight percent of the total weight of the composition. , or 30 to 70 weight percent, or 30 to 60 weight percent, or 30 to 50 weight percent, or 30 to 40 weight percent, or 40 to 90 weight percent, or 40 to 80 weight percent, or 40 or 70 weight percent, or 40 to 60 weight percent, or 40 to 50 weight percent, or 50 to 90 weight percent, or 50 to 80 weight percent, or 50 to 70 weight percent, or 50 to 60 weight percent, or 60 to 90 weight percent, or 60 to 80 weight percent, or 60 to 70 weight percent, or 80 to 90 weight percent, or 70 to 80 weight percent, or 80 to 90 weight percent, including any intermediate values and subranges therebetween.
[0118] Without being bound by any particular theory, the inventors believe that relatively high concentrations of water-absorbing (e.g., water-swellable) polymers such as sodium starch glycolate and cross-linked sodium carboxymethylcellulose (e.g., relative to compositions utilizing such polymers as disintegrants)) are associated with the generation of a viscous medium when in contact with an aqueous solution (e.g., gastric acid), which restricts diffusion around the composition, which is significantly different from their effect at lower concentrations (e.g., promoting disintegration of solid compositions).
[0119] Compositions utilizing such polymers as disintegrants further differ from compositions according to some embodiments of the present invention in that disintegrants are typically used in compositions that also include a large amount of insoluble components such as microcrystalline cellulose (e.g., as opposed to compositions that include a large amount of water-soluble components such as SNAC); for example, because the mechanism of the disintegrant involves exerting internal forces on solid insoluble ingredients and / or because the largely water-soluble components render the composition readily soluble, the disintegrant would be superfluous.
[0120] In any of some of the embodiments described herein in connection with unit dosage forms, the polysaccharide is characterized by a degree of substitution of at least 0.1; for example, in the range of from 0.1 to 2, or from 0.1 to 1.5, or from 0.1 to 1, or from 0.1 to 0.5, or from 0.1 to 0.3, or from 0.1 to 0.2, including any intermediate values and subranges therebetween. In some such embodiments, the degree of substitution is at least 0.2; for example, in the range of from 0.2 to 2, or from 0.2 to 1.5, or from 0.2 to 1, or from 0.2 to 0.5, including any intermediate values and subranges therebetween. In some embodiments, the degree of substitution is at least 0.3; for example, in the range of from 0.3 to 2, or from 0.3 to 1.5, or from 0.3 to 1, or from 0.3 to 0.5, including any intermediate values and subranges therebetween. In some embodiments, the degree of substitution is at least 0.4; for example, in a range from 0.4 to 2, or from 0.4 to 1.5, or from 0.4 to 1, including any intermediate values and subranges therebetween.
[0121] Herein, "degree of substitution" refers to the ratio of functional groups containing a basic group or its conjugate acid, such as carboxylate or carboxylic acid groups (such as carboxymethyl groups), to monomers (backbone units) of the polymer, such as sugar units of a polysaccharide.
[0122] In any embodiment of some embodiments of the corresponding embodiments described herein, the concentration of the basic groups of the polymer in the composition is at least 0.03 mmol per gram of the composition; for example, 0.03 to 5 mmol / gram, or 0.03 to 2 mmol / gram, or 0.03 to 1 mmol / gram, 0.03 to 0.5 mmol / gram, or 0.03 to 0.2 mmol / gram (including any intermediate values and subranges therebetween). In some embodiments, the concentration of the basic groups of the polymer is at least 0.1 mmol per gram of the composition; for example, 0.1 to 5 mmol / gram, or 0.1 to 2 mmol / gram, 0.1 to 1 mmol / gram, or 0.1 to 0.5 mmol / gram (including any intermediate values and subranges therebetween). In some embodiments, the concentration of the basic groups of the polymer is at least 0.2 millimoles per gram of composition; for example, 0.2 to 5 millimoles / gram, or 0.2 to 2 millimoles / gram, or 0.2 to 1 millimoles / gram, or 0.2 to 0.5 millimoles / gram (including any intermediate values and subranges therebetween). In some embodiments, the concentration of the basic groups of the polymer is at least 0.5 millimoles per gram of composition; for example, 0.5 to 5 millimoles / gram, or 0.5 to 2 millimoles / gram, or 0.5 to 1 millimoles / gram (including any intermediate values and subranges therebetween). In some embodiments, the concentration of the basic groups of the polymer is at least 1 millimole per gram of composition; for example, 1 to 5 millimoles / gram, or 1 to 2 millimoles / gram (including any intermediate values and subranges therebetween).
[0123] In some embodiments described herein, the composition is a unit dosage composition, and the amount of basic groups of the polymer in the unit dosage (related to the acid neutralization capacity of the polymer in the unit dosage) is at least 0.03 mmol; for example, 0.03 to 10 mmol, or 0.03 to 3 mmol, or 0.03 to 1 mmol, or 003 to 0.3 mmol, including any intermediate values and sub-ranges therebetween. In some embodiments, the amount of basic groups in the unit dosage is at least 0.1 mmol; for example, 0.1 to 10 mmol, 0.1 to 3 mmol, or 0.1 to 1 mmol, including any intermediate values and sub-ranges therebetween. In some embodiments, the amount of basic groups in the unit dosage is at least 0.3 mmol; for example, 0.3 to 10 mmol or 0.3 to 3 mmol, including any intermediate values and sub-ranges therebetween. In some embodiments, the amount of basic groups in the unit dosage is at least 1 mmol; for example, 1 to 10 mmol, including any intermediate values and sub-ranges therebetween.
[0124] As described above, according to any of the corresponding embodiments described herein, the polymer containing basic groups may optionally include two or more (e.g., at least 3, or at least 4) different polymers (e.g., a mixture) containing multiple basic groups. Thus, for example, sodium starch glycolate may represent a portion of all polymers containing basic groups, for example, at least 10 weight percent, or at least 20 weight percent, or at least 30 weight percent, or at least 40 weight percent, or at least 50 weight percent, or at least 60 weight percent, or at least 70 weight percent, or at least 80 weight percent, or at least 90 weight percent of the polymer containing basic groups (according to any of the corresponding embodiments described herein), and the remainder is one or more polymers containing basic groups other than sodium starch glycolate. Alternatively or additionally, croscarmellose sodium may represent a portion of all polymers containing basic groups, for example, at least 10 weight percent, or at least 20 weight percent, or at least 30 weight percent, or at least 40 weight percent, or at least 50 weight percent, or at least 60 weight percent, or at least 70 weight percent, or at least 80 weight percent, or at least 90 weight percent of the polymers containing basic groups (according to any of the corresponding embodiments described herein), the remainder being one or more polymers containing basic groups other than croscarmellose sodium.
[0125] It is noteworthy that polymers generally contain populations of molecules of different sizes and slightly different geometries (e.g., branching patterns and / or sequences of monomers in copolymers). According to standard practice in the art, such populations of molecules are not considered to represent "different polymers." Rather, "different polymers" refer to chemical differences, such as polymers composed of different monomers (backbone units) and / or cross-linking agents and / or different degrees of cross-linking.
[0126] The effect of polymer on the absorption of therapeutically active agents can optionally be determined by comparing the absorption of a composition according to an embodiment of the present invention when administered orally with a corresponding composition containing the same amount of other ingredients except the polymer containing basic groups (e.g., when the polymer containing basic groups does not exceed 50 weight percent of the composition according to an embodiment of the present invention), such as making the total mass lower (due to the absence of the compound containing basic groups). In some such embodiments, both compositions are in the form of tablets, the tablets have the same cross-section (e.g., the diameter of the circular cross-section), and the lighter tablet is thinner on an axis perpendicular to the cross-section of the tablet.
[0127] Alternatively, the effect of the polymer on the absorption of the therapeutically active agent can optionally be determined by comparing the absorption of a composition according to embodiments of the present invention when administered orally with a corresponding composition comprising an absorption enhancer in place of the polymer containing a basic group (e.g., the corresponding composition is identical in all respects except for the presence of the additional absorption enhancer in place of the polymer), such that the total mass of the composition is the same (e.g., when the basic group-containing polymer exceeds 50 weight percent of the composition according to embodiments of the present invention).
[0128] In any of some embodiments of the respective embodiments described herein, the C of the composition (ie, the therapeutically active agent in the composition) after oral administration is 最大 and / or bioavailability compared to the corresponding composition without the basic polymer 最大 and / or bioavailability is at least 20% higher. In some embodiments, after oral administration, C 最大 and / or bioavailability compared to the corresponding composition of the polymer without basic groups 最大 and / or bioavailability is at least 50% higher (150% level). In some embodiments, after oral administration, C 最大 and / or bioavailability compared to the corresponding composition of the polymer without basic groups 最大 and / or bioavailability is at least two times higher (200% level). In some embodiments, after oral administration, C 最大 and / or bioavailability compared to the corresponding composition of the polymer without basic groups 最大 and / or bioavailability is at least four times higher (level of 400%). In some embodiments, after oral administration, C 最大 and / or bioavailability compared to the corresponding composition of the polymer without basic groups 最大 and / or bioavailability is at least six times higher (level of 600%). In some embodiments, after oral administration, C 最大 and / or bioavailability compared to the corresponding composition of the polymer without basic groups 最大 and / or the bioavailability is at least ten times higher (1000% level).
[0129] C 最大 And / or bioavailability can alternatively be determined by orally administering the composition to a subject (eg, a human subject) and determining the level of the therapeutically active agent in the blood at frequent intervals by collecting blood samples.
[0130] Bioavailability can be determined by comparing the area under the curve for oral administration (e.g., within 12 or 24 hours) to the ratio of the area under the curve for intravenous administration of the therapeutically active agent over the same time period using standard techniques known in the art (e.g., data processing algorithms). The therapeutically active agent may be injected at a lower dose (e.g., for safety reasons), and the area under the curve normalized to the amount administered.
[0131] Absorption Enhancers:
[0132] According to any of the preferred embodiments described herein, the composition according to any of the corresponding embodiments described herein comprises an effective amount of an absorption enhancer, ie an amount of the absorption enhancer effective to enhance absorption of the therapeutically active agent in the composition.
[0133] As used herein, the term "absorption enhancer" refers to compounds known to enhance the absorption of macromolecular drugs (e.g., compounds having a molecular weight of at least 1 kDa) and / or BCS Class III drugs (as described herein) from the gastrointestinal tract into the circulation following oral administration of the drug. One skilled in the art will recognize many such absorption enhancers. In some embodiments of any of the foregoing embodiments, the absorption enhancer is a compound that enhances the absorption of a macromolecular drug.
[0134] In some embodiments of any of the embodiments described herein, the absorption enhancer is a fatty acid, optionally with a terminal N-(2-hydroxybenzoyl)amino group (at the ω position, i.e., distal to the fatty acid carboxylic acid group), or a salt thereof (e.g., a monosodium salt or a disodium salt). Alternatively, the fatty acid can optionally be an unsubstituted fatty acid (e.g., caproic acid, caprylic acid, capric acid, lauric acid, oleic acid, and / or stearic acid).
[0135] The fatty acid (substituted or unsubstituted) is preferably 4 to 20 carbon atoms in length, 4 to 16 carbon atoms in length, 4 to 14 carbon atoms in length, 4 to 12 carbon atoms in length, 4 to 10 carbon atoms in length (including any intermediate values and subranges therebetween). In some embodiments of any embodiment described herein, the fatty acid (substituted or unsubstituted) is 6 to 20 carbon atoms in length, 6 to 18 carbon atoms in length, 6 to 16 carbon atoms in length, 6 to 14 carbon atoms in length, 6 to 12 carbon atoms in length, 6 to 10 carbon atoms in length, and 8 to 10 carbon atoms in length (including any intermediate values and subranges therebetween). The fatty acid moiety can be saturated (eg, caprylic acid in 8-N-(2-hydroxybenzoyl)aminocaprylic acid and capric acid in 10-N-(2-hydroxybenzoyl)aminodecanoic acid) or unsaturated (ie, contain at least one unsaturated carbon-carbon bond).
[0136] Examples of suitable fatty acids (eg, substituted with a terminal N-(2-hydroxybenzoyl)amino group) include, but are not limited to, butyric acid, caprylic acid, and capric acid.
[0137] N-(2-hydroxybenzoyl)amino may optionally be substituted or unsubstituted (e.g., on its aromatic ring). Suitable substituents include, for example, halogen (optionally chlorine) and alkoxy (optionally methoxy). Examples of substituted N-(2-hydroxybenzoyl)amino include, but are not limited to, N-(5-chlorosalicyloyl)amino, N-(4-chloro-2-hydroxybenzoyl)amino, and N-(2-hydroxy-4-methoxybenzoyl)amino.
[0138] Examples of suitable absorption enhancers include, but are not limited to, NAC (8-N-(2-hydroxybenzoyl) aminocaprylic acid) and NAD (10-N-(2-hydroxybenzoyl) aminodecanoic acid) and their salts (e.g., monosodium and disodium salts); and their derivatives (e.g., derivatives substituted with chlorine and / or methoxy groups), such as 5-CNAC (8-N-(5-chlorosalicyloyl) aminocaprylic acid) and 4-MOAC (8-N(2-hydroxy-4-methoxybenzoyl) aminohexanoic acid) and their salts (e.g., monosodium and disodium salts). 4-CNAB (4-N-(2-hydroxy-4-chlorobenzoyl) aminobutyric acid) and its salts (e.g., monosodium and disodium salts) are additional examples of suitable absorption enhancers.
[0139] In some embodiments of any of the embodiments described herein, the absorption enhancer is in the form of a salt thereof, such as a sodium salt. In an exemplary embodiment, the sodium salt is a monosodium salt.
[0140] In some embodiments of any of the embodiments described herein, the absorption enhancer is NAC or NAC, or a salt thereof. In some such embodiments, the absorption enhancer is NAC or a salt thereof.
[0141] As shown in the figure below, the structure of NAD (represented as its sodium salt, also known as "SNAD") differs from that of NAC (represented as its sodium salt, also known as "SNAC") only in the length of the fatty acid portion. Based on the different fatty acid lengths, additional absorption enhancers associated with NAC and NAD will be readily apparent to those skilled in the art.
[0142]
[0143] Without being bound by any particular theory, the inventors believe that many absorption enhancers tend to be more active (in terms of enhancing absorption) in ionic form (e.g., carboxylate anions, such as fatty acid anions) than in less soluble non-ionic forms (e.g., carboxylic acids, such as fatty acid esters), and that the overall activity of the absorption enhancer is strongly dependent on the concentration of the more active form. For example, the activity of the less soluble non-ionic form may be reduced by precipitation. The inventors further believe that the amount of the absorption enhancer that dissolves in ionic form after oral administration can be increased by providing the absorption enhancer in salt form and / or by controlling the local pH in the vicinity of the absorption enhancer upon oral administration (e.g., by acid neutralization of the basic groups of the polymers described herein and / or even by other molecules of the absorption enhancer).
[0144] According to any of some of the embodiments described herein, the absorption enhancer is an ionizable material (compound), and in some of these embodiments, the absorption enhancer is more active in its ionic form.
[0145] According to any of some of the embodiments described herein, the absorption enhancer is inactivated by gastric acid as described herein, in some of these embodiments, the absorption enhancer is ionizable and is more active in its ionic form, while at least a portion of the absorption enhancer exists in a non-ionic form (less active) when contacted with gastric acid (e.g., due to precipitation).
[0146] The inventors further believe that the formation of a viscous medium can enhance the effect of an absorption enhancer (which is not inactivated by gastric acid), for example, by maintaining a higher local concentration of the absorption enhancer near the therapeutically active agent and / or promoting adhesion of the composition to the stomach wall (e.g., as described herein).
[0147] Additionally or alternatively, control of the local pH associated with the polymer can protect the therapeutically active agent from inactivation by gastric acid (regardless of whether the absorption enhancer is inactivated by gastric acid), for example, where the agent is a polypeptide, inactivation associated with pepsin activity in the presence of moderately acidic pH (e.g., as described elsewhere herein).
[0148] According to any of some of the embodiments described herein, the absorption enhancer is not inactivated by gastric acid, e.g., it is not ionizable and / or its ionic and non-ionic forms exhibit the same activity and / or is not converted into a less active form when in contact with gastric acid (e.g., the absorption enhancer itself is acidic).
[0149] Examples of absorption enhancers that are not expected to be inactivated by gastric acid include, but are not limited to, alkyl fatty acid esters (e.g., isopropyl myristate); phospholipids (e.g., phosphatidylcholine); quaternary ammonium salts, such as tetraalkylammonium salts (e.g., cetyltrimethylammonium salts, such as cetyltrimethylammonium bromide) and alkylpyridinium salts (e.g., cetylpyridinium salts, such as cetylpyridinium chloride); nonionic surfactants, such as sorbitan fatty acid esters (e.g., sorbitan monolaurate, sorbitan monostearate, sorbitan tristearate) and polysorbates (i.e., ethoxylated sorbitan fatty acid esters, such as polysorbate 20, polysorbate 40, polysorbate 60, and polysorbate 80); and N-dodecylcaprolactam.
[0150] In any of some of the embodiments described herein, the concentration of the absorption enhancer (according to any of the corresponding embodiments described herein) in the composition (according to any of the corresponding embodiments described herein) is at least 10 weight percent; for example, from 10 to 90 weight percent, or from 10 to 80 weight percent, or from 10 to 70 weight percent, or from 10 to 60 weight percent, or from 10 to 50 weight percent, or 10 to 40 weight percent, or 10 to 30 weight percent (including any intermediate values and sub-ranges therebetween). In some such embodiments, the concentration of the absorption enhancer is at least 20 weight percent; for example, from 20 to 90 weight percent, or from 20 to 80 weight percent, or from 20 to 70 weight percent, or from 20 to 60 weight percent, or from 20 to 50 weight percent, or from 20 to 40 weight percent (including any intermediate values and sub-ranges therebetween). In some embodiments, the concentration of the absorption enhancer is at least 30 weight percent; for example, from 30 to 90 weight percent, or from 30 to 80 weight percent, or from 30 to 70 weight percent, or from 30 to 60 weight percent, or from 30 to 50 weight percent (including any intermediate values and sub-ranges therebetween). In some embodiments, the concentration of the absorption enhancer is at least 40 weight percent; for example, from 40 to 90 weight percent, or from 40 to 80 weight percent, or from 40 to 70 weight percent, or from 40 to 60 weight percent (including any intermediate values and sub-ranges therebetween). In some embodiments, the concentration of the absorption enhancer is at least 50 weight percent; for example, from 50 to 90 weight percent, or from 50 to 80 weight percent, or from 50 to 70 weight percent (including any intermediate values and sub-ranges therebetween). In some embodiments, the concentration of the absorption enhancer is at least 60 weight percent; for example, from 60 to 90 weight percent, or from 60 to 80 weight percent (including any intermediate values and sub-ranges therebetween). In some embodiments, the concentration of the absorption enhancer is at least 70 weight percent; for example, from 70 to 90 weight percent, or from 70 to 80 weight percent (including any intermediate values and subranges therebetween). In some embodiments, the concentration of the absorption enhancer is at least 80 weight percent; for example, from 80 to 90 weight percent (including any intermediate values and subranges therebetween).
[0151] In some embodiments of any of the above embodiments, the absorption enhancer is NAC, NAD, 5-CNAC, 4-MOAC and / or 4-CNAB, or a salt thereof (eg, a sodium salt thereof).
[0152] In any of some of the embodiments described herein, the total concentration of the absorption enhancer (according to any of the corresponding embodiments described herein) and the polymer containing the basic group (according to any of the corresponding embodiments described herein) is at least 80 weight percent (e.g., 80 to 100 weight percent, including any intermediate values and sub-ranges therebetween). In some such embodiments, the concentration of the absorption enhancer is at least 10 weight percent, or at least 20 weight percent, or at least 30 weight percent, or at least 40 weight percent, or at least 50 weight percent, or at least 60 weight percent, or at least 70 weight percent (e.g., according to any of the corresponding embodiments described herein). Alternatively or additionally, in some embodiments, the concentration of the polymer containing the basic group is at least 10 weight percent, or at least 20 weight percent, or at least 30 weight percent, or at least 40 weight percent, or at least 50 weight percent, or at least 60 weight percent, or at least 70 weight percent (e.g., according to any of the corresponding embodiments described herein). In some embodiments of any of the above embodiments, the absorption enhancer is NAC, NAD, 5-CNAC, 4-MOAC and / or 4-CNAB, or a salt thereof (eg, a sodium salt thereof).
[0153] In any of some of the embodiments described herein, the total concentration of the absorption enhancer (according to any of the corresponding embodiments described herein) and the polymer containing the basic group (according to any of the corresponding embodiments described herein) is at least 90 weight percent (e.g., 90 to 100 weight percent, including any intermediate values and sub-ranges therebetween). In some such embodiments, the concentration of the absorption enhancer is at least 10 weight percent, or at least 20 weight percent, or at least 30 weight percent, or at least 40 weight percent, or at least 50 weight percent, or at least 60 weight percent, or at least 70 weight percent, or at least 80 weight percent (e.g., according to any of the corresponding embodiments described herein). Alternatively or additionally, in some embodiments, the concentration of the polymer containing the basic group is at least 10 weight percent, or at least 20 weight percent, or at least 30 weight percent, or at least 40 weight percent, or at least 50 weight percent, or at least 60 weight percent, or at least 70 weight percent, or at least 80 weight percent (e.g., according to any of the corresponding embodiments described herein). In some embodiments of any of the above embodiments, the absorption enhancer is NAC, NAD, 5-CNAC, 4-MOAC and / or 4-CNAB, or a salt thereof (eg, a sodium salt thereof).
[0154] In any of some of the embodiments described herein, the total concentration of the absorption enhancer (according to any of the corresponding embodiments described herein) and the polymer containing the basic group (according to any of the corresponding embodiments described herein) is at least 95% by weight (e.g., 95 to 100% by weight, including any intermediate values and sub-ranges therebetween). In some such embodiments, the concentration of the absorption enhancer is at least 10% by weight, or at least 20% by weight, or at least 30% by weight, or at least 40% by weight, or at least 50% by weight, or at least 60% by weight, or at least 70% by weight, or at least 80% by weight (e.g., according to any of the corresponding embodiments described herein). Alternatively or additionally, in some embodiments, the concentration of the polymer containing the basic group is at least 10% by weight, or at least 20% by weight, or at least 30% by weight, or at least 40% by weight, or at least 50% by weight, or at least 60% by weight, or at least 70% by weight, or at least 80% by weight (e.g., according to any of the corresponding embodiments described herein). In some embodiments of any of the above embodiments, the absorption enhancer is NAC, NAD, 5-CNAC, 4-MOAC and / or 4-CNAB, or a salt thereof (eg, a sodium salt thereof).
[0155] In any of some of the embodiments described herein, the total concentration of the absorption enhancer (according to any of the corresponding embodiments described herein) and the polymer containing the basic group (according to any of the corresponding embodiments described herein) is at least 98 weight percent. In some such embodiments, the concentration of the absorption enhancer is at least 10 weight percent, or at least 20 weight percent, or at least 30 weight percent, or at least 40 weight percent, or at least 50 weight percent, or at least 60 weight percent, or at least 70 weight percent, or at least 80 weight percent (e.g., according to any of the corresponding embodiments described herein). In some embodiments, the concentration of the polymer containing the basic group is at least 10 weight percent, or at least 20 weight percent, or at least 30 weight percent, or at least 40 weight percent, or at least 50 weight percent, or at least 60 weight percent, or at least 70 weight percent, or at least 80 weight percent (e.g., according to any of the corresponding embodiments described herein). In some embodiments of any of the above embodiments, the absorption enhancer is NAC, NAD, 5-CNAC, 4-MOAC and / or 4-CNAB, or a salt thereof (e.g., a sodium salt thereof).
[0156] In any of some of the embodiments described herein relating to unit dosage forms, the amount of absorption enhancer in the unit dosage form is at least 25 mg; e.g., 25 to 1000 mg, or 25 to 500 mg, or 25 to 250 mg, or 25 to 100 mg, or 25 to 50 mg, including any intermediate values and subranges therebetween. In some embodiments, the amount of absorption enhancer in the unit dosage form is at least 50 mg; e.g., 50 to 1000 mg, or 50 to 500 mg, or 50 to 250 mg, or 50 to 100 mg, including any intermediate values and subranges therebetween. In some embodiments, the amount of absorption enhancer in the unit dosage form is at least 75 mg; e.g., 75 to 1000 mg, or 75 to 500 mg, or 75 to 250 mg, including any intermediate values and subranges therebetween. In some embodiments, the amount of absorption enhancer in the unit dosage form is at least 100 mg; for example, 100 to 1000 mg, or 100 to 500 mg, or 100 to 250 mg, including any intermediate values and subranges therebetween. In some embodiments, the amount of absorption enhancer in the unit dosage form is at least 150 mg; for example, 150 to 1000 mg, or 150 to 500 mg, or 150 to 250 mg, including any intermediate values and subranges therebetween. In some embodiments, the amount of absorption enhancer in the unit dosage form is at least 200 mg; for example, 200 to 1000 mg, or 200 to 500 mg, including any intermediate values and subranges therebetween. In some embodiments, the amount of absorption enhancer in the unit dosage form is at least 300 mg; for example, 300 to 1000 mg, or 300 to 500 mg, including any intermediate values and subranges therebetween. In some embodiments of any of the above embodiments, the absorption enhancer is NAC (8-N-(2-hydroxybenzoyl)aminocaprylic acid or a salt thereof (eg, sodium 8-N-(2-hydroxybenzoyl)aminocaprylate).
[0157] In any of some embodiments of the corresponding embodiments described herein, the weight ratio of the absorption enhancer to the therapeutically active agent in the composition is at least 1:1 (absorption enhancer:therapeutic active agent), optionally in the range of from 1:1 to 1000:1, or from 1:1 to 500:1, or from 1:1 to 300:1, or from 1:1 to 200:1, or from 1:1 to 100:1, or from 1:1 to 50:1, or from 1:1 to 30:1, or from 1:1 to 20:1, or from 1:1 to 10:1, or from 1:1 to 5:1, or from 1:1 to 3:1, or from 1:1 to 2:1 (absorption enhancer:therapeutically active agent), including any intermediate values and sub-ranges therebetween. In some of the above embodiments, the absorption enhancer is NAC (8-N-(2-hydroxybenzoyl)aminocaprylic acid) or a salt thereof (eg, sodium 8-N-(2-hydroxybenzoyl)aminocaprylic acid).
[0158] In any of some embodiments of the corresponding embodiments described herein, the weight ratio of the absorption enhancer to the therapeutically active agent in the composition is at least 2:1 (absorption enhancer: therapeutically active agent), optionally in the range of from 2:1 to 1000:1, or from 2:1 to 500:1, or from 2:1 to 300:1, or from 2:1 to 200:1, or from 2:1 to 100:1, or from 2:1 to 50:1, or from 2:1 to 30:1, or from 2:1 to 20:1, or from 2:1 to 10:1, or from 2:1 to 5:1, or from 2:1 to 3:1 (absorption enhancer: therapeutically active agent), including any intermediate values and subranges therebetween. In some of the above embodiments, the absorption enhancer is NAC (8-N-(2-hydroxybenzoyl)aminocaprylic acid) or a salt thereof (e.g., sodium 8-N-(2-hydroxybenzoyl)aminocaprylate).
[0159] In any of some embodiments of the embodiments described herein, the weight ratio of the absorption enhancer to the therapeutically active agent in the composition is at least 3:1 (absorption enhancer: therapeutically active agent), optionally in the range of from 3:1 to 1000:1, or from 3:1 to 500:1, or from 3:1 to 300:1, or from 3:1 to 200:1, or from 3:1 to 100:1, or from 3:1 to 50:1, or from 3:1 to 30:1, or from 3:1 to 20:1, or from 3:1 to 10:1, or from 3:1 to 5:1 (absorption enhancer: therapeutically active agent), including any intermediate values and sub-ranges therebetween. In some of the above embodiments, the absorption enhancer is NAC (8-N-(2-hydroxybenzoyl)aminocaprylic acid) or a salt thereof (e.g., sodium 8-N-(2-hydroxybenzoyl)aminocaprylate).
[0160] In any of some of the embodiments described herein, the weight ratio of the absorption enhancer to the therapeutically active agent in the composition is at least 5:1 (absorption enhancer: therapeutically active agent), optionally in the range of from 5:1 to 1000:1, or from 5:1 to 500:1, or from 5:1 to 300:1, or from 5:1 to 200:1, or from 5:1 to 100:1, or from 5:1 to 50:1, or from 5:1 to 30:1, or from 5:1 to 20:1, or from 5:1 to 10:1 (absorption enhancer: therapeutically active agent), including any intermediate values and subranges therebetween. In some of the above embodiments, the absorption enhancer is NAC (8-N-(2-hydroxybenzoyl)aminocaprylic acid) or a salt thereof (e.g., sodium 8-N-(2-hydroxybenzoyl)aminocaprylate).
[0161] The weight ratio of the absorption enhancer to the therapeutically active agent in the composition is at least 10:1 (absorption enhancer: therapeutically active agent), optionally in the range of from 10:1 to 1000:1, or from 10:1 to 500:1, or from 10:1 to 300:1, or from 10:1 to 200:1, or from 10:1 to 100:1, or from 10:1 to 50:1, or from 10:1 to 30:1, or from 10:1 to 20:1 (absorption enhancer: therapeutically active agent), including any intermediate values and subranges therebetween. In some of the above embodiments, the absorption enhancer is NAC (8-N-(2-hydroxybenzoyl)aminocaprylic acid) or a salt thereof (e.g., sodium 8-N-(2-hydroxybenzoyl)aminocaprylate).
[0162] In some embodiments of any of the embodiments described herein, the weight ratio of the absorption enhancer to the therapeutically active agent in the composition is at least 20:1 (absorption enhancer: therapeutically active agent), optionally in the range of from 20:1 to 1000:1, or from 20:1 to 500:1, or from 20:1 to 300:1, or from 20:1 to 200:1, or from 20:1 to 100:1, or from 20:1 to 50:1, or from 20:1 to 30:1 (absorption enhancer: therapeutically active agent), including any intermediate values and subranges therebetween. In some of the above embodiments, the absorption enhancer is NAC (8-N-(2-hydroxybenzoyl)aminocaprylic acid) or a salt thereof (e.g., sodium 8-N-(2-hydroxybenzoyl)aminocaprylate).
[0163] In some embodiments of any of the embodiments described herein, the weight ratio of the absorption enhancer to the therapeutically active agent in the composition is at least 30:1 (absorption enhancer: therapeutically active agent), optionally in the range of from 30:1 to 1000:1, or from 30:1 to 500:1, or from 30:1 to 300:1, or from 30:1 to 200:1, or from 30:1 to 100:1, or from 30:1 to 50:1 (absorption enhancer: therapeutically active agent), including any intermediate values and subranges therebetween. In some of the above embodiments, the absorption enhancer is NAC (8-N-(2-hydroxybenzoyl)aminocaprylic acid) or a salt thereof (e.g., sodium 8-N-(2-hydroxybenzoyl)aminocaprylate).
[0164] In any of some of the embodiments described herein, the weight ratio of the absorption enhancer to the therapeutically active agent in the composition is at least 50:1 (absorption enhancer: therapeutically active agent), optionally in the range of from 50:1 to 1000:1, or from 50:1 to 500:1, or from 50:1 to 300:1, or from 50:1 to 200:1, or from 50:1 to 100:1 (absorption enhancer: therapeutically active agent), including any intermediate values and subranges therebetween. In some of the above embodiments, the absorption enhancer is NAC (8-N-(2-hydroxybenzoyl)aminocaprylic acid) or a salt thereof (e.g., sodium 8-N-(2-hydroxybenzoyl)aminocaprylate).
[0165] In some embodiments of any of the embodiments described herein, the weight ratio of the absorption enhancer to the therapeutically active agent in the composition is at least 100:1 (absorption enhancer: therapeutically active agent), optionally in the range of from 100:1 to 1000:1, or from 100:1 to 500:1, or from 100:1 to 300:1, or from 100:1 to 200:1 (absorption enhancer: therapeutically active agent), including any intermediate values and subranges therebetween. In some of the above embodiments, the absorption enhancer is NAC (8-N-(2-hydroxybenzoyl)aminocaprylic acid) or a salt thereof (e.g., sodium 8-N-(2-hydroxybenzoyl)aminocaprylate).
[0166] In some embodiments of any of the embodiments described herein, the weight ratio of the absorption enhancer to the therapeutically active agent in the composition is at least 200:1 (absorption enhancer: therapeutically active agent), optionally in the range of from 200:1 to 1000:1, or from 200:1 to 500:1, or from 200:1 to 300:1 (absorption enhancer: therapeutically active agent), including any intermediate values and subranges therebetween. In some of the above embodiments, the absorption enhancer is NAC (8-N-(2-hydroxybenzoyl)aminocaprylic acid) or a salt thereof (e.g., sodium 8-N-(2-hydroxybenzoyl)aminocaprylate).
[0167] In some embodiments of any of the embodiments described herein, the weight ratio of the absorption enhancer to the therapeutically active agent in the composition is at least 300:1 (absorption enhancer: therapeutically active agent), optionally in the range of from 300:1 to 1000:1, or from 300:1 to 500:1 (absorption enhancer: therapeutically active agent), including any intermediate values and subranges therebetween. In some of the above embodiments, the absorption enhancer is NAC (8-N-(2-hydroxybenzoyl)aminocaprylic acid) or a salt thereof (e.g., sodium 8-N-(2-hydroxybenzoyl)aminocaprylate).
[0168] In some embodiments of any of the embodiments described herein, the weight ratio of the absorption enhancer to the therapeutically active agent in the composition is at least 500:1 (absorption enhancer: therapeutically active agent), optionally in the range of from 500:1 to 1000:1 (absorption enhancer: therapeutically active agent), including any intermediate values and subranges therebetween. In some of the above embodiments, the absorption enhancer is NAC (8-N-(2-hydroxybenzoyl)aminocaprylic acid) or a salt thereof (e.g., sodium 8-N-(2-hydroxybenzoyl)aminocaprylate).
[0169] Therapeutically active agents:
[0170] The compositions described herein are particularly useful for enhancing the absorption of therapeutically active agents whose absorption is limited upon oral administration, for example, by large molecular weight, high hydrophilicity (e.g., which inhibits crossing lipid membranes in the gastrointestinal tract), and / or degradation in the gastrointestinal tract (e.g., by proteolysis), such as degradation by pepsin and / or gastric acid in the stomach.
[0171] In any embodiment of some embodiments of the embodiments described herein, the therapeutically active agent according to any corresponding embodiment described herein has a molecular weight of at least 0.5 kDa. In some embodiments, the molecular weight is in the range of 0.5 to 150 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 0.5 to 100 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 0.5 to 75 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 0.5 to 50 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 0.5 to 30 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 0.5 to 20 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 0.5 to 10 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 0.5 to 7.5 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 0.5 to 5 kDa, including any intermediate values and subranges therebetween.
[0172] In any of some embodiments described herein, the molecular weight of the therapeutically active agent is at least 1 kDa. In some embodiments, the molecular weight is in the range of 1 to 150 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 1 to 100 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 1 to 75 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 1 to 50 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 1 to 30 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 1 to 20 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 1 to 10 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 1 to 7.5 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 1 to 5 kDa, including any intermediate values and sub-ranges therebetween.
[0173] In any of some embodiments described herein, the molecular weight of the therapeutically active agent is at least 2 kDa. In some embodiments, the molecular weight is in the range of 2 to 150 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 2 to 100 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 2 to 75 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 2 to 50 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 2 to 30 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 2 to 20 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 2 to 10 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 2 to 7.5 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 2 to 5 kDa, including any intermediate values and sub-ranges therebetween.
[0174] In any of some embodiments described herein, the molecular weight of the therapeutically active agent is at least 3 kDa. In some embodiments, the molecular weight is in the range of 3 to 150 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 3 to 100 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 3 to 75 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 3 to 50 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 3 to 30 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 3 to 20 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 3 to 10 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 3 to 7.5 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 3 to 5 kDa, including any intermediate values and sub-ranges therebetween.
[0175] In any of some embodiments described herein, the molecular weight of the therapeutically active agent is at least 4 kDa. In some embodiments, the molecular weight is in the range of 4 to 150 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 4 to 100 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 4 to 75 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 4 to 50 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 4 to 30 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 4 to 20 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 4 to 10 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 4 to 7.5 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 4 to 5 kDa, including any intermediate values and sub-ranges therebetween.
[0176] In any of some embodiments described herein, the molecular weight of the therapeutically active agent is at least 5 kDa. In some embodiments, the molecular weight is in the range of 5 to 150 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 5 to 100 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 5 to 75 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 5 to 50 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 5 to 30 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 5 to 20 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 5 to 10 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 5 to 7.5 kDa, including any intermediate values and sub-ranges therebetween.
[0177] In any of some embodiments described herein, the molecular weight of the therapeutically active agent is at least 10 kDa. In some embodiments, the molecular weight is in the range of 10 to 150 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 10 to 100 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 10 to 75 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 10 to 50 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 10 to 30 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 10 to 20 kDa, including any intermediate values and sub-ranges therebetween.
[0178] In any of some embodiments described herein, the molecular weight of the therapeutically active agent is at least 20 kDa. In some embodiments, the molecular weight is in the range of 20 to 150 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 20 to 100 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 20 to 75 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 20 to 50 kDa, including any intermediate values and sub-ranges therebetween. In some embodiments, the molecular weight is in the range of 20 to 30 kDa, including any intermediate values and sub-ranges therebetween.
[0179] In any of some embodiments described herein, the molecular weight of the therapeutically active agent is at least 50 kDa. In some embodiments, the molecular weight is in the range of 50 to 150 kDa, including any intermediate values and subranges therebetween. In some embodiments, the molecular weight is in the range of 50 to 100 kDa, including any intermediate values and subranges therebetween. In some embodiments, the molecular weight is in the range of 50 to 75 kDa, including any intermediate values and subranges therebetween.
[0180] Without being bound by any particular theory, the inventors believe that pharmaceutical agents having relatively high molecular weights (e.g., at least 0.5 kDa, at least 1 kDa, at least 2 kDa, at least 3 kDa, at least 4 kDa) tend to be less efficiently absorbed when orally administered than relatively smaller molecules (e.g., molecules having a molecular weight of less than 0.5 kDa or less than 1 kDa), and therefore, their absorption is particularly susceptible to being enhanced by the activity of absorption enhancers (e.g., NAC or a salt thereof) according to any of the corresponding embodiments described herein.
[0181] In any of some of the embodiments described herein, the therapeutically active agent is a polypeptide or a nucleic acid.
[0182] Without being bound by any particular theory, the inventors believe that substances such as polypeptides or nucleic acids are often poorly absorbed after oral administration, for example, due to their polarity and / or relatively large molecular weight; therefore, their absorption is particularly susceptible to the enhancement of the activity of absorption enhancers (such as NAC or its salts), and the increase in the activity of the absorption enhancer by the polymer containing basic groups according to any corresponding embodiment described herein. The inventors further believe that the absorption of polypeptides is further subject to pH-dependent degradation by the activity of enzymes such as pepsin, and that the increase in pH associated with the polymer containing basic groups can enhance the absorption of polypeptides by reducing pepsin activity (in addition to increasing the activity of the absorption enhancer, as described herein).
[0183] In any of the embodiments described herein, the therapeutically active agent is a hormone and / or cytokine (e.g., a hormone), an enzyme and / or an antigen (e.g., where the composition is used as a vaccine). In some embodiments, the hormone and / or cytokine is a polypeptide hormone and / or cytokine, or an analog thereof.
[0184] Herein, "analogs" of a given polypeptide or nucleic acid include various derivatives of the polypeptide / nucleic acid (e.g., synthetic analogs), such as homologues (as defined herein), fragments (fragments comprising homologues), and substituted derivatives (e.g., comprising substituents for enhancing stability and / or half-life) or homologues and / or fragments of the polypeptide / nucleic acid. Preferably, the analogs exhibit the biological activity of the polypeptide / nucleic acid.
[0185] According to embodiments of the present invention, examples of polypeptides (either themselves or their analogs) that can be used as therapeutic active agents include, but are not limited to, antibodies (e.g., monoclonal antibodies), anti-pathogenic peptides, such as antimicrobial peptides (e.g., bacitracin, boceprevir, dalbavancin, daptomycin, enfuvirtide, oritavancin, teicoplanin, telaprevir, telavancin, vancomycin, and guajillotin) and antiviral peptides (e.g., bulevirtide), coagulation factors, C-type natriuretic peptides (including derivatives thereof, such as vosiritide), calcitonin, desitatide, endomorphins (e.g., endomorphin-1 and / or, endomorphin-2), erythropoietin (e.g., darbepoetin), etelcalcitide, gastric inhibitory peptide (GIP) or other GIP receptor agonists (e.g., tesipa GLP-1 (glucagon-like peptide-1, including its derivatives, such as liraglutide, semaglutide, tasiglutide, albiglutide and dulaglutide), GLP-1 receptor agonists (including GLP-1 receptor / glucagon receptor dual agonists), such as exenatide-4 (including exenatide and lixisenatide), GLP-2 (glucagon-like peptide-2, including its derivatives, apraglutide and glipaglutide) or other GLP-2 receptor agonists (including GLP-2 receptor / glucagon receptor or GLP-2 receptor / GLP-1 receptor dual agonists, or GLP-2 receptor / GLP-1 receptor / glucagon receptor triple agonists), glucocerebrosidase, gonadotropin (for example, follicle-stimulating hormone, including its derivatives, such as follicle-stimulating hormone α (corifolitropin alfa), gonadotropin-releasing hormone (GnRH) or other GnRH receptor agonists (e.g., leuprolide, buserelin, histrelin, goserelin, deslorelin, nafarelin, and triptorelin), GnRH receptor antagonists (e.g., degarelix, acillin, cetrorelix, and ganirelix), granulocyte colony-stimulating factor (G-CSF, e.g., filgrastim), growth factors (e.g., insulin-like growth factor 1 (IGF-1), fibroblast growth factor (FGF), activity-dependent neurotrophic factor (including dalfnetide), and / or ciliary neurotrophic factors (including axokine, homologues of ciliary neurotrophic factor fragments), growth hormones (e.g., growth hormone (also known as growth hormone 1) and / or growth hormone 2 and / or long-acting acylated somapatin), somatostatin, also known as somatostatin or other somatostatin receptor agonists (including octreotide, romotetide, lanreotide, and pasireotide), growth hormone-releasing hormone (including sermorelin, CJC-1293 and CJC-1295), icatibant, insulin, interferon, interleukin, kappa opioid receptor agonists,For example, peripherally restricted kappa opioid receptor agonists (e.g., difacillin, CR665, JT09, and dynorphin), leptin, oxytocin or other oxytocin receptor agonists, melanocortin or other melanocortin receptor agonists (e.g., melanocyte stimulating hormone, avatrombopag, bremelanotide, melanocortin II, modimelanotide, selenanotide, asacostatin, and teicostatin), motilin, omentin, parathyroid hormone, parathyroid hormone-related protein (including abaloparatide, thyroxine), Homologs of parathyroid hormone-related protein fragments, parathyroid hormone, and the long-acting analog eneboparatide (ENEBOTIDE) (AZP-3601), peptide YY, pituitary adenylate cyclase activating peptide (PACAP), thymopentin, thymosin (e.g., thymosin α1), TNF inhibitors (e.g., infliximab, adalimumab, becelimumab, golimumab and / or etanercept), vasoactive intestinal peptide (e.g., actidil), and vasopressin (including derivatives thereof, such as desmopressin). Insulin, glucagon, GLP-1, GLP-2, parathyroid hormone, parathyroid hormone-related protein, erythropoietin, calcitonin, gastric inhibitory peptide, gonadotropin-releasing hormone, somatostatin, melanocortin, motilin, leptin, peptide YY, vasopressin, vasoactive intestinal peptide, pituitary adenylate cyclase activating peptide (PACAP), growth hormone, growth factor and G-CSF are non-limiting examples of polypeptide hormones. Interferon, interleukin, erythropoietin, omentin and G-CSF are non-limiting examples of polypeptide cytokines.
[0186] According to any of some of the embodiments described herein, the polypeptide is selected from an antibody, an anti-pathogenic peptide, a coagulation factor, a C-type natriuretic peptide, a calcitonin, a desitatide, an endomorphin, an erythropoietin, a glucagon, a glucagon receptor agonist, a GLP-1 (glucagon-like peptide-1), a GLP-1 receptor agonist (including a GLP-1 receptor / glucagon receptor dual agonist), a gastric inhibitory peptide (GIP), a gastric inhibitory peptide receptor agonist (including a GLP-2 receptor / glucagon receptor dual agonist, a GLP-2 receptor / GLP-1 receptor dual agonist, or a GLP-2 receptor-GIP receptor dual agonist), a glucocerebrosidase, a gonadotropin, a gonadotropin-releasing hormone, a gonadotropin-releasing hormone receptor agonist agents, gonadotropin-releasing hormone receptor antagonists, granulocyte colony stimulating factor, growth factors, growth hormone, somatostatin, somatostatin receptor agonists, somapatin, growth hormone-releasing hormone, icatibant, antiviral peptides (e.g., bublavir peptide), insulin, interferons, interleukins, kappa opioid receptor agonists (e.g., peripherally restricted kappa opioid receptor agonists), leptin, oxytocin, oxytocin receptor agonists, melanocortin, melanocortin receptor agonists, motilin, omentin, parathyroid hormone or fragments thereof or long-acting analogs thereof, parathyroid hormone-related protein, peptide YY, pituitary adenylate cyclase activating peptide (PACAP), thymopentin, thymosin, TNF inhibitors, vasoactive intestinal peptide and vasopressin and their analogs.
[0187] According to some of any embodiments described herein, the polypeptide has a relatively long plasma half-life due to, for example, the presence of a functional group in the acylated peptide that has a high affinity for plasma albumin. Such polypeptides are also referred to herein as long-acting polypeptides or long-acting analogs. Exemplary such polypeptides include, for example, semaglutide, liraglutide, tirzepatide, enebopatide (AZP-3601), and somapacitan.
[0188] The therapeutically active agents according to the embodiments of the present invention may optionally exhibit multiple activities described herein; for example, the GLP-1 receptor agonist may optionally be a GLP-1 receptor / GLP-2 receptor dual agonist (e.g., dapiglutide), a GIP receptor / GLP-1 receptor dual agonist and / or a glucagon receptor / GIP receptor / GLP1 receptor triple agonist, and the GLP-2 receptor agonist may optionally be a glucagon receptor / GLP2 receptor dual agonist and / or a GIP receptor / GLP-2 receptor dual agonist.
[0189] The antibody according to any respective embodiment described herein may optionally be a single domain antibody.
[0190] Herein and in the art, "single domain antibody" (also referred to as "nanobody" in the art) refers to an antibody fragment consisting of a monomeric variable antibody domain (e.g., in contrast to a typical antibody structure comprising four polypeptide chains, each polypeptide chain comprises a variable antibody domain). Single domain antibodies can alternatively be prepared by duplicating a more conventional antibody (e.g., 4-chain antibody) or a single variable domain of a heavy chain antibody from camelids or cartilaginous fish (e.g., shark) (e.g., by recombinant protein technology).
[0191] Without being bound by any particular theory, the inventors believe that the molecular weight of single domain antibodies (typically about 12 kDa to about 15 kDa) is particularly suitable for oral administration using an absorption enhancer (according to any of the embodiments described herein).
[0192] In any of some embodiments described herein, the therapeutically active agent is parathyroid hormone (PTH) or a fragment thereof.
[0193] Herein, the term "parathyroid hormone" or its abbreviation "PTH" includes parathyroid hormone (having a naturally occurring amino acid sequence, such as the 84 amino acid sequence of humans) and fragments and / or homologues and / or long-acting derivatives or analogs of parathyroid hormone.
[0194] Teriparatide is an example of a fragment of parathyroid hormone, consisting of amino acids 1 to 34 (i.e., the N-terminal portion) of the whole human parathyroid hormone polypeptide. The term "teriparatide" is used interchangeably herein with the terms "hPTH (1-34)" and "human parathyroid hormone (1-34)".
[0195] Eneboparatide (AZP-3601) is an example of a long-acting analog of parathyroid hormone.
[0196] Herein, for brevity, the term "parathyroid hormone" or its abbreviation "PTH" includes parathyroid hormone (having a naturally occurring amino acid sequence, e.g., in humans), fragments thereof, and homologs or analogs (e.g., long-acting) of parathyroid hormone or fragments thereof, unless otherwise indicated.
[0197] According to embodiments of the present invention, examples of nucleic acids (either themselves or their analogs) that can be used as therapeutic active agents include, but are not limited to, antisense nucleic acids (e.g., milasen, eteplirsen, fomiversen, golodirsen, inotesen, mipomersen, nusinersen, tofersen, tominersen, viltolarsen and volanesorsen), small interfering RNA (e.g., givosiran, inclisiran, lumasiran and patisiran), microRNA, RNA aptamers (e.g., pegapatib), messenger RNA (e.g., messenger RNA of mRNA vaccines) and DNA (e.g., messenger ribonucleic acid of DNA vaccines).
[0198] It has been reported that therapeutically active preparations that meet one or more of the following criteria tend to be poorly absorbed when administered orally (when given alone), a phenomenon known in the art as the "Lipinski 5" rule:
[0199] (i) The total number of nitrogen-hydrogen bonds and oxygen-hydrogen bonds (usually hydrogen bond donors) is greater than 5;
[0200] (ii) the total number of nitrogen atoms and oxygen atoms (usually hydrogen bond acceptors) is greater than 5;
[0201] (iii) an octanol-water partition coefficient (log P) greater than 5; and / or
[0202] (iv) A molecular weight of at least 500 Da (0.5 kDa).
[0203] The above criteria (i) and (ii) are related to hydrogen bonding and hydrophilicity; whereas criterion (iii) is related to lipophilicity.
[0204] As described herein, therapeutically active agents that are poorly absorbed when administered orally alone are particularly suitable for inclusion in the compositions described herein to enhance their absorption.
[0205] In any of the embodiments described herein, the therapeutic agent satisfies at least one of the above criteria (i), (ii), (iii), and (iv). In some embodiments, the therapeutic agent satisfies at least two of the above criteria (i), (ii), (iii), and (iv). In some embodiments, the therapeutic agent satisfies at least three of the above criteria (i), (ii), (iii), and (iv). In some embodiments, the therapeutic agent satisfies all four of the above criteria (i), (ii), (iii), and (iv).
[0206] In any of some embodiments described herein, according to any of the embodiments described herein regarding a molecular weight of at least 0.5 kDa, the therapeutically active agent has a molecular weight of at least 0.5 kDa and further satisfies at least one of the above criteria (i), (ii) and (iii). In some such embodiments, the therapeutically active agent satisfies at least two of the above criteria (i), (ii) and (iii).
[0207] Dihydroergotamine and fondaparinux are non-limiting examples of non-peptide agents having a molecular weight of at least 0.5 kDa that are poorly absorbed following oral administration.
[0208] In any of the embodiments described herein, the therapeutic agent has a molecular weight of less than 0.5 kDa and satisfies at least one of the above criteria (i), (ii), and (iii). In some such embodiments, the therapeutic agent satisfies at least two of the above criteria (i), (ii), and (iii). In some such embodiments, the therapeutic agent satisfies all three of the above criteria (i), (ii), and (iii).
[0209] Furthermore, ionic molecules are often poorly absorbed after oral administration, generally due to their greatly reduced ability to cross lipid membranes. Whether a molecule is ionic or non-ionic generally depends on pH, which varies depending on location in the gastrointestinal tract. In general, the inventors believe that the more ionic forms of a therapeutically active agent are in the gastrointestinal tract, the greater the likelihood of poor absorption after oral administration.
[0210] In any of the embodiments described herein, the therapeutically active agent is ionic in aqueous solution at pH 7.0.
[0211] In any of the embodiments described herein, the therapeutically active agent is ionic in aqueous solution at a pH of 6.0.
[0212] In any of the embodiments described herein, the therapeutically active agent is ionic in aqueous solution at a pH of 5.0.
[0213] In any of the embodiments described herein, the therapeutically active agent is ionic in aqueous solution at pH 4.0.
[0214] In any of the embodiments described herein, the therapeutically active agent is ionic in aqueous solution at pH 3.0.
[0215] In any of the embodiments described herein, the therapeutically active agent is ionic in aqueous solution at pH 2.0.
[0216] In any of the embodiments described herein, the therapeutically active agent is ionic in aqueous solution at pH 1.0.
[0217] Examples of such agents include, but are not limited to, compounds comprising at least one basic group (eg, an amino group) that is positively charged at pH 7.0 (or lower).
[0218] As used herein, when a compound comprises at least one functional group, the compound is considered to be "ionic" when at least 50% of the molecules in a population of molecules of the compound are charged under specified conditions (e.g., in aqueous solution at a specified pH or pH range). One skilled in the art will be able to readily determine whether a functional group is charged in at least 50% of the molecules, for example, by determining the pKa value associated with the functional group. An ionic compound as defined herein may optionally have a net negative charge, optionally have a net positive charge, and optionally have an equal number of negatively charged functional groups and positively charged functional groups, resulting in no net charge.
[0219] In any of the embodiments described herein, the therapeutically active agent is ionic in aqueous solution at all pH values in the range of 5.0 to 7.0. In some embodiments, the therapeutically active agent is ionic in aqueous solution at all pH values in the range of 5.0 to 8.0. In some embodiments, the therapeutically active agent is ionic in aqueous solution at all pH values in the range of 4.0 to 9.0. In some embodiments, the therapeutically active agent is ionic in aqueous solution at all pH values in the range of 3.0 to 10.0. In some embodiments, the therapeutically active agent is ionic in aqueous solution at all pH values in the range of 2.0 to 11.0.
[0220] In any of the embodiments described herein, the therapeutically active agent is ionic at a pH value and / or range according to any of the above embodiments, and further has a molecular weight of at least 0.5 kDa, according to any of the embodiments described herein relating to a molecular weight of at least 0.5 kDa.
[0221] In any of the embodiments described herein, the therapeutically active agent is ionic at a pH value and / or range according to any of the above embodiments, and further has a molecular weight of less than 0.5 kDa.
[0222] Examples of ionic therapeutically active agents that tend to have a molecular weight less than 0.5 kDa and that tend to exhibit poor absorption when administered orally include, but are not limited to, bisphosphonates (e.g., used to treat osteoporosis and related diseases), such as alendronate, clodronate, etidronate, ibandronate, neridronate, olpadronate, and pamidronate; and cromolyn (e.g., cromolyn sodium).
[0223] In any of some embodiments described herein, the therapeutically active agent is a Class III agent according to the Biopharmaceutical Classification System (BCS) provided by the U.S. Food and Drug Administration, ie, the therapeutically active agent is characterized by low permeability and high solubility.
[0224] In the context of BCS, the phrase "low permeability" is used herein and in the art to mean that a given drug is less than 90% absorbed after oral administration in humans (in the absence of absorption enhancers) as determined by mass balance and / or compared to an intravenous dose.
[0225] In some embodiments, the absorption of the Class III therapeutically active agent after oral administration (in the absence of an absorption enhancer) is less than 50%. In some embodiments, the absorption rate after oral administration is less than 20% (in the absence of an absorption enhancer). In some embodiments, the absorption rate after oral administration is less than 10% (in the absence of an absorption enhancer). In some embodiments, the absorption rate after oral administration is less than 5% (in the absence of an absorption enhancer). In some embodiments, the absorption rate after oral administration is less than 2% (in the absence of an absorption enhancer). In some embodiments, the absorption rate after oral administration is less than 1% (in the absence of an absorption enhancer). In some of the above embodiments, the absorption enhancer is NAC (8-N-(2-hydroxybenzoyl)aminocaprylic acid) or a salt thereof (e.g., sodium 8-N-(2-hydroxybenzoyl)aminocaprylate).
[0226] In the context of BCS, the phrase "highly soluble" is used herein and in the art to mean that the therapeutically active agent in an administered dose is soluble in 250 ml or less of water within the pH range of 1 to 7.5.
[0227] In some embodiments described herein, the composition is a unit dosage composition, the unit dosage comprising at least 50 micrograms of the therapeutically active agent. In some embodiments, the unit dosage comprises at least 100 micrograms of the therapeutically active agent. In some embodiments, the unit dosage comprises at least 200 micrograms of the therapeutically active agent. In some embodiments, the unit dosage comprises at least 500 micrograms of the therapeutically active agent. In some embodiments, the amount of the absorption enhancer in the unit dosage is in accordance with any ratio of the absorption enhancer to the therapeutically active agent described herein. In some of the above embodiments, the absorption enhancer is NAC (8-N-(2-hydroxybenzoyl)aminocaprylic acid) or a salt thereof (e.g., sodium 8-N-(2-hydroxybenzoyl)aminocaprylate).
[0228] In some embodiments described herein, the composition is a unit dosage composition, the unit dosage comprising 3000 micrograms or less of the therapeutically active agent. In some embodiments, the unit dosage comprises 2000 micrograms or less of the therapeutically active agent. In some embodiments, the unit dosage comprises 1000 micrograms or less of the therapeutically active agent. In some embodiments, the amount of the absorption enhancer in the unit dosage is in accordance with any ratio of the absorption enhancer to the therapeutically active agent described herein. In some of the above embodiments, the absorption enhancer is NAC (8-N-(2-hydroxybenzoyl)aminocaprylic acid) or a salt thereof (e.g., sodium 8-N-(2-hydroxybenzoyl)aminocaprylate).
[0229] In any of the embodiments described herein, the composition is a unit dosage composition, the unit dosage comprising 100 to 3000 micrograms of the therapeutically active agent, including any intermediate values and subranges therebetween. In some embodiments, the unit dosage comprises 200 to 2000 micrograms of the therapeutically active agent, including any intermediate values and subranges therebetween. In some embodiments, the unit dosage comprises 500 to 1000 micrograms of the therapeutically active agent, including any intermediate values and subranges therebetween. In some embodiments, the unit dosage comprises 1000 to 3000 micrograms of the therapeutically active agent, including any intermediate values and subranges therebetween. In some embodiments, the unit dosage comprises 1500 to 2500 micrograms of the therapeutically active agent, including any intermediate values and subranges therebetween. In some embodiments, the therapeutically active agent is parathyroid hormone or a fragment thereof. In some embodiments, the therapeutically active agent is teriparatide. In some embodiments, the amount of the absorption enhancer in the unit dosage is in accordance with any ratio of the absorption enhancer to the therapeutically active agent described herein. In some of the above embodiments, the absorption enhancer is NAC (8-N-(2-hydroxybenzoyl)aminocaprylic acid) or a salt thereof (eg, sodium 8-N-(2-hydroxybenzoyl)aminocaprylate).
[0230] In any of some embodiments of the embodiments described herein, when the therapeutically active agent is a polypeptide, the composition further comprises at least one protease inhibitor, for example, according to any of U.S. Patent Application Publication No. 2011 / 0142800, International Patent Application Publication No. WO 2016 / 128972, and WO 2018 / 033927, the type of protease inhibitor, the concentration and / or absolute amount of the protease inhibitor, and / or the ratio of the protease inhibitor to the absorption enhancer and / or the therapeutically active agent in any embodiment regarding protease inhibitors, the contents of which (particularly those related to protease inhibitors) are incorporated herein.
[0231] In this article, the term "protease inhibitor" refers to a compound that reduces the proteolytic activity of a protease, for example, a proteolytic activity that inactivates a therapeutic agent described herein. For example, the term "protease inhibitor" includes macromolecules (such as proteins) and small molecules, as well as natural and synthetic compounds.
[0232] In some embodiments of any of the embodiments described herein, the at least one protease inhibitor comprises at least one trypsin inhibitor. In some embodiments, the at least one protease inhibitor consists essentially of one or more trypsin inhibitors.
[0233] Examples of trypsin inhibitors useful in any of the embodiments described herein include, but are not limited to, lima bean trypsin inhibitor, aprotinin, soybean trypsin inhibitor, ovomucoid trypsin inhibitor, and any combination thereof. In some embodiments, the at least one trypsin inhibitor comprises soybean trypsin inhibitor (SBTI). In some embodiments, the at least one trypsin inhibitor (optionally at least one protease inhibitor) consists essentially of SBTI.
[0234] In some embodiments of any of the embodiments described herein, the at least one protease inhibitor comprises at least one serine protease inhibitor (serpin). In some embodiments, the at least one protease inhibitor consists essentially of one or more serine protease inhibitors.
[0235] Examples of serine protease inhibitors that can be used in any of the embodiments described herein include, but are not limited to, alpha 1-antitrypsin, antitrypsin-related protein, alpha 1-antichymotrypsin, kallistatin, protein C inhibitor, cortisol binding globulin, thyroxine-binding globulin, angiotensinogen, centerin, protein Z-related protease inhibitor, vaspin, monocyte / neutrophil elastase inhibitor, plasminogen activator inhibitor-2, and leukocyte antigen 2 inhibitor. The following are the inhibitors of leukemia / lysine triphosphate (LTT) and leukemia / lysine triphosphate (LTP) in the presence of leukemia / lysine triphosphate (RTP) agonists: leukemia / lysine triphosphate (LTP) agonists: leukemia / lysine triphosphate (RT ...
[0236] In some embodiments of any of the embodiments described herein, the at least one protease inhibitor comprises at least one cysteine protease inhibitor. In some embodiments, the at least one protease inhibitor consists essentially of one or more cysteine protease inhibitors.
[0237] Examples of cystatins that can be used in any of the embodiments described herein include, but are not limited to, type 1 cystatins, type 2 cystatins, human cystatins C, D, S, SN and SA, cystatin E / M, cystatin F and type 3 cystatins (including kininogens).
[0238] In some embodiments of any of the embodiments described herein, the at least one protease inhibitor comprises at least one threonine protease inhibitor. In some embodiments, the at least one protease inhibitor consists essentially of one or more threonine protease inhibitors.
[0239] Examples of threonine protease inhibitors that can be used in any of the embodiments described herein include, but are not limited to, bortezomib, MLN-519, ER-807446, and TMC-95A.
[0240] In some embodiments of any of the embodiments described herein, the at least one protease inhibitor comprises at least one aspartic protease inhibitor. In some embodiments, the at least one protease inhibitor consists essentially of one or more aspartic protease inhibitors.
[0241] Examples of aspartic protease inhibitors that can be used in any of the embodiments described herein include, but are not limited to, α 2 Macroglobulin (α 2 -macroglobulin), pepstatin A, aspartase inhibitor 11, aspartate protease inhibitor 1, aspartic anhydride protease inhibitor 2, aspartyl protease inhibitor 3, aspartate protease inhibitor 4, aspartyl transferase inhibitor 5, aspartyl protease inhibitor 6, aspartic alcohol protease inhibitor 7, aspartate protease inhibitor 8, aspartate protease inhibitor 9, pepsin inhibitor Dit33 and protease A inhibitor 3.
[0242] In some embodiments of any of the embodiments described herein, the at least one protease inhibitor comprises at least one metalloprotease inhibitor. In some embodiments, the at least one protease inhibitor consists essentially of one or more metalloprotease inhibitors.
[0243] Examples of metalloproteinase inhibitors that can be used in any of the embodiments described herein include, but are not limited to, angiotensin-1-converting enzyme inhibitory peptide, antihemorrhagic factor BJ46a, β-casein, protease inhibitor CeKI, venom metalloproteinase inhibitor DM43, carboxypeptidase A inhibitor, smpI, IMPI, alkaline protease, latexin, carboxypeptidase inhibitor, antihemorrhagic factor HSF, testicular proteoglycan 3, SPOCK3, TIMP1, metalloproteinase inhibitor 1, metalloproteinase inhibitor 2, TIMP2, metalloproteinase inhibitor 3, TIMP3, metalloproteinase inhibitor 4, TIMP4, putative metalloproteinase inhibitor tag-225, tissue inhibitor of metalloproteinases, WAP, kazal inhibitor, immunoglobulin and kunitz and NTR domain-containing protein 1.
[0244] Examples of protease inhibitors that can be used in any of the embodiments described herein also include, but are not limited to, AEBSF-HCl, ε-aminocaproic acid, α1-antichymotypsin, antipain, antithrombin III, α1-antitrypsin, APMSF (4-amidinophenyl-methanesulfonyl fluoride), sprotinin, benzamidine, chymostatin, DFP (diisopropylfluorophosphate;), leupeptin, 4-(2-aminoethyl)-benzenesulfonyl fluoride hydrochloride, PMSF (phenylmethylsulfonyl fluoride), TLCK (1-chloro-3-p-toluenesulfonylamino-7-amino-2-heptanone), TPCK (1-fluoro-3-p-toluenesulfonylamino-4-phenyl-2-butanone), pentamidine isosulfate, pepstatin, guanidine, α2-macroglobulin, zinc chelators, and iodoacetate.
[0245] In any embodiment of some embodiments of the embodiments described herein, the amount of protease inhibitor in the unit dosage form described herein is at least about 0.1 mg. In some embodiments, the amount of protease inhibitor in the unit dosage form described herein is at least about 0.2 mg. In some embodiments, the amount of protease inhibitor in the unit dosage form described herein is at least about 0.3 mg. In some embodiments, the amount of protease inhibitor in the unit dosage form described herein is at least about 0.4 mg. In some embodiments, the amount of protease inhibitor in the unit dosage form described herein is at least about 0.6 mg. In some embodiments, the amount of protease inhibitor in the unit dosage form described herein is at least about 0.8 mg. In some embodiments, the amount of protease inhibitor in the unit dosage form described herein is at least about 1 mg. In some embodiments, the amount of protease inhibitor in the unit dosage form described herein is at least about 1.5 mg. In some embodiments, the amount of protease inhibitor in the unit dosage form described herein is at least about 2 mg. In some embodiments, the amount of protease inhibitor in the unit dosage form described herein is at least about 2.5 mg. In some embodiments, the amount of protease inhibitor in the unit dosage form described herein is at least about 3 mg. In some embodiments, the amount of protease inhibitor in the unit dosage form described herein is at least about 5 mg. In some embodiments, the amount of protease inhibitors in the unit dosage forms described herein is at least about 7 milligrams. In some embodiments, the amount of protease inhibitors in the unit dosage forms described herein is at least about 10 milligrams. In some embodiments, the amount of protease inhibitors in the unit dosage forms described herein is at least about 12 milligrams. In some embodiments, the amount of protease inhibitors in the unit dosage forms described herein is at least about 15 milligrams. In some embodiments, the amount of protease inhibitors in the unit dosage forms described herein is at least about 20 milligrams. In some embodiments, the amount of protease inhibitors in the unit dosage forms described herein is at least about 30 milligrams. In some embodiments, the amount of protease inhibitors in the unit dosage forms described herein is at least about 50 milligrams. In some embodiments, the amount of protease inhibitors in the unit dosage forms described herein is at least about 70 milligrams. In some embodiments, the amount of protease inhibitors in the unit dosage forms described herein is at least about 100 milligrams.
[0246] In any embodiment of some embodiments of the embodiments described herein, the amount of the protease inhibitor in the unit dosage form described herein is in the range of from 0.1 to 1 mg. In some embodiments, the amount of the protease inhibitor in the unit dosage form described herein is in the range of from 0.2 to 1 mg. In some embodiments, the amount of the protease inhibitor in the unit dosage form described herein is in the range of from 0.3 to 1 mg. In some embodiments, the amount of the protease inhibitor in the unit dosage form described herein is in the range of from 0.5 to 1 mg.
[0247] In any embodiment of some embodiments of the embodiments described herein, the amount of the protease inhibitor in the unit dosage form described herein is in the range of from 0.1 to 2 milligrams. In some embodiments, the amount of the protease inhibitor in the unit dosage form described herein is in the range of from 0.2 to 2 milligrams. In some embodiments, the amount of the protease inhibitor in the unit dosage form described herein is in the range of from 0.3 to 2 milligrams. In some embodiments, the amount of the protease inhibitor in the unit dosage form described herein is in the range of from 0.5 to 2 milligrams. In some embodiments, the amount of the protease inhibitor in the unit dosage form described herein is in the range of from 1 to 2 milligrams.
[0248] In any of some of the embodiments described herein, the amount of the protease inhibitor in the unit dosage form described herein is in the range of from 1 to 10 mg. In some embodiments, the amount of the protease inhibitor in the unit dosage form described herein is in the range of from 2 to 10 mg. In some embodiments, the amount of the protease inhibitor in the unit dosage form described herein is in the range of from 3 to 10 mg. In some embodiments, the amount of the protease inhibitor in the unit dosage form described herein is in the range of from 5 to 10 mg.
[0249] In any embodiment of some embodiments of the embodiments described herein, the amount of the protease inhibitor in the unit dosage form described herein is in the range of from 1 to 20 mg. In some embodiments, the amount of the protease inhibitor in the unit dosage form described herein is in the range of from 2 to 20 mg. In some embodiments, the amount of the protease inhibitor in the unit dosage form described herein is in the range of from 3 to 20 mg. In some embodiments, the amount of the protease inhibitor in the unit dosage form described herein is in the range of from 5 to 20 mg. In some embodiments, the amount of the protease inhibitor in the unit dosage form described herein is in the range of from 10 to 20 mg.
[0250] In any embodiment of some embodiments of the embodiments described herein, the amount of the protease inhibitor in the unit dosage form described herein is in the range of from 10 to 100 milligrams. In some embodiments, the amount of the protease inhibitor in the unit dosage form described herein is in the range of from 20 to 100 milligrams. In some embodiments, the amount of the protease inhibitor in the unit dosage form described herein is in the range of from 30 to 100 milligrams. In some embodiments, the amount of the protease inhibitor in the unit dosage form described herein is in the range of from 50 to 100 milligrams.
[0251] In any embodiment of some embodiments of the embodiments described herein, the amount of protease inhibitors in the unit dosage forms described herein is in the range of from 10 to 200 milligrams. In some embodiments, the amount of protease inhibitors in the unit dosage forms described herein is in the range of from 20 to 200 milligrams. In some embodiments, the amount of protease inhibitors in the unit dosage forms described herein is in the range of from 30 to 200 milligrams. In some embodiments, the amount of protease inhibitors in the unit dosage forms described herein is in the range of from 50 to 200 milligrams. In some embodiments, the amount of protease inhibitors in the unit dosage forms described herein is in the range of from 100 to 200 milligrams.
[0252] In any embodiment of some embodiments of the embodiments described herein, the amount of the protease inhibitor in the unit dosage form described herein is at least about 10 kallikrein inactivator units (kiu). In some embodiments, the amount of the protease inhibitor in the unit dosage form described herein is at least about 12 k.iu. In some embodiments, the amount of the protease inhibitor in the unit dosage form described herein is at least about 15 k.iu. In some embodiments, the amount of the protease inhibitor in the unit dosage form described herein is at least about 20 k.iu. In some embodiments, the amount of the protease inhibitor in the unit dosage form described herein is at least about 30 k.iu. In some embodiments, the amount of the protease inhibitor in the unit dosage form described herein is at least about 40 k.iu. In some embodiments, the amount of the protease inhibitor in the unit dosage form described herein is at least about 50 k.iu. In some embodiments, the amount of the protease inhibitor in the unit dosage form described herein is at least about 70 k.iu. In some embodiments, the amount of the protease inhibitor in the unit dosage form described herein is at least about 100 k.iu. In some embodiments, the amount of the protease inhibitor in the unit dosage form described herein is at least about 150 k.iu. In some embodiments, the amount of protease inhibitors in the unit dosage forms described herein is at least about 200 k.iu. In some embodiments, the amount of protease inhibitors in the unit dosage forms described herein is at least about 300 k.iu. In some embodiments, the amount of protease inhibitors in the unit dosage forms described herein is at least about 500 k.iu. In some embodiments, the amount of protease inhibitors in the unit dosage forms described herein is at least about 700 k.iu. In some embodiments, the amount of protease inhibitors in the unit dosage forms described herein is at least about 1000 k.iu. In some embodiments, the amount of protease inhibitors in the unit dosage forms described herein is at least about 1500 k.iu. In some embodiments, the amount of protease inhibitors in the unit dosage forms described herein is at least about 3000 k.iu. In some embodiments, the amount of protease inhibitors in the unit dosage forms described herein is at least about 4000 k.iu. In some embodiments, the amount of protease inhibitors in the unit dosage forms described herein is at least about 5000 k.iu.
[0253] As used herein and in the art, a "kallikrein inactivator unit" (kiu) refers to the amount of a protease inhibitor that inhibits 2 units of kallikrein by 50% (eg, in aqueous solution at an optimal pH and solution volume for protease inhibitor activity).
[0254] In any of some embodiments of the embodiments described herein, the weight ratio of the protease inhibitor to the therapeutically active agent is in the range of 1:1 to 5:1 (protease inhibitor: therapeutically active agent). In some embodiments, the weight ratio of the protease inhibitor to the therapeutically active agent is in the range of 5:1 to 10:1. In some embodiments, the weight ratio of the protease inhibitor to the therapeutically active agent is in the range of 10:1 to 20:1. In some embodiments, the weight ratio of the protease inhibitor to the therapeutically active agent is in the range of 20:1 to 30:1. In some embodiments, the weight ratio of the protease inhibitor to the therapeutically active agent is in the range of 30:1 to 40:1. In some embodiments, the weight ratio of the protease inhibitor to the therapeutically active agent is in the range of 40:1 to 50:1. In some embodiments, the weight ratio of the protease inhibitor to the therapeutically active agent is in the range of 50:1 to 75:1. In some embodiments, the weight ratio of the protease inhibitor to the therapeutically active agent is in the range of 75:1 to 100:1. In some embodiments, the weight ratio of the protease inhibitor to the therapeutically active agent is in the range of 100:1 to 200:1. In some embodiments, the weight ratio of the protease inhibitor to the therapeutically active agent is in the range of 200: 1 to 300: 1. In some embodiments, the weight ratio of the protease inhibitor to the therapeutically active agent is in the range of 300: 1 to 400: 1. In some embodiments, the weight ratio of the protease inhibitor to the therapeutically active agent is in the range of 400: 1 to 500: 1. In some embodiments, the protease inhibitor is soybean trypsin inhibitor.
[0255] Uses and Indications:
[0256] In any of some of the embodiments described herein, the composition according to any of the corresponding embodiments described herein is used to treat a condition treatable by the therapeutically active agent (according to any of the corresponding embodiments described herein), and the treatment comprises oral administration of the composition.
[0257] According to one aspect of some embodiments of the present invention, a method for treating a disease treatable by an oral therapeutic agent (according to any embodiment of the corresponding embodiments described herein) in a subject in need thereof is provided, the method comprising orally administering to the subject a composition according to any embodiment of the corresponding embodiments described herein, wherein the composition comprises the corresponding therapeutic agent (according to any embodiment of the corresponding embodiments described herein).
[0258] One skilled in the art will be able to determine which conditions may be treated by oral administration of any given therapeutically active agent described herein.
[0259] Examples of conditions that can be treated according to embodiments of the present invention include, but are not limited to, hyperglycemia and / or diabetes (e.g., where the therapeutic agent is insulin-like growth factor, insulin, GLP-1 or a GLP-1 receptor agonist, or another agent that lowers blood glucose levels); hypoglycemia (e.g., where the therapeutic agent is somatostatin, glucagon, or another agent that increases blood glucose levels); osteoporosis and diseases associated with fractures or bone defects (e.g., where the therapeutic agent is PTH, parathyroid hormone-related protein, GLP-2 or a GLP-2 receptor agonist, or calcitonin); hypoparathyroidism (e.g., where the therapeutic agent is PTH); obesity (e.g., where the therapeutic agent is PTH); For example, wherein the therapeutic agent is peptide YY, ciliary neurotrophic factor, GLP-1 or a GLP-1 receptor agonist, somatostatin or growth hormone); osteoarthritis (e.g., wherein the therapeutic agent is GLP-1, a GLP-1 receptor agonist and / or PTH), inflammatory diseases and / or autoimmune diseases (e.g., wherein the therapeutic agent is a TNF inhibitor, an interferon, an interleukin, growth hormone or vasoactive intestinal peptide); pain and / or pruritus, such as uremic pruritus (e.g., wherein the therapeutic agent is an endomorphine and / or a kappa opioid receptor agonist); growth defects (e.g., wherein the therapeutic agent is growth hormone); hereditary angioedema (e.g., wherein The therapeutic agent is icatibant); lipodystrophy (e.g., where the therapeutic agent is leptin or growth hormone releasing hormone); fatty liver disease, such as nonalcoholic steatohepatitis (e.g., where the therapeutic agent is growth hormone releasing hormone); short bowel syndrome (e.g., where the therapeutic agent is GLP-2 or a GLP-2 receptor agonist, or growth hormone); hormone or enzyme deficiency (e.g., where the therapeutic agent is a hormone or enzyme for a deficiency described herein); tissue damage (e.g., where the therapeutic agent is a growth factor); bleeding due to tissue damage or a bleeding disorder such as hemophilia (e.g., where the therapeutic agent is a coagulation factor or vasopressin); anemia (e.g., where the therapeutic agent is is erythropoietin); leukopenia (e.g., where the therapeutic agent is g-CSF); proliferative diseases or disorders, such as cancer, endometriosis, or acromegaly (e.g., where the therapeutic agent is an interleukin, an interferon, erythropoietin, somatostatin, GnRH, a GnRH receptor antagonist, or desitatide); infertility or other diseases treatable by in vitro fertilization (e.g., where the therapeutic agent is gonadotropin or a gonadotropin receptor agonist, GnRH or a GnRH receptor agonist, or a GnRH receptor antagonist); and infections, such as bacterial or viral infections (e.g., where the therapeutic agent is an antipathogenic peptide, antibody, or interferon).
[0260] Without being bound by any particular theory, the inventors believe that the compositions described herein facilitate absorption in the stomach rather than in the intestine, which may be particularly advantageous in treating subjects who may have inadequate intestinal function, such as short bowel syndrome.
[0261] Examples of suitable conditions in which growth hormone and / or its analogs are active include, but are not limited to, burns, fibromyalgia, growth hormone deficiency, heart failure, inflammatory and / or autoimmune diseases (e.g., Crohn's disease, ulcerative colitis, and / or multiple sclerosis), muscle degeneration (e.g., AIDS-related wasting), obesity, short bowel syndrome, and short stature and / or growth deficiency (e.g., severe idiopathic short stature or short stature associated with Turner syndrome, chronic renal failure, Prader-Willi syndrome, and / or intrauterine growth restriction).
[0262] Examples of suitable conditions for which the activity of GHRH and / or its analogs and / or the induction of growth hormone release are beneficial include, but are not limited to, cognitive dysfunction (e.g., drug-related, such as mild cognitive impairment, with pre-Alzheimer's disease symptoms (early-onset Alzheimer's disease) and / or dementia); sleep disorders (e.g., age-related sleep disorders); diseases or disorders associated with fat accumulation and / or hypercholesterolemia; catabolic / wasting disorders; growth hormone deficiency (e.g., for providing growth hormone replacement therapy, and / or treating idiopathic short stature); diseases or disorders associated with immune deficiency; diseases or disorders associated with cholesterol levels, non-HDL cholesterol levels, triglyceride levels and / or Diseases or disorders associated with an elevated total cholesterol / HDL cholesterol ratio (e.g., to reduce elevated levels and / or ratios); diseases or disorders associated with body weight excluding fat and / or elevated trunk fat, visceral fat, visceral adipose tissue, visceral fat / subcutaneous adipose tissue ratio, and / or abdominal circumference (e.g., to improve any of the above parameters); decreased fertility in women (e.g., as part of female fertility treatment); failure to breastfeed; GHRH receptor-associated tumors; hypothalamic pituitary dwarfism; wounds and / or burns (e.g., to promote healing); debilitating infections (acute or chronic); and diseases or disorders associated with insufficient and / or reduced bone formation (e.g., osteoporosis).
[0263] Examples of diseases or disorders associated with fat accumulation and / or hypercholesterolemia include, but are not limited to, obesity (abdominal obesity, optionally with metabolic disturbances and / or relative GH deficiency), abdominal adiposity, metabolic syndrome, lipohypertrophy, lipodystrophy, lipodystrophy (such as HIV-associated lipodystrophy), dyslipidemia, hypertriglyceridemia, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
[0264] Without being bound by any particular theory, the inventors believe that the composition comprising GHRH (or its analog) according to any corresponding embodiment described herein can promote absorption in a short time (e.g., by promoting short absorption in the stomach), thereby producing a pulse-like pharmacokinetic profile. This pharmacokinetic profile may be advantageous because it mimics the characteristics of GHRH injection.
[0265] Treatment according to any of the embodiments described herein (eg, using GHRH or a related agent) may optionally be used to enhance the immune response, for example, to treat a disease or disorder associated with immune deficiency.
[0266] Examples of diseases or disorders associated with immunodeficiency include, but are not limited to, T-cell immunodeficiency, immunodeficiency associated with aging, immunodeficiency associated with HIV infection / AIDS, and immunodeficiency associated with high-dose chemotherapy and / or radiation therapy.
[0267] Treatment according to any of the embodiments described herein (eg, using GHRH or related agents) may optionally be used to enhance anabolism (eg, for example, to increase muscle mass and / or function), for example, for the treatment of catabolic / wasting diseases.
[0268] Examples of catabolic / wasting disorders include, but are not limited to, acute or chronic renal failure (e.g., acute or chronic renal failure asthenia), chronic heart failure (e.g., chronic heart failure asthenia), chronic obstructive pulmonary disease (COPD), cystic fibrosis (e.g., adult cystic fibrosis asthenia), frailty, burns, infections (e.g., sepsis), muscular dystrophy, congestive heart failure, neurodegenerative diseases (e.g., Alzheimer's disease or early-onset Alzheimer's syndrome and / or amyotrophic lateral sclerosis), AIDS, protein malnutrition after long-term corticosteroid therapy, nonunion of fractures, hip fractures, after trauma or major surgery (e.g., postoperative problems), osteoporosis, long-term immobilization, cancer-related cachexia, sarcopenia (e.g., age-related sarcopenia), and gastrointestinal malabsorption (such as short bowel syndrome and / or Crohn's disease), e.g., in elderly subjects.
[0269] Examples of suitable conditions in which the activity of GLP-1 and / or its analogs (e.g., GLP-1 receptor agonists) is beneficial include, but are not limited to, addiction (e.g., alcohol addiction and / or drug abuse), adipocyte dysfunction, Alzheimer's disease, arthritis (e.g., osteoarthritis and / or gout), cardiovascular diseases and disorders (e.g., atherosclerosis (including coronary artery disease), angina pectoris, endothelial dysfunction, impaired vascular compliance, left ventricular hypertrophy, hypertension, myocardial infarction (e.g., necrosis and / or apoptosis), peripheral arterial disease, peripheral vascular disease, pulmonary hypertension, stroke (e.g., hemorrhagic stroke and / or ischemic stroke), thrombosis, transient ischemic attack and / or congestive heart failure), cataracts, cirrhosis, diabetes (including type 1 diabetes and / or type 2 diabetes);Such as prediabetes (including impaired fasting glucose), idiopathic type 1 diabetes (type 1b), latent autoimmune diabetes in adults, early-onset type 2 diabetes, atypical diabetes of the young, malnutrition-related diabetes, gestational diabetes and maturity-onset diabetes of the young), diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, dyslipidemia (including hyperlipidemia, hypertriglyceridemia, elevated total cholesterol, high low-density lipoprotein cholesterol and low high-density lipoprotein cholesterol), eating disorders (including binge eating syndrome, bulimia nervosa, excessive sugar craving and syndromic obesity, such as Prader-Willi syndrome and Bardet-Biedl syndromes), erectile dysfunction, fibrosis, gastrointestinal diseases and disorders (such as inflammatory bowel disease, short bowel syndrome, Crohn's disease disease), colitis, ulcerative colitis, and / or irritable bowel syndrome), hepatocellular carcinoma, hyperlipoprotein B, hyperglycemia, hyperinsulinemia, hyperuricemia, impaired cognitive function, impaired glucose metabolism, impaired glucose tolerance, insulin resistance (including hepatic insulin resistance), intermittent claudication, ketosis, renal diseases and disorders (such as acute kidney disease, chronic renal failure, glomerulosclerosis, tubular dysfunction and / or proinflammatory changes in the proximal tubules), macular degeneration, metabolic acidosis, metabolic syndrome, non-alcoholic fatty liver, non-alcoholic steatohepatitis), obesity (including hypothalamic obesity and monogenic obesity) and related comorbidities (such as osteoarthritis and urinary incontinence), osteoporosis, Parkinson's disease, polycystic ovary syndrome, postprandial dyslipidemia, premenstrual syndrome, psoriasis, restenosis (such as vascular restenosis and / or restenosis after angioplasty), schizophrenia, skin and connective tissue diseases and disorders, sleep apnea, traumatic brain injury, ulcers (such as foot ulcers), visceral fat deposition, and weight gain associated with weight gain associated with therapeutic agents (such as steroids and / or antipsychotic drugs).
[0270] Examples of suitable conditions in which the activity of GLP-2 and / or its analogs (e.g., GLP-2 receptor agonists) is beneficial include, but are not limited to, chemotherapy-induced adverse effects (e.g., abdominal cramps, bacterial translocation, diarrhea, gastrointestinal bleeding, malabsorption, mucositis and / or vomiting), cul-de-sac syndrome, digestive disorders, enteritis (e.g., radiation enteritis and / or infectious or post-infectious enteritis), inflammatory bowel disease, malabsorption syndrome, malnutrition (e.g., cachexia and / or anorexia), short bowel syndrome (e.g., associated with surgical resection, congenital defects and / or disease-related loss of intestinal absorption), small intestinal damage (e.g., associated with chemotherapy and / or toxic substances thereto), sprue (e.g., gluten-induced enteropathy or celiac disease), tropical sprue, hypogammaglobulinemic sprue, ulcers (e.g., peptic ulcers, drug-induced ulcers and / or ulcers associated with pathogens), and ulcerative colitis.
[0271] Treatment according to any embodiment described herein (e.g., using GHRH, growth hormone, GLP-1, GLP-2 or related agents) can optionally be used to improve parameters related to lipids and / or body structure. Examples of such improvements include, but are not limited to, lowering cholesterol levels, non-HDL cholesterol levels, triglyceride levels, and / or total cholesterol / HDL cholesterol ratios, increasing body mass excluding fat, reducing trunk fat, visceral fat, visceral adipose tissue, visceral adipose tissue / subcutaneous adipose tissue ratio, and / or abdominal circumference.
[0272] According to any corresponding embodiment described herein, for a condition associated with chemotherapy, the chemotherapeutic agent can be, for example, altretamine, bleomycin, busulfan, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, crisantaspase, cyclophosphamide, cytarabin e), dacarbazine, dactinomycin, daunorubicin, docetaxel, doxorubicin, epirubicin, etoposide, fludarabine, fluorouracil, gemcitabine, hydroxycarbamide, idarubicin, ifosfamide, irinotecan irinotecan, liposomaldoxorubicin, leucovorin, lomustine, melphalan, mercaptopurine, mesna, methotrexate, mitomycin, mitoxantrone, oxaliplatin, paclitaxel, pemetrexed, pentostatin in), procarbazine, raltitrexed, streptozocin, tegafur-uracil, temozolomide, thiotepa, thioguanine, topotecan, treosulfan, vinblastine, vincristine, vindesine, and / or vinorelbine.
[0273] Examples of suitable conditions in which activity (e.g., peripheral activity) of kappa opioid receptors and / or kappa opioid receptor agonists is beneficial include, but are not limited to, congestive heart failure, edema (e.g., associated with congestive heart disease and / or inappropriate secretion of antidiuretic hormone), glaucoma, hypertension, ileus (e.g., postoperative ileus and / or opioid-induced bowel dysfunction), inflammation (e.g., autoimmune inflammation, throat inflammation, and / or inflammation associated with drugs such as nonsteroidal anti-inflammatory drugs), hypokalemia, hyponatremia, cirrhosis, nephrotic syndrome, pain (e.g., acute pain, chronic pain, cutaneous pain, hyperalgesia, neuropathic pain, ocular pain, somatic pain, throat pain, and / or visceral pain), pruritus, and cough.
[0274] Examples of neuropathic pain that can be treated according to any corresponding embodiment of the present invention include, but are not limited to, diabetic pain, chemotherapy-induced pain, migraine, neuroinvasive metastatic cancer pain, trigeminal neuralgia, viral pain (e.g., herpes zoster-related pain), and neuropathic pain associated with traumatic injury and / or surgery.
[0275] Examples of ocular pain that may be treated according to any corresponding embodiment of the invention include, but are not limited to, pain associated with chemical burns, conjunctivitis, corneal abrasions and / or irritation, corneal ulcers, episcleritis, herpetic eye, stromal keratitis, iritis (e.g., acute iritis), keratitis sicca, ocular lacerations, orbital cellulitis, orbital floor fractures, orbital pseudotumors, pemphigus, photorefractive keratectomy, scleritis, sclerotic keratitis, trachoma, and / or uveitis.
[0276] Examples of throat pain that can be treated according to any corresponding embodiment of the present invention include, but are not limited to, pain associated with bronchitis (e.g., acute bronchitis), burns (e.g., pharyngeal burns), cancer (e.g., laryngeal cancer), the common cold, contact ulcers, gingivitis (e.g., acute necrotizing ulcerative gingivitis), herpes simplex lesions, influenza, mononucleosis, laryngitis (e.g., acute laryngitis), peritonsillar abscess, pharyngitis, rhinitis (e.g., allergic rhinitis), sinusitis (e.g., acute sinusitis) and / or tonsillitis.
[0277] Further examples of pain treatable according to any respective embodiment of the invention include, but are not limited to, pain associated with arthritis (e.g., rheumatoid arthritis and / or osteoarthritis), cancer (e.g., breakthrough cancer pain), cirrhosis, dysmenorrhea, endometriosis, gastrointestinal diseases or disorders (e.g., bile duct stones, cholecystitis, colitis, diverticulitis, dyspepsia, esophagitis, gallstones, gastritis, gastroenteritis, gastroesophageal reflux disease, gastric or duodenal ulcer, inflammatory bowel disease, intestinal obstruction, irritable bowel syndrome, pancreatitis, perforated ulcer, ulcerative colitis), liver abscess, hepatitis, interstitial cystitis, kidney stones, menopause (e.g., hot flashes), ovarian cysts, mastitis, pelvic inflammatory disease, peritonitis, polynephritis (e.g., nephritis), cystitis, ... e.g., acute multiple nephropathy), prostatitis, pyelonephritis (e.g., acute pyelonephritis), surgery (e.g., arthroplasty) or other medical procedures, such as biopsy (e.g., following appendectomy, cervical biopsy, cholecystectomy, colectomy, colonic resection, colonoscopy, colostomy, cystoscopy, endometrial biopsy, gastrectomy, hernia repair, hysterectomy, hysteroscopy, open colorectal surgery, pelvic laparoscopy, prostatectomy, splenectomy, tubal ligation and / or vasectomy), toxins (e.g., insect toxins), urinary tract stones, and / or pain associated with uterine spasms.
[0278] Examples of pruritus treatable according to any corresponding embodiment of the invention include, but are not limited to, anal pruritus (e.g., associated with hemorrhoids), drug-induced pruritus (e.g., mu opioid-induced pruritus), ocular pruritus (e.g., associated with conjunctivitis), otitis pruritus, uremic pruritus (e.g., in subjects receiving hemodialysis), and pruritus associated with cholestasis (e.g., associated with primary biliary cholangitis, intrahepatic cholestasis of pregnancy, chronic cholestatic liver disease, uremia, malignant cholestasis, and / or jaundice), animal (e.g., insect) bites or stings, and / or skin diseases or disorders (e.g., dermatitis (including atopic dermatitis and contact dermatitis), lichen planus, lichen simplex chronicus, pediculosis, polycythemia vera, psoriasis, scabies, hyperthyroidism, tinea pedis, urticaria, and / or vaginitis).
[0279] In the context of medical conditions associated with bone fractures, the terms "treating" and "treatment" include, for example, at least partially substantially healing a bone fracture (e.g., a nonunion of a bone fracture that cannot heal without intervention), substantially increasing the rate of bone fracture healing, substantially improving or preventing the appearance of symptoms of a bone fracture (e.g., pain, loss of function of a body part, defective bone formation), and, for example, the likelihood of a bone fracture occurring due to a medical condition (e.g., prophylaxis). Treatment of bone fractures as described herein may optionally be performed in conjunction with standard treatments for bone fractures, such as bone fixation (e.g., with a cast) and / or surgery.
[0280] Examples of conditions associated with bone fractures include, but are not limited to, nonunion of a bone fracture, any medical condition associated with a stress fracture (optionally, the condition itself is a stress fracture),
[0281] As used herein and in the art, the phrase "nonunion of a fracture" means that the medical condition of a fracture is present and there is no reasonable expectation that the fracture will heal without intervention.
[0282] One skilled in the art will be able to readily determine whether a fracture nonunion exists.
[0283] In some embodiments according to any of the embodiments relating to nonunion, nonunion of the fracture is determined based on nonconsolidation of the fracture site six months after fracture formation and / or based on the lack of progression of callus formation at the fracture site within a four-week interval (e.g., as described by Giannotti et al. [Clin Cases Miner Bone Metab 2013, 10:116-120]).
[0284] As used herein and in the art, the phrase "stress fracture" refers to a bone fracture caused by repeated stress over time (eg, through running and / or jumping).
[0285] In some embodiments, treating a medical symptom associated with a stress fracture comprises increasing the rate of healing of an existing stress fracture.
[0286] In some embodiments, treating a medical symptom associated with stress fractures comprises reducing the likelihood of a stress fracture occurring, e.g., in a subject susceptible to stress fractures. Subjects susceptible to stress fractures include, but are not limited to, athletes, runners, soldiers, and others who engage in extensive physical activity.
[0287] As used herein, the phrase "bone defect" includes any missing portion of a bone, including bone loss due to trauma (e.g., where a bone fracture results in the loss of bone fragments), surgery (e.g., surgical removal of bone to remove cancer cells), resorption of bone, acquired disease (e.g., an acquired disease causes a portion of a bone to disappear through resorption) and / or congenital disease (e.g., a congenital bone deformity associated with one or more defects in the bone structure), the space between a bone and an implant intended to be incorporated into the bone (including, but not limited to, an implant anchored in the bone, for example, by bolts or screws).
[0288] Examples of medical conditions involving bone resorption include, but are not limited to, bone resorption associated with inflammatory conditions such as periodontitis, which may include bone resorption near the site of inflammation and alveolar bone resorption associated with missing teeth.
[0289] As used herein, the terms "osseointegration" and "osseointegrated" refer to the formation of a direct structural connection between living bone and an implant (e.g., without intervening connective tissue); and include, but are not limited to, bone growth into an implant (e.g., a porous implant), a process also referred to in the art as "osseoincorporation."
[0290] In the context of medical conditions associated with bone defects, the terms "treating" and "treatment" include, for example, substantially curing a bone defect at least in part (e.g., replacing at least a portion of the missing bone by bone regeneration), substantially increasing the rate of bone defect healing (e.g., the rate of bone regeneration), substantially improving or preventing the appearance of symptoms of a bone defect (e.g., pain, loss of function of a body part, defective bone formation), and preventing or reducing the formation of a bone defect (e.g., bone defect formation by bone resorption) (e.g., prophylaxis). Treatment of a bone defect as described herein may optionally be combined with standard treatment of the corresponding bone defect.
[0291] In some embodiments according to any corresponding embodiment described herein, the medical condition is resorption of alveolar bone. In some of these embodiments, the method or treatment is used to preserve and / or regenerate alveolar bone. Examples of alveolar bone resorption include but are not limited to resorption associated with missing teeth and resorption associated with inflammation (such as periodontitis).
[0292] In some embodiments, the method or treatment is used to preserve and / or regenerate alveolar bone around a dental implant (e.g., a dental implant containing or supporting a denture, crown, bridge, and / or fixed bracket), for example to secure the dental implant in place, thereby increasing the effectiveness of the implant and / or the likelihood of successful dental implantation. In some embodiments, the method or treatment is performed after implantation of the dental implant, for example, to promote regeneration of alveolar bone (e.g., the alveolar bone is characterized by a bone defect associated with bone resorption due to edentulism and / or periodontitis). In alternative or additional embodiments, the method or treatment is performed prior to implantation of the dental implant, for example, to protect the alveolar bone by preventing or reducing alveolar bone resorption (e.g., when teeth are missing, a considerable amount of time is expected to pass before implantation of the dental implant).
[0293] In some embodiments according to any respective embodiment described herein, the bone defect is located in the skull (cranium or mandible). In some embodiments, the bone defect is a calvarial bone defect.
[0294] Without being bound by any particular theory, the inventors believe that bones in the skull (eg, calvaria) are particularly susceptible to poor healing of bone defects and that promoting bone growth would be beneficial.
[0295] In some embodiments according to any of the corresponding embodiments described herein, the method and / or treatment comprises promoting osseointegration of the implant, for example, by promoting bone growth in the space between the bone (e.g., calvaria) and the implant. The medical condition can optionally be any medical condition for which osseointegration of the implant is beneficial.
[0296] Examples of implants that can promote bone integration include, but are not limited to, dental implants, bone grafts (e.g., allografts), chin implants, craniofacial prostheses (e.g., artificial ears, eyes, and / or noses), bone-anchored limb prostheses, bone-anchored hearing aids, and joint prostheses (e.g., for hip and / or knee replacements).
[0297] As used herein, the term "implant" refers to any device wherein at least a portion of the device is placed within a subject, including artificial devices and transplanted tissue, and may include synthetic materials, autologous grafts (e.g., bone harvested from a different region of the subject, such as the iliac crest or jaw), allografts (e.g., bone from an individual other than the subject, optionally a cadaver), xenografts (e.g., bone from a different species, optionally bovine bone or coral), or any combination thereof. Examples of synthetic materials that may be included in an implant (e.g., an implant intended for bone integration) include, but are not limited to, hydroxyapatite, calcium carbonate, tricalcium phosphate, polymers (e.g., polymethyl methacrylate, polyhydroxyethyl methacrylate), ceramics, and metals (e.g., titanium).
[0298] In some embodiments of any one of the embodiments described herein related to the use of PTH to treat osteoporosis and / or conditions associated with fractures or bone defects, oral administration according to any corresponding embodiment described herein is performed 1 to 4 times per day. In some such embodiments, oral administration according to any corresponding embodiment described herein is performed 1 to 3 times per day. In some embodiments, oral administration according to any corresponding embodiment described herein is performed once or twice per day. In some embodiments, oral administration according to any corresponding embodiment described herein is performed once per day.
[0299] In any of some embodiments described herein, the use of PTH to treat a condition associated with a bone fracture or bone defect is performed once a day or less. In some such embodiments, oral administration is performed once every two days. In some such embodiments, oral administration is performed twice a week. In some such embodiments, oral administration is performed once a week or less.
[0300] In any of the embodiments described herein relating to oral administration once a day or less, the treatment is a prophylactic treatment (for preventing or reducing the likelihood and / or size of bone fractures and / or bone defects), that is, the subject does not necessarily have a bone fracture and / or bone defect at the time of treatment.
[0301] In some embodiments, the prophylactic treatment is for stress fractures, eg, a subject susceptible to stress fractures (eg, as described herein).
[0302] In some embodiments, the preventive treatment is used to prevent or reduce alveolar bone loss associated with alveolar bone resorption, e.g., in a subject susceptible to alveolar bone resorption (e.g., as described herein). Subjects suffering from periodontitis and / or edentulous subjects are non-limiting examples of subjects susceptible to alveolar bone resorption.
[0303] Without being bound by any particular theory, the inventors believe that relatively low doses (eg, via relatively infrequent oral administration) are more suitable for prophylactic use than high doses.
[0304] Compositions for oral administration (as described herein) may be particularly convenient for indications requiring frequent administration of the therapeutically active agent.
[0305] In any of some embodiments described herein related to PTH treatment of hypoparathyroidism, oral administration according to any corresponding embodiment described herein is performed at least twice a day (e.g., 2 to 6 times a day). In some such embodiments, oral administration according to any corresponding embodiment described herein is performed at least 3 times a day (e.g., 3 to 6 times a day). In some embodiments, oral administration according to any corresponding embodiment described herein is performed at least 4 times a day (e.g., 4 to 6 times a day).
[0306] Without being bound by any particular theory, the inventors believe that frequent administration of PTH, as described in any corresponding example herein, can result in a relatively stable increase in PTH levels in the body, which is beneficial for treating hypoparathyroidism.
[0307] Without being bound by any particular theory, the inventors believe that the compositions according to some embodiments of the present invention are characterized by rapid absorption (e.g., absorption through gastric tissue before reaching the intestine), which is particularly advantageous for certain applications; for example, for obtaining a pulse-like pharmacokinetic profile (e.g., GHRH or PTH), or for treating acute, difficult to tolerate conditions or symptoms, such as pain and / or itching.
[0308] In some embodiments, rapid dosing is characterized by an average T of the composition after oral administration. 最大 No more than 60 minutes, or no more than 50 minutes, or no more than 40 minutes, or no more than 30 minutes, or no more than 20 minutes, or no more than 15 minutes, or even no more than 10 minutes.
[0309] As used herein, the term “ 最大 "" refers to the time point from administration to when the maximum concentration of the administered agent in the blood (e.g., plasma level) occurs, and can be determined by measuring the level of the agent at different time points after administration, as described herein.
[0310] In some embodiments, the composition (e.g., a unit dosage form of the composition) is formulated such that the absorption of the therapeutically active agent after oral administration is characterized by AUC and C 最大 In some embodiments, the ratio of AUC to C 最大 In some embodiments, the ratio of AUC to C 最大 In some embodiments, the ratio of AUC to C 最大 In some embodiments, the ratio of AUC to C 最大 In some embodiments, the ratio of AUC to C 最大 In some embodiments, the ratio of AUC to C 最大In some embodiments, the ratio of AUC to C 最大 In some embodiments, the ratio of AUC to C 最大 In some embodiments, the ratio of AUC to C 最大 The ratio is 10 minutes or less.
[0311] As used herein, the term "AUC" refers to the area under the curve, which represents the level of an administered agent in the blood (e.g., plasma level) as a function of time after administration, and can be determined by measuring the plasma level of the agent at different time points after administration, as shown herein.
[0312] As used herein, the term “C 最大 ” refers to the maximum concentration of an administered agent in the blood (e.g., plasma levels), and can be determined by measuring levels of the agent at various time points after administration, as described herein.
[0313] AUC and C 最大 The ratio of AUC to C 最大 ) will depend on the nature of the pharmacokinetic profile of the composition, in particular on the shape of the curve representing the level of the therapeutically active agent in the blood (e.g., plasma level) as a function of time after administration. Pharmacokinetic profiles characterized by rapid increases and decreases over a short period of time tend to have relatively low AUC and C 最大 The pharmacokinetic characteristics of the drug that are characterized by a relatively slow increase and decrease over a longer period of time tend to have relatively high AUC and C 最大 ratio.
[0314] Therefore, without being bound by any particular theory, the inventors believe that, as described herein according to any corresponding embodiment, AUC and C 最大 A ratio of 3 hours or less is associated with relatively rapid increases and decreases in the level of the therapeutically active agent in the blood.
[0315] AUC and C 最大 The ratio of AUC to C can be calculated based on data from multiple administrations of the composition. In this case, it is preferred to calculate the AUC and C for each administration. 最大 The ratio calculated for each dose can then be averaged.
[0316] Similarly, C 最大 and / or T 最大 Alternatively, the calculation is based on data from multiple administrations of the composition. In this case, it is preferred to calculate the C for each administration. 最大 and / or T 最大 The C value can then be calculated for each dose 最大 or T最大 Perform an average.
[0317] Without being bound by any particular theory, the inventors believe that averaging data (e.g., measured blood levels of the therapeutically active agent) for different doses of the therapeutically active agent will generally result in a broader curve, lower C 最大 Values and greater AUC with C 最大 Therefore, the C calculated from the average data 最大 Values and AUC vs. C 最大 A ratio calculated for each administration (as opposed to an average of the ratios calculated for each administration as described above) is a less accurate indicator of the effectiveness of the composition after administration.
[0318] Composition formula:
[0319] Each composition and unit dosage form described herein optionally consists essentially of the functional ingredients as described above (e.g., the therapeutically active agent, absorption enhancer and basic group-containing polymer according to any embodiment described in any corresponding section herein), or alternatively, the composition further comprises a suitable pharmaceutically acceptable carrier and / or excipient.
[0320] Hereinafter, the phrases "physiologically acceptable carrier" and "pharmaceutically acceptable carrier" which are used interchangeably refer to a carrier or diluent that does not cause significant irritation to an organism and does not abrogate the activity (e.g., biological activity) and properties of a functional ingredient (e.g., a therapeutically active agent). Adjuvants are included under these phrases.
[0321] Herein, the term "excipient" refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient. Examples of excipients include, but are not limited to, calcium carbonate, calcium phosphate, various sugars and various types of starch (e.g., various types of unmodified starch), cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.
[0322] In any embodiment of some embodiments described herein, the composition is formulated as a solid composition, such as a solid unit dosage form. In some embodiments, the composition is formulated as a tablet or a combination of multiple tablets (e.g., multiple mini-tablets). In some embodiments, the composition is formulated as a capsule, as described herein, which contains, for example, multiple mini-tablets and / or powders, and which has a coating that is soluble in gastric fluid (e.g., in gastric pH), or releases the capsule contents immediately after contact with gastric fluid (e.g., less than 5 minutes, or less than 2 minutes, or less than 1 minute).
[0323] The ingredients of the formulation (including but not limited to any two or more of the basic group-containing polymer, absorption enhancer, and therapeutically active agent of any corresponding embodiment described herein) can be optionally mixed in a uniform manner, or distributed throughout the composition in a non-uniform manner.
[0324] Techniques for the formulation and administration of drugs may be found in "Remington's Pharmaceutical Sciences", Mack Publishing Co., Easton, PA, latest edition, which is incorporated herein by reference.
[0325] The pharmaceutical compositions and unit dosage forms of some embodiments of the present invention can be manufactured by methods well known in the art, for example, by conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing methods.
[0326] Therefore, the pharmaceutical composition and unit dosage form used according to some embodiments of the present invention can be prepared in a conventional manner using one or more physiologically acceptable carriers, and the carrier includes excipients and adjuvants, which help to process the active ingredient into a pharmaceutical preparation that can be used for pharmacy. Pharmaceutical compositions and unit dosage forms can be easily prepared by combining the active compound with a pharmaceutically acceptable carrier suitable for oral administration well known in the art. Such carriers optionally promote the preparation of pharmaceutical compositions, such as tablets (including mini tablets), granules (pellets), pills, lozenges, capsules, powders, microparticles (granules), elixirs (elixirs), tinctures, liquids, gels, syrups, pastes (slurries), suspensions, emulsions, etc., for oral administration to patients. Orally used pharmaceutical preparations can be prepared with solid excipients, and the resulting mixture is optionally ground, and processed into a granular mixture after adding suitable adjuvants to obtain tablets or lozenge cores. Pharmaceutical compositions and unit dosage forms suitable for oral administration include but are not limited to quick-release, time-controlled release, sustained-release and delayed-release pharmaceutical dosage forms. In some embodiments of any of the respective embodiments, the pharmaceutical composition formulated for oral administration is a solid composition, such as a tablet, capsule, powder, or microgranules.
[0327] Suitable excipients are, in particular, fillers, such as sugars, including lactose, sucrose, mannitol or sorbitol); cellulose preparations (e.g. corn starch, wheat starch, rice starch, potato starch), gelatin, tragacanth, methylcellulose, hydroxypropylmethylcellulose; and / or physiologically acceptable polymers, such as polyvinylpyrrolidone (PVP). If desired, lubricants such as talc or magnesium stearate may be added.
[0328] In some embodiments of any embodiment described herein, any one of the compositions or unit dosage forms described herein (e.g., formulated as tablets) further comprises a lubricant. In some embodiments, the concentration of the lubricant is 5 weight percent or less, optionally 2 weight percent or less, optionally about 1 weight percent. In some embodiments, the compositions or unit dosage forms described herein (e.g., formulated as tablets) are substantially composed of a therapeutically active agent (as described herein), an absorption enhancer, a lubricant, a polymer containing a basic group, and an optional protease inhibitor (as described herein). In some embodiments, the lubricant is magnesium stearate.
[0329] The compositions or unit dosage forms described herein (e.g., formulated as tablets) may alternatively or additionally comprise additives and / or adjuncts, such as antioxidants, solvents, odor absorbers, chelating agents, preservatives, thickeners, colorants or coloring agents (pigments, mother-of-pearl, water-soluble dyes), dispersants, fillers, flavoring agents, and bactericides.
[0330] The lozenge core may optionally be provided with a suitable coating. For this reason, a concentrated sugar solution may be used which may optionally contain gum arabic, talcum, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, lacquer solution and a suitable organic solvent or solvent mixture. Dyes or pigments may be added to tablets or lozenge coatings to identify or characterize the different combinations of active compound dosages.
[0331] Pharmaceutical compositions that can be used orally include push-in capsules made of gelatin, and soft sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol, pullulan or HPMC. Push-in capsules may contain the active ingredient mixed with a filler such as lactose, a binder such as starch, a lubricant such as talc or magnesium stearate, and an optional stabilizer. In soft capsules, the active ingredient may be dissolved or suspended in a suitable liquid such as a fatty oil, liquid paraffin or liquid polyethylene glycol. In addition, a stabilizer may be added.
[0332] In some embodiments of any of the embodiments described herein, the pharmaceutical composition and / or unit dosage form according to any corresponding embodiment described herein does not contain a gastrointestinal coating, or otherwise comprises a coating that is soluble in the gastrointestinal tract (e.g., gastric fluid) and / or releases the contents immediately upon contact with gastric fluid (e.g., within no more than 5 minutes, or within no more than 2 minutes, or within no more than 1 minute).
[0333] Pharmaceutical compositions suitable for use in some embodiments of the present invention include compositions in which the therapeutically active agent is present in an amount effective to achieve the intended purpose. More specifically, the composition preferably includes a therapeutically effective amount of the therapeutically active agent, i.e., a therapeutically active dose effective to prevent, alleviate or improve disease symptoms or prolong the survival time of the subject. In addition, an amount of an absorption enhancer is preferably effective to enhance the absorption of the therapeutically active agent (e.g., in a manner described herein); and an amount of a protease inhibitor (if present) is preferably effective to inhibit the degradation of the therapeutically active agent (e.g., a polypeptide agent) by a protease.
[0334] Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
[0335] For any formulation used in the methods of the invention, the therapeutically effective amount or dose can be estimated initially from in vitro and cell culture assays. For example, a dose can be formulated in an animal model to achieve a desired concentration or titer. This information can be used to more accurately determine a useful dose for humans.
[0336] The toxicity and efficacy of the therapeutically active agents described herein can be determined by standard pharmaceutical procedures in containers, cell cultures or experimental animals. The data obtained from these containers and cell culture tests and animal studies can be used to formulate dosage ranges for humans. The dosage can vary, depending on the dosage form used and the route of administration used. The specific formulation and dosage can be selected by the individual physician based on the patient's condition. (See Fingl et al., 1975, "Pharmacological Basis of Therapeutics", Chapter 1, page 1).
[0337] Dosage and interval can be adjusted individually to provide levels (e.g., plasma levels) of the therapeutically active agent sufficient to induce or inhibit a biological effect (minimum effective concentration, MEC). The MEC varies for each formulation but can be estimated based on container data. Doses required to achieve the MEC will depend on individual characteristics. Detection assays can be used to determine plasma concentrations.
[0338] Depending on the severity and responsiveness of the disease to be treated, administration may be single or multiple administrations, with the course of treatment lasting from a few hours to a few weeks, or until a cure or a reduction in the disease state occurs.
[0339] Of course, the amount of the composition administered will depend on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, and the like.
[0340] Each administration may optionally be carried out using a single dosage form or multiple unit dosage forms. According to any corresponding embodiment described in International Patent Application Publication No. WO 2018 / 033927, multiple unit dosage forms may optionally be used only for convenience (e.g., wherein two or three unit dosage forms are used), or alternatively, in order to reduce the variability of absorption, at least three or at least four unit dosage forms are used (e.g., 3 to 10 or 4 to 10, including any intermediate values and sub-ranges therebetween).
[0341] If desired, the compositions of some embodiments of the present invention may be presented in the form of a package or dispenser device, such as a kit approved by the FDA, which may include one or more unit dosage forms containing active ingredients. For example, the package may include metal or plastic foil, such as a blister package. The package or dispenser device may be accompanied by instructions for administration. The package or dispenser may also be accompanied by a notice associated with the container, the form of which is specified by a government agency that regulates the manufacture, use or sale of the drug, and the notice reflects the agency's approval of the composition form or human or veterinary medicine. For example, such a notice may be a prescription drug label approved by the U.S. Food and Drug Administration or an approved product insert. Compositions comprising the formulations of the present invention (e.g., as described herein) may also be prepared, placed in an appropriate container, and labeled for the treatment of a specified condition, as described in further detail herein.
[0342] Additional definitions:
[0343] Herein, the term "polypeptide" refers to a polymer comprising at least 4 amino acid residues, the amino acid residues being linked by peptide bonds or their analogs (as described herein), and optionally linked only by peptide bonds themselves. In some embodiments, the polypeptide comprises at least 10 amino acid residues or their analogs. In some embodiments, the polypeptide comprises at least 20 amino acid residues or their analogs. In some embodiments, the polypeptide comprises at least 30 amino acid residues or their analogs. In some embodiments, the polypeptide comprises at least 50 amino acid residues or their analogs. The term "polypeptide" includes native polypeptides (such as degradation products, artificially synthesized polypeptides and / or recombinant polypeptides), including but not limited to native proteins, fragments and substituted derivatives of native proteins, homologues of native proteins and / or fragments and / or substituted derivatives thereof; and peptidomimetics (usually artificially synthesized polypeptides) and peptide analogs of peptoids (peptoids) and half-peptides, which may have modifications such as making the polypeptide more stable in vivo or more able to penetrate into cells. Such modifications include but are not limited to N-terminal modifications, C-terminal modifications, peptide bond modifications, backbone modifications, and residue modifications. Methods for preparing peptidomimetic compounds are well known in the art, for example, "Quantitative Drug Design", CA Ramsden Gd., Chapter 17.2, F. Choplin Pergamon Press (1992), which is incorporated herein by reference as if fully set forth herein. More details in this regard are provided herein.
[0344] The peptide bonds (-CO-NH-) within a polypeptide may be replaced by, for example, N-methylated amide bonds (-N(CH 3 )-CO-), ester bond (-C(=O)-O-), ketomethylene bond (-CO-CH 2 -), sulfinylmethylene bond (-S(=O)-CH 2 -), α-aza bonds (-NH-N(R)-CO-), where R is any alkyl group (e.g., methyl), amine bonds (-CH 2 -NH-), sulfide bond (-CH 2 -S-), vinyl bond (-CH 2 -CH 2 -), hydroxyethylene bond (-CH(OH)-CH 2 -), thioamide bonds (-CS-NH-), olefin double bonds (-CH=CH-), fluorinated olefin double bonds (-CF=CH-), trans-amide bonds (-NH-CO-), peptide derivatives (-N(R)-CH 2 -CO-), where R is a "normal" side chain naturally occurring on a carbon atom.
[0345] These modifications can occur at any bond in the polypeptide chain, even at several (2 to 3) bonds simultaneously.
[0346] The natural aromatic amino acids Trp, Tyr and Phe can be substituted by non-natural aromatic amino acids, such as 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic), naphthylalanine, ring-methylated derivatives of Phe, halogenated derivatives of Phe or O-methyl-Tyr.
[0347] The polypeptides of some embodiments of the invention (eg, the therapeutically active agents described herein) may also include one or more modified amino acids or one or more non-amino acid monomers (eg, fatty acids, complex carbohydrates, etc.).
[0348] The term "amino acid" or "amino acids" is understood to include the 20 naturally occurring amino acids; those that are commonly modified in vivo post-translation, including hydroxyproline, phosphoserine, and phosphothreonine; and other less common amino acids, including but not limited to 2-aminoadipate, hydroxylysine, isodesmosine, norvaline, norleucine, and ornithine. In addition, the term "amino acid" includes D-amino acids and L-amino acids.
[0349] Tables A and B below list naturally occurring amino acids (Table A), as well as unconventional or modified amino acids (eg, synthetic, Table B) that can be used in some embodiments of the invention.
[0350] Table A
[0351]
[0352]
[0353] Table B
[0354]
[0355]
[0356]
[0357]
[0358]
[0359] (Table B continued)
[0360] The polypeptides of some embodiments of the invention (eg, the therapeutically active agents described herein) are preferably used in linear form, but it should be understood that cyclic forms of the polypeptides may also be used if cyclization does not significantly interfere with the properties of the polypeptide.
[0361] In any of some embodiments described herein, the polypeptide is water soluble, as defined herein.
[0362] The water-soluble polypeptide preferably comprises one or more non-natural or natural polar amino acids, including but not limited to serine and threonine, which can increase the water solubility of the polypeptide due to their hydroxyl-containing side chains. Alternatively, a homologue of the polypeptide is selected to make it more water-soluble than the parent polypeptide, for example, by replacing one or more amino acids in the polypeptide with polar amino acids.
[0363] The polypeptides of some embodiments of the present invention (e.g., therapeutic agents described herein) can be synthesized by any technique known to those skilled in the art of peptide synthesis. For solid phase peptide synthesis, a summary of many techniques can be found in JM Stewart and JD Young, Solid Phase Peptide Synthesis, WH Freeman Co. (San Francisco), 1963 and J. Meienhofer, Hormonal Proteins and Peptides, Vol. 2, p. 46, Academic Press (New York), 1973. For classical solution synthesis, see G. Schroder and K. Lupke, Polypeptides, Vol. 1, Academic Press (New York), 1965.
[0364] In general, these methods involve the sequential addition of one or more amino acids or appropriately protected amino acids to a growing polypeptide chain. Typically, the amino or carboxyl group of the first amino acid is protected by a suitable protecting group. The protected or derivatized amino acid is then linked to an inert solid support under conditions suitable for the formation of an amide bond, or by adding the next amino acid in the sequence in solution with the complementary group (amino or carboxyl) appropriately protected. The protecting group is then removed from this newly added amino acid residue, and the next amino acid (appropriately protected) is added, and so on. After all the desired amino acids have been linked in the appropriate order, any remaining protecting groups (and any solid support) are removed sequentially or simultaneously to provide the final polypeptide compound. By simple modifications to this general procedure, more than one amino acid can be added to the growing chain at a time, for example, a protected tripeptide can be coupled to a suitably protected dipeptide (under conditions that do not racemize the chiral center) to form a pentapeptide after deprotection, and so on. Further description of polypeptide synthesis is disclosed in U.S. Patent No. 6,472,505.
[0365] A preferred method for preparing the polypeptide compounds of some embodiments of the invention (eg, the therapeutically active agents described herein) involves solid phase peptide synthesis.
[0366] Large-scale peptide synthesis is described by Andersson et al. [Biopolymers 2000;55:227-250].
[0367] The term "nucleic acid" refers to a single-stranded or double-stranded oligomer or polymer of monomeric units of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or their mimetics. This term includes nucleic acids composed of naturally occurring bases, sugars, and covalent nucleoside bonds (such as backbones), as well as nucleic acids with non-natural portions that function similarly to the corresponding naturally occurring portions.
[0368] The nucleic acids designed according to the teachings of some embodiments of the present invention can be produced according to any nucleic acid synthesis method known in the art, such as enzymatic synthesis or solid phase synthesis. Equipment and reagents for performing solid phase synthesis can be commercially available from, for example, Applied Biosystems. Any other synthesis method can also be used; the actual synthesis of nucleic acids is entirely within the capabilities of those skilled in the art and can be accomplished by established methods, for example, "Molecular Cloning: A Laboratory Manual" Sambrook et al., (1989); "Current Protocols in Molecular Biology" Volumes I to III, Ausubel, RM Editor (1994); Ausubel et al., "Current Protocols in Molecular Biology", John Wiley and Sons Publishers, Baltimore, Maryland (1989); Perbal, "A Practical Guide to Molecular Cloning", J John Wiley Sons Publishers, New York (1988); and "Oligonucleotide Synthesis" Gait, MJ, Editor (1984) Detailed, using solid phase chemistry, such as cyanoethyl phosphoramidite, followed by deprotection, desalting and purification by, for example, automated trityl-on methods or HPLC.
[0369] The nucleic acids of some embodiments of the invention have at least 8, at least 13, at least 17, at least 18, at least 19, at least 20, at least 22, at least 25, at least 30, or at least 40 bases that specifically hybridize to the sequence changes described above.
[0370] The nucleic acid of some embodiments of the invention has a length of no more than 200, or no more than 50 (eg, 8 to 50), or no more than 25 (eg, 13 to 25) bases.
[0371] Nucleic acids of some embodiments of the present invention may comprise heterocyclic nucleosides composed of purine and pyrimidine bases, bound by 3' to 5' phosphodiester bonds.
[0372] Preferred nucleic acids for use are those modified in the backbone, nucleoside linkages or bases, as described extensively below.
[0373] According to some embodiments of the present invention, specific examples of preferred nucleic acids include nucleic acids containing modified backbones or non-natural nucleoside bonds. Nucleic acids with modified backbones include nucleic acids that retain phosphorus atoms in the backbone, such as U.S. Patents Nos. 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676 ; No. 5,405,939; No. 5,453,496; No. 5,455,233; No. 5,466,677; No. 5,476,925; No. 5,519,126; No. 5,536,821; No. 5,541,306; No. 5,550,111; No. 5,563,253; No. 5,571,799; No. 5,587,361; and No. 5,625,050.
[0374] Preferred modified nucleic acid backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkylphosphonates, including 3'-alkylenephosphonates and chiral phosphonates, phosphinates, phosphoramidates, including 3'-aminophosphoramidates and aminoalkylphosphoramidates, thiophosphoramidates, thioalkylphosphonates, thioalkylphosphotriesters and boranophosphates with normal 3'-5' bonds, analogs of these 2'-5' connections, and those with opposite polarity, wherein adjacent nucleoside units are connected 3'-5' to 5'-3' or 2'-5' to 5'-2' connections. Various salts, mixed salts and free acid forms can also be used.
[0375] Alternatively, the modified nucleic acid backbone containing no phosphorus atom has a backbone formed by short-chain alkyl or cycloalkyl nucleoside bonds, mixed heteroatoms and alkyl or cycloalkyl nucleoside bonds, or one or more short-chain heteroatoms or heterocyclic nucleoside bonds. These include those with morpholino bonds (partially formed by the sugar portion of the nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; acetyl and thioacetyl backbones; methyleneformyl and thioformyl backbones; olefin-containing backbones; aminosulfonate backbones; methyleneamino and methylenehydrazine backbones; sulfonate and sulfonamide backbones; amide backbones; and other components with mixed N, O, S and CH2 components, such as in U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; No. 5,264,564; No. 5,405,938; No. 5,434,257; No. 5,466,677; No. 5,470,967; No. 5,489,677; No. 5,541,307; No. 5,561,225; No. 5,596,086; No. 5,602,240; No. 5,610,289; No. 5,602,240; No. 5,608,046; No. 5,610,289; No. 5,618,704; No. 5,623,070; No. 5,663,312; No. 5,633,360; No. 5,677,437; and No. 5,677,439.
[0376] According to some embodiments of the present invention, other nucleic acids that can be used are those that have been modified in both the sugar and the internucleoside bond (i.e., the backbone of the nucleotide unit), which are replaced by new groups. The base unit is retained to complement the appropriate polynucleotide target. An example of such a nucleic acid mimetic includes peptide nucleic acid (PNA). PNA refers to a nucleic acid in which the sugar backbone is replaced by an amide-containing backbone, particularly an aminoethylglycine backbone. The base is retained and is directly or indirectly bound to the aza nitrogen atom of the backbone amide portion. U.S. patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Patent Nos. 5,539,082; 5,714,331; and 5,719,262, each of which is incorporated herein by reference. Other backbone modifications that can be used in some embodiments of the present invention are disclosed in U.S. Patent Application Publication No. 6,303,374.
[0377] The nucleic acids of some embodiments of the present invention may also include base modifications or substitutions. As used herein, "unmodified" or "natural" bases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified bases include but are not limited to other synthetic and natural bases, such as 5-methylcytosine (5-me-C), 5-hydroxymethylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyluracil and cytosine, 6-azouracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxy and other 8-substituted adenines and guanine, 5-halo, especially 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Other bases include those disclosed in U.S. Pat. No. 3,687,808, Concise Encyclopedia of Polymer Science and Engineering, pp. 858-859, Kroschwitz, JI, ed., John Wiley & Sons, 1990, Englisch et al., Angewandte Chemie, International Edition, 1991, 30613, and Sanghvi, YS, Chapter 15, Antisense Research and Applications, pp. 289-302, Crooke, ST and Lebleu, B., ed., CRC Press, 1993. According to some embodiments of the present invention, such bases are particularly useful for improving the binding affinity of oligomeric compounds. These include 5-substituted pyrimidines, 6-azapyrimidines, and N-2, N-6, and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil, and 5-propynylcytosine. Studies have shown that 5-methylcytosine substitution can increase the stability of nucleic acid duplexes by 0.6 to 1.2°C. [Sanghvi YS et al. (1993), Antisense Research and Applications, CRC Press, Boca Raton 276-278], and is currently the preferred base substitution, especially when used in combination with 2'-O-methoxyethyl sugar modification. Further base substitutions include non-standard bases disclosed in U.S. Pat. Nos. 8,586,303, 8,614,072, 8,871,469 and 9,062,336 to Benner et al.: For example, Benner et al. have demonstrated that non-standard dZ:dP nucleobase pairs can be incorporated into DNA by DNA polymerase to produce amplicons with multiple non-standard nucleotides.
[0378] Herein, the "homologue" of a given polypeptide or nucleic acid refers to a polypeptide or nucleic acid that has at least 80% homology, preferably at least 90% homology, more preferably at least 95% homology, and most preferably at least 98% homology with a given polypeptide or nucleic acid. In some embodiments, a homologue of a given polypeptide / nucleic acid also shares therapeutic activity with a given polypeptide / nucleic acid. Homology percentage refers to the percentage of amino acid residues in a first polypeptide sequence that match the corresponding residues of a second polypeptide sequence compared to the first polypeptide, or the percentage of nucleotides in a first nucleic acid sequence that match the corresponding nucleotides of a second polypeptide sequence compared to the first polypeptide. Typically, polypeptides / nucleic acids are aligned to obtain maximum homology. Various strategies for comparing amino acid or nucleotide sequences to assess the degree of identity are known in the art, including, for example, manual alignment, computer-assisted sequence alignment, and combinations thereof. Many algorithms (usually computer-implemented) for performing sequence alignment are widely available or can be generated by those skilled in the art. Representative algorithms include, for example, the local homology algorithm of Smith and Waterman (Adv. Appl. Math., 1981, 2: 482); the homology alignment algorithm of Needleman and Wunsch (J. Mol. Biol., 1970, 48: 443); the similarity search method of Pearson and Lipman (Proceedings of the National Academy of Sciences of the United States of America, 1988, 85: 2444); and / or computerized implementations of these algorithms (e.g., GAP, BESTFIT, FASTA and TFASTA in the Wisconsin Genetics Software Package Version 7.0, Genetics Computer Group, 575 Science Dr., Madison, Wis.). Ready-made computer programs that include such algorithms include, for example, BLASTN, BLASTP, Gapped BLAST, PILEUP, CLUSTALW, etc. When using BLAST and Gapped BLAST programs, the default parameters of the corresponding programs can be used. Alternatively, the practitioner may use non-default parameters according to his or her experimental and / or other requirements (eg, see the website at URL www.ncbi.nlm.nih.gov).
[0379] As used herein, the terms "amine" and "amino" each refer to a -NR'R' group, wherein R' and R" are each hydrogen or a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroalicyclic (bonded to the amine nitrogen through a ring carbon), aryl or heteroaryl (bonded to the amine nitrogen through a ring carbon), as defined herein. Alternatively, R' and R" may optionally be linked to form a heteroalicyclic (as defined herein). Optionally, R' and R" and R'" are hydrogen or an alkyl group containing from 1 to 4 carbon atoms. Optionally, at least one of R' and R" is hydrogen, and optionally both are hydrogen. When substituted, the carbon atoms of the hydrocarbon portion of R' and R" that are bound to the nitrogen atom of the amine are not substituted with oxo, and thus R' and R" are not, for example, carbonyl, C-carboxyl or amide, as these groups are defined herein.
[0380] As used throughout this article, the term "alkyl" refers to any saturated aliphatic hydrocarbon, which includes straight and branched chain groups. Preferably, the alkyl group has 1 to 20 carbon atoms. Whenever a numerical range, such as "1 to 20" is stated herein, the numerical range means that the group, in this case a hydrocarbon, can contain 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms. More preferably, the alkyl group is a medium-sized alkyl group having 1 to 10 carbon atoms. Unless otherwise specified, most preferably the alkyl group is a low alkyl group having 1 to 4 carbon atoms. The alkyl group may be substituted or unsubstituted. When substituted, the substituent can be, for example, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halogen, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, sulfonate, sulfate, cyano, nitro, azide, phosphino, phosphinyl, oxo, imine, oxime, hydrazone, carbonyl, thiocarbonyl, urea, thiourea, O-carbamoyl, N-carbamoyl, O-thiocarbamoyl, N-thiocarbamoyl, S-thiocarbamoyl, C-amino, N-amino, C-carboxy, O-carboxy, sulfonylamino, guanosyl, guanidinyl, hydrazine, hydrazide, thiohydrazide and amino, as defined herein.
[0381] As used herein, the term "alkenyl" describes an unsaturated aliphatic hydrocarbon containing at least one carbon-carbon double bond, including straight and branched groups. Preferably, the alkenyl has 2 to 20 carbon atoms. More preferably, the alkenyl is a medium-sized alkenyl having 2 to 10 carbon atoms. Unless otherwise indicated, most preferably the alkenyl is a lower alkenyl having 2 to 4 carbon atoms. The alkenyl may be substituted or unsubstituted. The substituted alkenyl group may have one or more substituents, wherein each substituent group may independently be, for example, alkynyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halogen, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, sulfonate, sulfate, cyano, nitro, azide, phosphino, phosphinyl, oxo, imine, oxime, hydrazone, carbonyl, thiocarbonyl, urea, thiourea, O-carbamoyl, N-carbamoyl, O-thiocarbamoyl, N-thiocarbamoyl, S-thiocarbamoyl, C-amino, N-amino, C-carboxyl, O-carboxyl, sulfonylamino, guanosyl, guanidinyl, hydrazine, hydrazide, thiohydrazide, and amino, as defined herein.
[0382] As used herein, the term "alkynyl" describes an unsaturated aliphatic hydrocarbon containing at least one carbon-carbon triple bond, including straight and branched chain groups. Preferably, the alkynyl group has 2 to 20 carbon atoms. More preferably, the alkynyl group is a medium-sized alkynyl group having 2 to 10 carbon atoms. Most preferably, unless otherwise indicated, the alkynyl group is a low-order alkynyl group having 2 to 4 carbon atoms. The alkynyl group may be substituted or unsubstituted. The substituted alkynyl group may have one or more substituents, wherein each substituent group may independently be, for example, cycloalkyl, alkenyl, aryl, heteroaryl, heteroalicyclic, halogen, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, sulfonate, sulfate, cyano, nitro, azide, phosphino, phosphinyl, oxo, imine, oxime, hydrazone, carbonyl, thiocarbonyl, urea, thiourea, O-carbamoyl, N-carbamoyl, O-thiocarbamoyl, N-thiocarbamoyl, S-thiocarbamoyl, C-amino, N-amino, C-carboxyl, O-carboxyl, sulfonylamino, guanosyl, guanidinyl, hydrazine, hydrazide, thiohydrazide, and amino.
[0383] "Cycloalkyl" groups refer to saturated or unsaturated all-carbon monocyclic or fused rings (i.e., rings that share a pair of adjacent carbon atoms) groups, wherein one or more rings do not have a completely conjugated π electron system. Examples of cycloalkyl groups include, but are not limited to, cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexadiene, cycloheptane, cycloheptatriene, and adamantane. Cycloalkyl groups may be substituted or unsubstituted. When substituted, the substituent can be, for example, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halogen, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, sulfonate, sulfate, cyano, nitro, azide, phosphinyl, phosphinyl, oxo, imine, oxime, hydrazone, carbonyl, thiocarbonyl, urea, thiourea, O-carbamoyl, N-carbamoyl, O-thiocarbamoyl, N-thiocarbamoyl, S-thiocarbamoyl, C-amino, N-amino, C-carboxyl, O-carboxyl, sulfonylamino, guanosyl, guanidinyl, hydrazine, hydrazide, thiohydrazide and amino, as defined herein. When the cycloalkyl is unsaturated, it can contain at least one carbon-carbon double bond and / or at least one carbon-carbon triple bond.
[0384] "Aryl" refers to an all-carbon monocyclic or fused-ring polycyclic ring (i.e., rings that share adjacent pairs of carbon atoms) with a completely conjugated π electron system. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, and anthracenyl. Aryl groups may be substituted or unsubstituted. When substituted, the substituent can be, for example, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halogen, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, sulfonate, sulfate, cyano, nitro, azide, phosphino, phosphinyl, oxo, imine, oxime, hydrazone, carbonyl, thiocarbonyl, urea, thiourea, O-carbamoyl, N-carbamoyl, O-thiocarbamoyl, N-thiocarbamoyl, S-thiocarbamoyl, C-amino, N-amino, C-carboxy, O-carboxy, sulfonamido, guanosyl, guanidinyl, hydrazine, hydrazide, thiohydrazide and amino, as defined herein.
[0385] "Heteroaryl" refers to a monocyclic or fused ring (i.e., a ring that shares an adjacent pair of atoms) having one or more atoms (e.g., nitrogen, oxygen, and sulfur) in the ring and, in addition, having a completely conjugated π electron system. Examples of heteroaryl groups include, but are not limited to, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrimidine, quinoline, isoquinoline, and purine. Heteroaryl groups may be substituted or unsubstituted. When substituted, the substituent can be, for example, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halogen, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, sulfonate, sulfate, cyano, nitro, azide, phosphino, phosphinyl, oxo, imine, oxime, hydrazone, carbonyl, thiocarbonyl, urea, thiourea, O-carbamoyl, N-carbamoyl, O-thiocarbamoyl, N-thiocarbamoyl, S-thiocarbamoyl, C-amino, N-amino, C-carboxy, O-carboxy, sulfonamido, guanosyl, guanidinyl, hydrazine, hydrazide, thiohydrazide and amino, as defined herein.
[0386] A "heteroalicyclic" group refers to a monocyclic or fused ring group having one or more atoms (such as nitrogen, oxygen and sulfur) in the ring. The multiple rings may also have one or more double bonds. However, the multiple rings do not have a completely conjugated π electron system. The heteroalicyclic ring may be substituted or unsubstituted. When substituted, the substituted group can be, for example, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halogen, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, sulfonate, sulfate, cyano, nitro, azide, phosphinyl, phosphinyl, oxo, imine, oxime, hydrazone, carbonyl, thiocarbonyl, urea, thiourea, O-carbamoyl, N-carbamoyl, O-thiocarbamoyl, N-thiocarbamoyl, S-thiocarbamoyl, C-amino, N-amino, C-carboxyl, O-carboxyl, sulfonylamino, guanosyl, guanidinyl, hydrazine, hydrazide, thiohydrazide and amino, as defined herein. Representative examples are piperidine, piperazine, tetrahydrofuran, tetrahydropyran, morpholine, etc.
[0387] An "azide" group refers to -N=N + =N - Group.
[0388] As defined herein, an "alkoxy" group refers to any of -O-alkyl, -O-alkenyl, -O-alkynyl, -O-cycloalkyl, and -O-heteroalicyclic groups.
[0389] An "aryloxy" group refers to both -O-aryl and -O-heteroaryl groups, as defined herein.
[0390] A "hydroxy" group refers to an -OH group.
[0391] A "thiol" or "thiol" group refers to a -SH group.
[0392] As defined herein, a "thioalkoxy" group refers to any of -S-alkyl, -S-alkenyl, -S-alkynyl, -S-cycloalkyl, and -S-heteroalicyclic groups.
[0393] A "thioaryloxy" group refers to both -S-aryl and -S-heteroaryl groups, as defined herein.
[0394] A "carbonyl" or "acyl" group refers to a -C(=O)-R' group, where R' is as defined above.
[0395] A "thiocarbonyl" group refers to a -C(=S)-R' group, where R' is as defined herein.
[0396] A "C-carboxy" group refers to a -C(=O)-O-R' group, where R' is as defined herein.
[0397] An "O-carboxy" group refers to a R'C(=O)-O- group, where R' is as defined herein.
[0398] A "carboxylic acid" group refers to a -C(=O)OH group.
[0399] An "oxo" group refers to an a=0 group.
[0400] An "imine" group refers to an a=N-R' group, where R' is as defined herein.
[0401] An "oxime" group refers to an a=N-OH group.
[0402] A "hydrazone" group refers to an A=N-NR'R" group, where R' and R" are as defined herein.
[0403] A "halogen" group refers to fluorine, chlorine, bromine or iodine.
[0404] "Sulfinyl" refers to a -S(=O)-R' group, where R' is as defined herein.
[0405] "Sulfonyl" refers to -S(=O) 2 An -R' group, wherein R' is as defined herein.
[0406] A "sulfonate" group refers to a -S(=O) 2 An -O-R' group, wherein R' is as defined herein.
[0407] A "sulfate" group refers to -OS(=O) 2 An -O-R' group, wherein R' is as defined herein.
[0408] As defined herein, a "sulfonamide" or "sulfonylamino" group includes S-sulfonylamino and N-sulfonylamino groups.
[0409] An "S-sulfonylamino" group refers to a -S(=O) 2 A -NR'R" group, wherein R' and R" are as defined herein.
[0410] An "N-sulfonylamino" group refers to R'S(=O) 2 -NR" group, wherein each of R' and R" are as defined herein.
[0411] An "O-carbamyl" group refers to a -OC(=O)-NR'R" group, where each of R' and R" are as defined herein.
[0412] An "N-carbamyl" group refers to a RR'OC(=O)-NR"- group, where each of R' and R" are as defined herein.
[0413] An "O-thiocarbamyl" group refers to a -OC(=S)-NR'R" group, where R' and R" are each as defined herein.
[0414] An "N-thiocarbamyl" group refers to a R'OC(=S)NR"- group, where each of R' and R" are as defined herein.
[0415] An "S-thiocarbamyl" group refers to a -SC(=O)-NR'R" group, where R' and R" are as defined herein.
[0416] As defined herein, "amide" or "amido" includes C-amido and N-amido groups.
[0417] "C-amido" refers to a -C(=O)-NR'R" group, where R' and R" are as defined herein.
[0418] An "N-amido" group refers to a R'C(=O)-NR"- group, where each of R' and R" are as defined herein.
[0419] "Urea" refers to a -N(R')-C(=O)-NR"R'" group, where each of R', R", and R'" are as defined herein.
[0420] "Thiourea" refers to a -N(R')-C(=S)-NR"R'" radical, where each of R', R", and R'" are as defined herein.
[0421] "Nitro" refers to -NO 2Group.
[0422] "Cyano" refers to a -CN group.
[0423] The term "phosphonyl" or "phosphonate" describes a -P(=O)(OR')(OR") group, where R' and R" are as defined above.
[0424] The term "phosphate;" describes a -OP(=O)(OR')(OR") group, wherein R' and R" are as defined above.
[0425] The term "phosphinyl" describes a -PR'R" group, wherein R' and R" are as defined above.
[0426] The term "hydrazino" describes a -NR'-NR"R'" group, where R', R", and R'" are as defined herein.
[0427] As used herein, the term "hydrazide" describes a -C(=O)-NR'-NR"R'" group, where R', R", and R'" are as defined herein.
[0428] As used herein, the term "thiohydrazide" describes a -C(=S)-NR'-NR"R'" group, where R', R", and R'" are as defined herein.
[0429] "Guanidinyl" refers to a -RaNC(=NRd)-NRbRc group, where each of Ra, Rb, Rc and Rd may be as defined herein for R' and R".
[0430] A "guanosyl" or "guanine" group refers to a RaRbNC(=NRd)- group, where Ra, Rb and Rd are as defined herein.
[0431] For any of the embodiments described herein, each compound described herein (including the therapeutically active agent, the absorption enhancer, and the polymer) can be in the form of a salt, such as a pharmaceutically acceptable salt, and / or in the form of a prodrug.
[0432] As used herein, the phrase "pharmaceutically acceptable salt" refers to charged species of a parent compound and its counter ions, which are generally used to alter the solubility characteristics of the parent compound and / or reduce any significant irritation of the parent compound to an organism, while not abolishing the biological activity and properties of the administered compound. Pharmaceutically acceptable salts of compounds as described herein can be formed during the synthesis of the compound, for example, during the isolation of the compound from a reaction mixture or during the recrystallization of the compound.
[0433] In the context of some embodiments of this embodiment, the pharmaceutically acceptable salts of the compounds described herein may optionally be acid addition salts and / or base addition salts.
[0434] Acid addition salts include compounds having at least one basic (e.g., amino and / or guanidinium) group in positively charged form (e.g., wherein the basic group is protonated), combined with at least one counterion derived from a selected acid to form a pharmaceutically acceptable salt. Thus, an acid addition salt of a compound described herein may be a complex formed between a compound having one or more basic groups and one or more equivalents of an acid.
[0435] Base addition salts include compounds having at least one acidic (e.g., carboxylic acid) group in negatively charged form (e.g., wherein the acidic group is deprotonated), combined with at least one counterion derived from a selected base to form a pharmaceutically acceptable salt. Thus, base addition salts of the compounds described herein can be complexes formed between compounds having one or more acidic groups and one or more equivalents of a base.
[0436] Acid addition salts and / or base addition salts can be single-addition salts or multiple-addition salts, depending on the stoichiometric ratio between the charged groups in the compound and the counterions in the salt.
[0437] As used herein, the phrase "mono-addition salt" refers to a salt wherein the stoichiometric ratio between the counterion and the charged form of the compound is 1:1, such that the addition salt contains one molar equivalent of the counterion per molar equivalent of the compound.
[0438] As used herein, the phrase "multiple addition salt" refers to a salt wherein the stoichiometric ratio between the counterion and the charged form of the compound is greater than 1:1, e.g., 2:1, 3:1, 4:1, etc., such that the addition salt contains two or more molar equivalents of the counterion per molar equivalent of the compound.
[0439] An example of a pharmaceutically acceptable salt is an ammonium cation or a guanidinium cation and its acid addition salts, and / or a carboxylate anion and its base addition salts.
[0440] Base addition salts may contain cationic counterions, such as sodium, potassium, ammonium, calcium, magnesium, and the like, which form pharmaceutically acceptable salts.
[0441] Acid addition salts may include various organic and inorganic acids, such as, but not limited to, hydrochloric acid to provide hydrochloric acid addition salts, hydrobromic acid to provide hydrobromic acid addition salts, acetic acid to provide acetic acid addition salts, ascorbic acid to provide ascorbic acid addition salts, benzenesulfonic acid to provide benzenesulfonate addition salts, camphorsulfonic acid to provide camphorsulfonic acid addition salts, citric acid to provide citric acid addition salts, maleic acid to provide maleic acid addition salts, malic acid to provide malic acid addition salts, methanesulfonic acid to provide methanesulfonic acid addition salts, naphthalenesulfonic acid to provide naphthalenesulfonic acid addition salts, oxalic acid to provide oxalic acid addition salts, phosphoric acid to provide phosphoric acid addition salts, toluenesulfonic acid to provide toluenesulfonic acid addition salts, succinic acid to provide succinic acid addition salts, sulfuric acid to provide sulfuric acid addition salts, tartaric acid to provide tartaric acid addition salts, and trifluoroacetic acid to provide trifluoroacetic acid addition salts. Each of these acid addition salts may be a single addition salt or a multiple addition salt, as defined herein.
[0442] As used herein, the term "prodrug" refers to a compound (e.g., a compound of the formula described above) that is converted into an active compound in vivo. Prodrugs are generally intended to facilitate administration, for example, by enhancing absorption. Prodrugs may include, for example, an active compound modified with an ester group, for example, wherein any one or more hydroxyl groups of the compound are replaced by an acyl group, optionally (C 1-4 )-acyl (e.g. acetyl) groups are modified to form ester groups, and / or any one or more carboxylic acid groups of the compound are modified with alkoxy or aryloxy groups, optionally (C 1-4 )-alkoxy (e.g., methyl, ethyl) to form an ester group.
[0443] Furthermore, each compound described herein (including therapeutically active agents, absorption enhancers and polymers), including salts thereof, may be in the form of a solvate or a hydrate thereof.
[0444] The term "solvate" refers to a complex of variable stoichiometry (eg, di-, tri-, tetra-, penta-, hexa-, etc.) formed by a solute (a heterocyclic compound described herein) and a solvent, wherein the solvent does not interfere with the biological activity of the solute.
[0445] The term "hydrate" refers to a solvate as described above wherein the solvent is water.
[0446] The compounds described herein may exist as polymorphs, and the present embodiments also encompass any isomers of the compounds and any combination thereof.
[0447] The compounds and structures described herein encompass any stereoisomer of the compounds described herein, including enantiomers and diastereomers, unless a particular stereoisomer is specifically indicated.
[0448] As used herein, the term "enantiomer" refers to a stereoisomer of a compound that is superposable relative to its counterpart only by complete inversion / reflection (mirror image) of each other. Enantiomers are referred to as having "handedness" because they refer to each other, like the right and left hands. Enantiomers have the same chemical and physical properties unless present in an environment that is chiral, such as all living systems. In the context of the present embodiment, the compound can exhibit one or more chiral centers, each of which exhibits (R) or (S) configuration and any combination, and the compound according to some embodiments of the present invention can have any chiral center that exhibits (R) or (S) configuration.
[0449] As used herein, the term "diastereomer" refers to stereoisomers that are not enantiomers of each other. Diastereomerism occurs when two or more stereoisomers of a compound have different configurations at one or more (but not all) equivalent (related) stereocenters and are not mirror images of each other. When two diastereomers differ from each other only at one stereocenter, they are epimers. Each stereocenter (chiral center) produces two different configurations, thereby producing two different stereoisomers. In the context of the present invention, embodiments of the present invention include compounds with multiple chiral centers, which appear in any combination of stereoconfigurations, i.e., any diastereomers.
[0450] It is expected that during the life of the patent expiring on this application, many therapeutic agents and related treatments for many conditions treatable by therapeutic agents will be developed, and the scope of the phrases "therapeutic agent" and "condition treatable by a therapeutic agent" is intended a priori to include all such new and technologies.
[0451] As used herein, the term "about" refers to ± 10%.
[0452] The terms "comprises," "comprising," "includes," "including," and "having" and their conjugations mean "including, but not limited to."
[0453] The term "consisting of" means "including and limited to."
[0454] The term "consisting essentially of" means that a composition, method or structure may include additional ingredients, steps and / or parts, but only if the additional ingredients, steps and / or parts do not materially change the basic and novel characteristics of the claimed composition, method or structure.
[0455] Throughout this application, various embodiments of the present invention can be presented in range format. It should be understood that the description of range format is only for convenience and brevity and should not be interpreted as an inflexible limitation on the scope of the present invention. Therefore, it should be considered that the description of the range has specifically disclosed all possible sub-ranges and each numerical value in the range. For example, the description of the range from 1 to 6 should be regarded as having a specifically disclosed sub-range, such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., and a single number in the range, such as 1, 2, 3, 4, 5 and 6. Regardless of the breadth of the scope, this applies.
[0456] Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integer) within the indicated range. The phrases "ranging" or "ranges between" and "ranging from" to" the first indicated numeral are used interchangeably herein and are meant to include the first indicated numeral and the second indicated numeral and all fractional and integer values therebetween.
[0457] As used herein, the term "method" refers to ways, means, techniques and procedures for accomplishing a given task, including but not limited to those ways, means, techniques and procedures known to or readily developable from known ways, means, techniques and procedures by practitioners in the fields of chemistry, pharmacology, biology, biochemistry and medicine.
[0458] As used herein, the term "treating" encompasses abrogating, substantially inhibiting, slowing or reversing the progression of a disease, substantially ameliorating the clinical or aesthetic symptoms of a disease, or substantially preventing the appearance of clinical or aesthetic symptoms of a disease.
[0459] It should be understood that certain features of the invention described in the context of separate embodiments for clarity may also be provided in combination in a single embodiment. Conversely, various features of the invention described in the context of a single embodiment for brevity may also be provided separately or in any suitable subcombination, or in any other described embodiment of the invention. Certain features described in the context of various embodiments should not be considered essential features of those embodiments, unless the embodiments would not function without those elements.
[0460] Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below will find experimental support in the following examples.
[0461] Example
[0462] Reference is now made to the following examples, which together with the above descriptions illustrate some embodiments of the invention in a non-limiting fashion.
[0463] Materials and methods
[0464] Material:
[0465] Cross-linked carboxymethyl cellulose sodium CCS; cross-linked; CAS No. 74811-65-7) was obtained from Merck.
[0466] Sodium alginate (CAS No. 9005-38-3), average molecular weight 300 to 350 kDa, room temperature viscosity 350 to 500 mPa (non-crosslinked), obtained from Carl Roth Company.
[0467] Sodium carboxymethyl cellulose (CMC), CAS No. 9004-32-4(non Cross-linked), low viscosity (43 mPa at room temperature) obtained from Merck or Ashland.
[0468] Sodium starch glycolate A Cross-linked; CAS No. 9063-38-1), average molecular weight 2000 kDa, viscosity less than 200 mPa at room temperature, obtained from DFE Pharma.
[0469] Determine pH using a pH meter:
[0470] The test substances were dissolved in different volumes of 0.1M HCl solution (pH 1.2) at concentrations of 1, 2, 4, 10, 20, 50, 100 and 150 mg / ml. Shortly after dissolution and after 26 hours, the solution pH was measured using an MP-103 pH meter (MRC, Israel) equipped with an ELC-10-00 electrode (MRC, Israel) or a thin electrode HI1083 (HANNA Instruments, Inc.) to ensure that the pH remained stable. The highest pH value obtained during the experiment was recorded to compare the acid neutralization capacity of each substance.
[0471] Other pH measurements are made by adding an appropriate colorimetric pH indicator solution to the test medium.
[0472] Example 1
[0473] Effect of basic polymer on pH value of simulated gastric fluid
[0474] HCl solution was used as simulated gastric fluid to study the effects of alkaline polymers on gastric fluid and the behavior of SNAC in gastric fluid.
[0475] SNAC and the basic polymers sodium alginate, carboxymethylcellulose sodium salt in non-crosslinked (Na-CMC) and crosslinked (croscarmellose sodium, CCS) forms, and sodium starch glycolate (SSG) were dissolved in different volumes of 0.1 M HCl solution (pH 1.2) at concentrations of 1, 2, 4, 10, 20, 50, 100, and 150 mg / mL, and the solution pH was measured using an MP-103 pH meter (MRC Corporation, Israel) equipped with an ELC-10-00 electrode (MRC Corporation, Israel) as described above in the Materials and Methods section.
[0476] like Figure 1 As shown, after adding HCl solution (pH 1.2), SNAC dissolved rapidly, and the pH value increased in a concentration-dependent manner, wherein the pH after adding 10 mg / mL SNAC for 5 minutes was about 1.5, the pH after adding 20 mg / mL SNAC for 5 minutes was about 6.5, and the pH after adding 100 mg / mL SNAC for 5 minutes was about 7.5.
[0477] These results suggest that under gastric conditions a significant portion of SNAC is converted from the salt to the corresponding carboxylic acid (NAC), which is substantially less water soluble than the salt and is not an effective permeation enhancer.
[0478] The effect of pH on pepsin peptide proteolysis was determined by incubating 13.5 μg / mL human parathyroid hormone (1-34) (hPTH(1-34)) with 150 μg / mL pepsin at different pH values and determining the residual percentage of hPTH(1-34). The amount of hPTH(1-34) remaining in the medium at different pH values was determined after the addition of 150 μg / mL pepsin at 37°C, followed by immediate (10 sec) vortexing and centrifugation at 4°C, 4000 RCF for 3 min. The following media were used: simulated gastric fluid (pH 2) prepared from 0.01 M HCl and NaCl; phthalate buffer (pH 4 or 5); and phosphate buffer (pH 6 or 7).
[0479] like Figure 2 As shown, when the pH is increased to about pH 6 or higher, the proteolysis of hPTH(1-34) is inhibited.
[0480] Taken together, the above results suggest that SNAC can inhibit peptide degradation by pepsin under gastric conditions by increasing the pH, but at the expense of losing at least a portion of the active salt form of the absorption enhancer.
[0481] In order to obtain a beneficial increase in pH while reducing the loss of the active form of the absorption enhancer, the effect of different concentrations of different polymers containing carboxylate groups (sodium alginate, sodium starch glycolate, sodium carboxymethylcellulose and cross-linked sodium carboxymethylcellulose) on the pH after the addition of 0.1 M HCl solution (pH 1.2) was also evaluated. Figure 3A represents the pH value measured by using a MP-103 pH meter (MRC, Israel) equipped with an ELC-10-00 electrode (MRC, Israel). Figure 3B The pH values were measured using an MP-103 pH meter (MRC, Israel) equipped with a thin electrode HI1083 (HANNA Instruments, Inc.).
[0482] like Figure 3A and 3B As shown, each polymer tested exhibited a concentration-dependent increase in pH, with pH values around 4 to 4.5 at the higher concentrations tested.
[0483] Sodium alginate, Na-CMC, CCS and sodium starch glycolate test powders formed gels (various viscosities) upon addition to aqueous media and the dispersion of the polymer in such gels could be heterogeneous. In order to assess whether the acid neutralization capacity of the polymers is determined by the concentration of the polymer in the gel, preliminary studies were performed on the insertion of the polymers in powder form into acidic media without mixing. The pH was determined using an appropriate pH indicator solution.
[0484] The polymers in powder form produced partial acid neutralization: sodium starch glycolate dissolved rapidly under strong acid neutralization, croscarmellose sodium dissolved rapidly under weak acid neutralization, sodium carboxymethylcellulose sodium salt dissolved poorly but showed some acid neutralization, and sodium alginate showed little acid neutralization (data not shown).
[0485] These results suggest that, of the polymers tested, sodium starch glycolate (and to some extent, croscarmellose sodium) has a particularly strong local acid neutralization effect in powder form, making it particularly suitable for non-enteric coated formulations containing absorption enhancers such as SNAC.
[0486] Without being bound by any particular theory, the inventors believe that the limited effectiveness of sodium carboxymethylcellulose and sodium alginate is related to the slow penetration of water into the polymer matrix, while the particularly effective acid neutralization of sodium starch glycolate is at least partially related to its rapid water absorption (swelling).
[0487] Because sodium starch glycolate and croscarmellose sodium exhibited the strongest local acid neutralization capabilities, additional experiments were performed with these polymers.
[0488] To evaluate the maximum acid neutralization capacity of the polymers, each polymer was compressed into tablet form and the experiment was repeated.
[0489] In a preliminary study, flat round 100 mg tablets were made from sodium starch glycolate or croscarmellose sodium using a 6 mm punch and 2 tons of compression force and placed in 40 ml of HCl solution at different pH levels - 1.2, 1.5 or 2.0 (static dissolution). The temperature was maintained at 37°C using a water bath. The resulting pH was measured using an appropriate pH indicator solution.
[0490] Although sodium starch glycolate and croscarmellose sodium tablets exhibited different swelling patterns, they exhibited comparable neutralization strengths in HCl solutions (data not shown). For each initial pH value tested, sodium starch glycolate tablets produced stronger acid neutralization than croscarmellose sodium tablets (where the efficacy of local acid neutralization was greater when the initial pH was higher).
[0491] These results indicate that, although sodium starch glycolate and croscarmellose sodium may have comparable efficacy in increasing the pH of gastric fluid to at least about 4, sodium starch glycolate is more effective than croscarmellose sodium in increasing the pH of gastric fluid to at least about 5, indicating that sodium starch glycolate is more effective than croscarmellose sodium in acid neutralization.
[0492] In a separate study, 100 mg sodium starch glycolate tablets were prepared using an 8 mm round punch and a compression force of 1.5 tons. The tablets were dissolved without shaking in a weighing dish containing 50 ml of 0.01 M HCl solution (pH 2.0, 37° C.), and the local pH was measured.
[0493] The pH near the tablet was measured by adding an indicator to the solution, which showed a local pH of approximately 7.
[0494] These results suggest that sodium starch glycolate raises the local pH to well above pH 5 (the pKa of SNAC), thereby promoting the dissolution of SNAC at concentrations effective for the function of SNAC and related compounds as absorption enhancers and inhibiting peptide degradation by pepsin (pepsin is only active at low pH).
[0495] Without being bound by any particular theory, the inventors believe that the localized nature of the observed pH increase is related to the formation of a viscous gel upon dissolution (hydration and relaxation upon wetting) of the polymer, which limits the transport of acid from the exterior to the localized region of higher pH. The inventors further believe that, due to this heterogeneity, determination of the local pH is more relevant than the pH of the entire medium. For example, a substantially smaller increase in the pH of the entire medium ( Figure 3Ato B) can be interpreted as reflecting the average of the pH values in the vicinity of the tablet where the acid is effectively neutralized and the pH values in the distal regions where the pH values are less affected.
[0496] In other studies, 100 mg tablets were made from various polymers (e.g., sodium starch glycolate, croscarmellose sodium, carboxymethylcellulose, and sodium alginate) using an 8 mm round punch and a 2 ton compression force. The tablets were placed in a 0.01 M HCl solution (pH 2.0, 37°C) to compare the effect of the tablets on local pH. The pH was determined by adding an indicator to the solution.
[0497] The sodium starch glycolate tablets swelled and disintegrated rapidly, producing a strong local acid neutralization effect; the croscarmellose sodium tablets also disintegrated rapidly, but the local acid neutralization effect was weaker; the sodium carboxymethylcellulose tablets swelled slowly and showed some local acid neutralization; the sodium alginate tablets remained intact and showed little local acid neutralization (data not shown).
[0498] In addition, a control group of tablets prepared with hydroxypropyl methylcellulose (HPMC), a polymer containing no anionic groups and showing no significant effect on pH, was tested in a similar manner.
[0499] As the tablets gradually hydrate, the acid neutralization effect of the polymer in the swollen matrix may not be uniform. Therefore, the pH of the tablet matrix at different locations was evaluated in additional experimental sets, as shown below.
[0500] 200 mg tablets were prepared from sodium alginate, Na-CMC, CCS or sodium starch glycolate (SSG) using a 10 mm round punch and 1 ton compression force. Each tablet was placed in the center of a petri dish containing 100 ml of 0.01 M HCl solution (pH 2.0, room temperature) and after hydration, the local pH was measured at four different points of the swollen tablet matrix, as Fig. 6A (for SSG), Figure 6B (for CCS), Figure 6C (for Na-CMC; CMC-Na) and Fig.6D (for sodium alginate; Alg-Na) as follows: (i) in the HCl solution outside the boundary of the formed gel (approximately 2 to 3 cm from the surface of the expanded matrix); (ii) at the surface of the expanded matrix; (iii) at a distance intermediate between the surface and the center of the expanded matrix (approximately 0.5 to 1 cm from the surface and the center respectively); and (iv) at the center of the expanded matrix). The local pH value within the tablet can be measured by using a pH meter with a thin electrode (as described in the "Materials and Methods" section).
[0501] like Figures 6A to 6DAs shown, SSG tablets swelled and disintegrated rapidly and produced a strong local acid neutralization effect, reaching a pH of 5.7 ( Fig. 6A CCS tablets also swell rapidly and produce a slightly weaker local acid neutralization effect ( Figure 6B CMC-Na tablets swell slowly and show strong local acid neutralization ( Figure 6C ); and Alg-Na tablets showed the slowest swelling rate and similar local acid neutralization as CCS ( Fig.6D ). For all polymers tested, the pH values measured in the center of the swollen matrix were higher than those in other areas, further supporting the concentration-dependent acid neutralization ability of the polymers.
[0502] The results of these two sets of experiments show that for all basic polymers tested, the local pH inside the matrix increased to a pH of approximately 5 to 6. Such a pH corresponds to the required pH to maintain SNAC in a soluble salt form, since SNAC has a pKa of approximately 5. Therefore, this increase in pH reduced precipitation of SNAC, thereby achieving higher concentrations of dissolved SNAC, which is necessary for its function as an absorption enhancer (and other absorption enhancers). The increase in local pH also inhibited degradation of the peptide by pepsin (which is only active at low pH). These results further suggest that alkaline (basic) polymers can have stronger and / or more sustained effects on pH by exhibiting limited diffusion in acidic solutions and thus affecting pH primarily in a localized manner.
[0503] In another set of experiments, SSG (as an example of a fast swelling polymer that produces a high local pH) and CMC-Na (as an example of a slow swelling polymer that produces a high local pH) were further tested in porcine gastric fluid (endoscopically removed from sedated adult female domestic pigs (sus scrofa domesticus)). 200 mg tablets were prepared from each polymer using a 10 mm round punch and 1 ton compression force. Each tablet was placed in the center of a petri dish containing 100 ml of porcine gastric fluid at room temperature and, after hydration (wetting), the swollen tablet matrix was placed in a 100 ml plate as described above. Figures 6A to 6D The data shown are from four different points (i) to (iv) where the local pH was measured. The results of SSG are shown in Fig. 7A As shown, the results of CMC-Na are as follows Figure 7B As shown, respectively Fig. 6A and 6C The results shown are similar.
[0504] In summary, the above results indicate that polymers containing basic groups, particularly sodium starch glycolate and crosslinked sodium carboxymethylcellulose, can effectively neutralize acid in a local area (e.g., in the stomach), thereby reducing protonation and inactivation of SNAC in that area, as well as degradation of the peptide by pepsin. This phenomenon will be particularly important when the polymer, SNAC, and peptide or polypeptide are co-located (e.g., in a single dosage form), allowing for prolonged absorption of the peptide or polypeptide induced by SNAC.
[0505] Example 2
[0506] Effect of sodium starch glycolate on the absorption of peptides in vivo
[0507] The ability of sodium starch glycolate (SSG) to enhance drug absorption was evaluated in an in vivo rat model using teriparatide (hPTH(1-34)) as a model peptide drug and SNAC as a model absorption enhancer.
[0508] Formulations were prepared with the compositions shown in Table 1. All materials were in dry powder form and geometrically mixed using a mortar and pestle. Mini tablets were then prepared from the mixture at 0.5 t / cm2 using a 2 mm punch and die.
[0509] Table 1: Composition of an exemplary formulation (comprising 90 μg of hPTH (1-34), about 14.4 mg of SNAC, and about 0.15 mg of magnesium stearate) administered to rats in different experimental groups
[0510]
[0511] Male Wistar rats (250-300 g) were divided into groups to receive different formulations (as described in Table 1); fasted the night before and during the experiment, and no water was given 1 hour before and during the experiment. Rats were given mini tablets using a custom intragastric gavage. Blood was collected from the cheek at predetermined time points. Plasma was separated and hPTH (1-34) was quantified using a commercial Elisa kit for the determination of hPTH (1-34) in plasma or cell culture medium (Quidel, Athens, OH, USA, Cat No. 60-3900).
[0512] like Figure 4 As shown in Table 2 below, the addition of 20% sodium starch glycolate to an exemplary formulation containing SBTI resulted in a C 最大 and the median AUC (area under the curve) increased by approximately 1.5 times.
[0513] like Figure 5 As shown in Table 2 below, the addition of 30% sodium starch glycolate to the exemplary formulation (without SBTI) resulted in a C最大 and median AUC (area under the curve) increased approximately 4-fold.
[0514] like Figure 4 and Figure 5 It was further shown that sodium starch glycolate increased the plasma levels of hPTH(1-34) during the elimination phase, indicating a prolonged absorption time.
[0515] Table 2: Pharmacokinetic parameters (median and range) of hPTH (1-34) of exemplary formulations after oral administration of the formulations to male Wistar rats
[0516]
[0517] These results support the results of Example 1 and demonstrate that sodium starch glycolate is able to significantly increase the absorption of polypeptides co-administered with absorption enhancers such as SNAC and modulate the pharmacokinetic profile in the presence or absence of protease inhibitors.
[0518] Example 3
[0519] Effect of sodium starch glycolate on the absorption of peptides in a porcine model in vivo
[0520] The ability of sodium starch glycolate (SSG) to enhance drug absorption was further evaluated in an in vivo porcine model, which allowed testing of conventionally sized unit dosage forms for use in humans using teriparatide (hPTH(1-34)) as a model peptide drug and SNAC as a model absorption enhancer.
[0521] The compositions shown in Table 3 were prepared with or without 25% SSG. All materials were in dry powder form and geometrically mixed using a mortar and pestle. Tablets were then prepared from the mixture using a hand press.
[0522] Female Sinclair piglets (18-20 kg) were orally administered the obtained tablets at different visits. The pigs were fasted the night before and during the experiment, and no water was given one hour before and during the experiment. Administration was facilitated by a custom-made oral dosing device and about 30 ml of water. Blood was collected from the jugular vein at a predetermined time point by an indwelling cannula. Plasma was separated and hPTH (1-34) was quantified using a commercially available Elisa kit for determination of hPTH (1-34) in plasma or cell culture medium (Quidel, Athens, Ohio, USA, Cat#60-3900).
[0523] Table 3: Composition of exemplary formulations administered to pigs, comprising teriparatide (hPTH(1-34)), SNAC, and magnesium stearate, with or without 25% SSG
[0524]
[0525] As shown in Table 4, formulations containing sodium starch glycolate consistently produced higher C 最大 and AUC values, and plasma levels also remained high during the elimination phase.
[0526] These results further demonstrate the ability of polymers containing basic groups to enhance the absorption of polypeptides in the presence of absorption enhancers.
[0527] Table 4: Pharmacokinetic parameters (median ± SEM) of teriparatide (hPTH (1-34)) after oral administration of exemplary formulations to female Sinclair minipigs (p < 0.05 compared with the control group by Wilcoxon signed rank test)
[0528]
[0529]
[0530] Example 4
[0531] Effect of sodium starch glycolate on the absorption of GLP-2 in vivo
[0532] Teduglutide is a commercially available 33-amino acid peptide that is significantly more stable to metabolic degradation than endogenous glucagon-like peptide 2 (GLP-2). It is used clinically to treat short bowel syndrome. Current methods of using teduglutide involve subcutaneous (SC) injections, as its instability and impermeability in the gastrointestinal tract make the oral (PO) bioavailability of the drug negligible.
[0533] The effects of SNAC as an exemplified absorption enhancer and SSG as an exemplified basic polymer on the oral bioavailability of teduglutide were tested.
[0534] The formulation was prepared with 0.7 mg of teduglutide (2.34 mg / kg), 15 mg of SNAC, 0.2 mg of stearate and 5.33 mg of SSG. All substances were in dry powder form and geometrically mixed. Mini tablets were then prepared from the mixture at 1 ton / cm2 using a 2 mm punch and die.
[0535] The study was conducted in 7 male Sprague Dawley (SD) rats weighing approximately 299 g (290 to 320 g). The animals were fasted 12 to 15 hours before dosing. Water supply was stopped one hour before dosing and resumed one hour after dosing. Mini tablets were administered by flexible intragastric gavage, with a tip suitable for solid dosage form administration without the aid of water. Thereafter, blood samples were collected at predetermined time points, plasma was separated, and ELISA kit for detection of endogenous GLP-2 in plasma (Abcam, Cat No. ab222863) was used according to the manufacturer's method version 7, with modifications when necessary.
[0536] Figure 8 The obtained plasma concentration profiles of teduglutide over time are shown in , indicating that the combination of SNAC and a buffering polymer (SSG) can be used for oral delivery of teduglutide.
[0537] Example 5
[0538] Effect of Sodium Starch Glycolate on Absorption of Kappa Opioid Receptor Agonists in an In Vivo Model The ability of sodium starch glycolate (SSG) to enhance drug absorption was evaluated in an in vivo dog model using an exemplary commercially available peripherally restricted kappa opioid receptor agonist (approximately 1 kDa) and SNAC as a model absorption enhancer.
[0539] The compositions shown in Table 5 were used to prepare formulations with or without 30% SSG. All materials were in dry powder form and geometrically mixed. After that, test tablets were prepared using a manual single punch tablet press using an 8 mm punch and die set. Tablets for the control group were prepared on a manual press at 0.7 ton / cm2 using a 5 mm punch and die.
[0540] Table 5: Composition of exemplary formulations administered to dogs, comprising an exemplary kappa opioid receptor agonist (approximately 1 kDa), labeled "peptide", SNAC, and excipients, with or without 30% SSG
[0541]
[0542] This study was conducted with 6 male dogs (8-11 kg, 8-9 months old). The dogs were fasted overnight, had free access to water (approximately 14-18 hours), and were fed 4 hours after dosing. Three dogs were given the control tablets by intragastric gavage, and the other three dogs were given the test tablets. 10 ml of water was given after the gavage. 5% HEC (hydroxyethylcellulose; a polymer with no buffering capacity) was added to the control tablets to maintain similar dissolution rates of the formulations.
[0543] Thereafter, blood samples are collected at predetermined time points, plasma is separated, and the plasma level of the peptide is quantified by an ELISA kit or other method acceptable in the art to detect systemic exposure of the peptide.
[0544] The data obtained are shown in Table 6, indicating that the addition of SSG to the tablets resulted in a significant increase in the AUC values compared with the control group. 最大 The dissolution rates of the two formulations were similar (50 min vs. 55 min).
[0545] Table 6
[0546]
[0547] SSG - sodium starch glycolate. AUC values were adjusted to 0.1 mg / kg dose. N = 3 male dogs per group. There was a statistically significant difference between the two groups (T test, P < 0.05).
[0548] To further understand the effect of SNAC conjugation with a basic polymer on the systemic exposure of the delivered peptide, an additional study was conducted in 12 dogs. Two groups of 6 dogs were orally administered tablets containing the same approximately 1 kDa therapeutic peptide co-formulated with SNAC and varying amounts of SSG as shown in Table 7. The tablets were prepared as described above. The study was conducted as described above and the data obtained are shown in Tables 8 and Fig. 9 shown.
[0549] Table 7
[0550]
[0551] Table 8
[0552]
[0553] SSG-sodium starch glycolate. N = 6 male dogs per group. There was a statistically significant difference between the two groups (T test, P < 0.05).
[0554] From Table 8 and Fig. 9 As can be seen, the systemic exposure (AUC) was higher for the tablet with higher SSG content (Formulation 2).
[0555] These data further support the finding that the combination of SNAC and a basic polymer described herein, such as SSG, represents an innovative approach to oral delivery of therapeutically active agents, such as peptides and proteins, which is otherwise limited, and significantly improves the oral bioavailability of the therapeutically active agents.
[0556] Although the present invention has been described in conjunction with specific embodiments of the present invention, it is self-evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Therefore, it is intended to include all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.
[0557] It is the intention of the applicant that all publications, patents and patent applications mentioned in this specification are incorporated herein by reference in their entirety, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, any reference cited or identified in this application shall not be construed as an admission that such reference may be used as prior art of the present invention. For the scope of the use of section headings, they should not be construed as necessary limitations. In addition, any priority documents of this application are incorporated herein by reference in their entirety.
Claims
1. A pharmaceutical composition, It is characterized in that The composition comprises a therapeutically active agent, an absorption enhancer and a polymer comprising a plurality of basic groups, wherein the concentration of the polymer in the composition is at least 10 weight percent of the total weight of the composition, and the absorption enhancer is a substituted or unsubstituted fatty acid or a salt thereof.
2. The composition according to claim 1, It is characterized in that The plurality of basic groups are a plurality of carboxylate groups and / or a plurality of amino groups.
3. The composition according to claim 1 or 2, It is characterized in that At least a portion of the plurality of basic groups are a plurality of carboxylate groups.
4. The composition according to claim 2 or 3, It is characterized in that At least a portion of the plurality of carboxylate groups are in the form of a pharmaceutically acceptable salt.
5. The composition according to claim 4, It is characterized in that At least a portion of the plurality of carboxylate groups are in the form of a sodium salt.
6. The composition according to any one of claims 1 to 5, It is characterized in that The absorption enhancer is selected from NAC, i.e. 8-N-(2-hydroxybenzoyl)aminocaprylic acid, NAD, i.e. 10-N-(2-hydroxybenzoyl)aminodecanoic acid, 5-CNAC, i.e. 8-N-(5-chlorosalicyloyl)aminocaprylic acid, 4-MOAC, i.e. 8-N-(2-hydroxy-4-methoxybenzoyl)aminocaprylic acid, 4-CNAB, i.e. 4-N-(2-hydroxy-4-chlorobenzoyl)aminobutyric acid and salts thereof.
7. The composition according to claim 6, It is characterized in that The absorption enhancer comprises NAC or a salt thereof.
8. The composition according to any one of claims 1 to 7, It is characterized in that The absorption enhancer is present in a concentration of at least 50 weight percent.
9. The composition according to any one of claims 1 to 8, It is characterized in that The concentration of the polymer is at least 20 weight percent.
10. The composition according to any one of claims 1 to 9, It is characterized in that The total concentration of the absorption enhancer and the polymer is at least 80 weight percent.
11. The composition according to any one of claims 1 to 10, It is characterized in that The concentration of the basic groups in the composition is at least 0.1 mmol / g.
12. The composition according to any one of claims 1 to 11, It is characterized in that The polymer is a cross-linked polymer.
13. The composition according to any one of claims 1 to 12, It is characterized in that The polymer comprises a polysaccharide.
14. The composition of claim 13, It is characterized in that The polysaccharide is selected from starch derivatives and cellulose derivatives.
15. The composition according to any one of claims 1 to 14, It is characterized in that The polymer comprises carboxymethyl groups.
16. The composition according to any one of claims 1 to 15, It is characterized in that The polymers are characterized by a pKa in the range of from 1.2 to 7.
5.
17. The composition according to any one of claims 1 to 16, It is characterized in that The polymer is sodium starch glycolate and / or cross-linked sodium carboxymethyl cellulose.
18. The composition according to any one of claims 1 to 17, It is characterized in that The composition has a C 最大 and / or bioavailability compared to the corresponding composition without the polymer 最大 and / or at least 50% higher bioavailability.
19. The composition according to any one of claims 1 to 18, It is characterized in that The molecular weight of the therapeutically active agent is in the range of 0.5 kDa to 100 kDa.
20. The composition according to any one of claims 1 to 19, It is characterized in that The therapeutically active agent is a BCS class III agent.
21. The composition according to any one of claims 1 to 20, It is characterized in that The therapeutically active agent is a polypeptide or a nucleic acid.
22. The composition of claim 21, It is characterized in that The polypeptide is selected from antibodies, anti-pathogenic polypeptides, antiviral peptides, coagulation factors, C-type natriuretic peptides, calcitonin, desitatide, endomorphin, erythropoietin, gastric inhibitory peptide (GIP), gastric inhibitory peptide receptor agonist, glucagon, glucagon receptor agonist, GLP-1 (glucagon-like peptide-1), GLP-1 receptor agonist, GLP-2 (glucagon-like peptide-2), GLP-2 receptor agonist, GLP-1 receptor / glucagon receptor dual agonist, GIP receptor / GLP-1 receptor dual agonist, glucagon receptor / GIP receptor / GLP-1 receptor triple agonist, GLP-2 receptor / glucagon receptor dual agonist, GLP-2 receptor / GLP-1 receptor dual agonist, GLP-2 receptor / GLP-1 receptor dual agonist, GLP-2 receptor dual agonists of the steroid / GIP receptor, glucocerebrosidase, gonadotropin, gonadotropin-releasing hormone, gonadotropin-releasing hormone receptor agonist, gonadotropin-releasing hormone receptor antagonist, granulocyte colony stimulating factor, growth factor, growth hormone, somatostatin, somatostatin receptor agonist, growth hormone-releasing hormone, icatibant, insulin, interferon, interleukin, kappa opioid receptor agonist, leptin, oxytocin, oxytocin receptor agonist, melanocortin, melanocortin receptor agonist, motilin, omentin, parathyroid hormone or fragments thereof, parathyroid hormone-related protein, peptide YY, pituitary adenylate cyclase activating peptide (PACAP), thymopentin, thymosin, TNF inhibitors, vasoactive intestinal peptide, vasopressin and analogs thereof.
23. The composition of claim 22, It is characterized in that The polypeptide comprises teriparatide.
24. The composition of claim 22, It is characterized in that The antibodies comprise single domain antibodies.
25. The composition according to any one of claims 1 to 24, It is characterized in that The composition is in unit dosage form.
26. The composition of claim 25, It is characterized in that The amount of the basic group in the unit dosage form is at least 0.03 mmol.
27. The composition of claim 25 or 26, It is characterized in that The unit dosage form comprises at least 50 mg of the absorption enhancer.
28. A composition according to any one of claims 25 to 27, It is characterized in that The unit dosage form comprises one or more tablets.
29. The composition according to any one of claims 1 to 28, It is characterized in that The composition is used to treat a condition treatable by the therapeutically active agent, wherein the treatment comprises oral administration of the composition.
